Scenario,PMID,QID,Question,Type,Human Answer,Updated Human Answer,GPT-4o base Answer,GPT-4o base Correct,GPT-4o FT Answer,GPT-4o FT Correct,GPT-4o AP Answer,GPT-4o AP Correct,gpt5-mini Answer,gpt5-mini Correct,Llama3.1-70B base Answer,Llama3.1-70B base Correct,Llama3.1-70B FT Answer,Llama3.1-70B FT Correct,llama-3.1-70B AP Answer,llama-3.1-70B AP Correct
Human Answer,18715920,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,"No. The sequences reported were derived from in vitro–selected laboratory virus stocks, not from patient samples.",1,No,1,No,1,Yes,0
Human Answer,18715920,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,18715920,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No public sequence accession numbers or depositions are reported in the paper.,1,No,1,No,1,No,1
Human Answer,18715920,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,18715920,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,None — no individuals; sequencing was performed on in vitro virus populations and recombinant viruses.,1,0,1,0,1,Not reported,1
Human Answer,18715920,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable to patient-derived samples; the laboratory virus materials were provided by institutes in Belgium (Antwerp and Brussels).,1,No,1,No,1,Not reported,1
Human Answer,18715920,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not reported; the paper provides selection durations in days/passages but does not specify calendar years for sample collection.,1,No,1,No,1,Not reported,1
Human Answer,18715920,8,Were samples cloned prior to sequencing?,Boolean,No,,Yes,0,No,1,Not applicable,1,"No for the population sequencing of selected viruses — population-based sequencing was used; however, site-directed mutant (SDM) constructs were cloned for recombinant virus studies.",1,No,1,No,1,Not reported,1
Human Answer,18715920,9,Which HIV genes were reported to have been sequenced?,List,IN,,"Integrase, IN",1,"RT, IN",1,Not applicable,0,The integrase (IN) coding region of pol was sequenced (IN was the target); cDNA for reverse transcriptase and IN was generated but genotyping focused on the IN region.,1,No,0,IN,1,"IN, pol",1
Human Answer,18715920,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Not Reported,0,Automated population-based Sanger sequencing (ABI Prism BigDye Terminator cycle sequencing) of PCR products.,1,No,0,No,0,Sanger sequencing,1
Human Answer,18715920,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Viral RNA extracted from culture supernatant or virus stock (in vitro–selected virus populations and regrown virus stocks) were sequenced.,0,No,1,Virus stock,0,"Plasma, virus stock",0
Human Answer,18715920,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No. The paper did not sequence viruses from individuals with virological failure; sequences were derived from in vitro selections and recombinant constructs.,1,No,1,No,1,Yes,0
Human Answer,18715920,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not Reported,1,No — there were no patients in the study; experiments were in vitro using laboratory viruses and recombinant constructs.,1,No,1,No,1,Not reported,1
Human Answer,18715920,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No. The reported sequences were from in vitro–selected viruses and recombinant constructs, not from previously treated individuals.",1,No,1,No,1,Yes,0
Human Answer,18715920,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — there were no individuals in the study. The study tested integrase inhibitors (and one NRTI was mentioned) on in vitro viruses.,1,INSTI,0,No,1,"INSTI, NRTI",0
Human Answer,18715920,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — there were no individuals; experimentally, the studied compounds included elvitegravir (EVG), raltegravir (RAL), L-870,810, PACA, PICA, L-731,988, and zidovudine.",1,"RAL, EVG, DTG, BIC, CAB, LEN",0,No,1,"Elvitegravir, raltegravir",0
Human Answer,19104010,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes.,0
Human Answer,19104010,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes.,1
Human Answer,19104010,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No accession numbers or sequence depositions are reported in the paper.,1,No,1,No,1,No.,1
Human Answer,19104010,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in the paper.,1,No,1,No,1,Not reported.,1
Human Answer,19104010,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Zero patient individuals; sequencing was performed on viral material from cell culture passages and cloned PCR products.,1,0,1,0,1,Not reported.,1
Human Answer,19104010,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,"Not applicable / not reported (sequenced material derived from laboratory virus strains and in vitro selections, not from patient samples).",1,No,1,No,1,United States.,0
Human Answer,19104010,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not reported.,1,No,1,No,1,Not reported.,1
Human Answer,19104010,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Yes.,0,No,1,No,1,Yes.,0
Human Answer,19104010,9,Which HIV genes were reported to have been sequenced?,List,IN,,No,0,No,0,Not applicable,0,Integrase (IN) gene; PCR fragment spanned from RT through Vpr but sequencing focused on IN.,1,"Integrase, IN",1,No,0,"RT, Vpr.",0
Human Answer,19104010,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Cycle sequencing with the BigDye terminator v3.1 kit and analysis on an ABI Prism 3100 genetic analyzer (Sanger sequencing chemistry).,0,No,1,No,1,Sanger sequencing.,0
Human Answer,19104010,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,"Viral DNA extracted from infected cell culture passages, amplified by PCR and cloned into plasmid clones (plasmid-derived inserts were sequenced).",0,No,1,No,1,Whole blood.,0
Human Answer,19104010,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,No,1,No,1,Not applicable.,1
Human Answer,19104010,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No. The study was preclinical and performed in vitro; clinical development was discontinued after pharmacokinetic evaluation in healthy volunteers.,1,No,1,No,1,Not reported.,1
Human Answer,19104010,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,Yes,0,No,1,Not applicable.,1
Human Answer,19104010,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no individuals in the study had samples sequenced; sequences were from in vitro virus cultures.,1,INSTI,0,No,1,Not reported.,1
Human Answer,19104010,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"None — no individuals' samples were sequenced; however, in vitro selections used drugs including 3TC, EFV, and APV.",1,"GS-9160, L-870,810, GS-9137, MK-0518",0,No,1,Not reported.,1
Human Answer,21115794,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,21115794,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,21115794,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — GenBank or other public accession numbers are not reported in the paper.,1,No,1,No,1,Yes,0
Human Answer,21115794,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,21115794,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Zero (no patient-derived samples were sequenced).,1,0,1,0,1,Not reported,1
Human Answer,21115794,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable / Not reported.,1,No,1,No,1,Not reported,1
Human Answer,21115794,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not reported / Not applicable.,1,No,1,No,1,Not reported,1
Human Answer,21115794,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No — PCR products from infected cells were sequenced (no cloning step described for sequencing).,1,No,1,No,1,Not reported,1
Human Answer,21115794,9,Which HIV genes were reported to have been sequenced?,List,IN,,No,0,No,0,Not applicable,0,The integrase coding region (integrase).,1,No,0,No,0,Pol,0
Human Answer,21115794,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Sequencing of PCR products was performed by Operon Biotechnologies' sequencing service.,0,No,1,No,1,Sanger sequencing,0
Human Answer,21115794,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Proviral DNA from infected cell cultures (DNA extracted from infected cells following in vitro passage).,0,No,1,No,1,Plasma,0
Human Answer,21115794,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No sequences from such individuals were reported as being obtained in this paper.,1,No,1,No,1,Not reported,1
Human Answer,21115794,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,No — this is a preclinical in vitro study; patients were not enrolled in this study.,1,No,1,No,1,Not reported,1
Human Answer,21115794,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the sequenced material derives from in vitro infected cells and laboratory strains, not from ARV-experienced individuals.",1,No,1,No,1,Not reported,1
Human Answer,21115794,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no individuals' samples were sequenced in this study.,1,INSTI,0,No,1,Not reported,1
Human Answer,21115794,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — no patient-derived samples were sequenced, so no individual drug exposures are reported in relation to sequenced samples.",1,"Raltegravir (RAL), Elvitegravir(EVG)",0,No,1,Not reported,1
Human Answer,23749954,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No — the study used laboratory-generated NL4-3 clones and public database consensus sequences rather than patient-derived sequences.,1,No,1,No,1,No,1
Human Answer,23749954,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,Yes,0,Yes,0,Yes — the paper reports in vitro cell culture drug selection experiments assessing resistance mutation selection under drug pressure.,0,Yes,0,We recently reported the preferential selection of the K65R resistance,0,Yes,0
Human Answer,23749954,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported — the paper does not provide GenBank accession numbers or state that newly generated sequences were deposited.,0,No,1,No,1,No,1
Human Answer,23749954,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,23749954,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,None — no patient samples were obtained for sequencing in this study.,1,Not specified,0,0,1,Not reported,1
Human Answer,23749954,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — the study did not sequence patient-derived samples from any countries.,1,No,1,No,1,Not reported,1
Human Answer,23749954,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no newly sequenced patient samples or associated collection years are reported.,1,No,1,No,1,Not reported,1
Human Answer,23749954,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not applicable for patient samples; the authors did generate cloned NL4-3 plasmids with specific mutations in the laboratory.,1,No,1,No,1,Not reported,1
Human Answer,23749954,9,Which HIV genes were reported to have been sequenced?,List,RT,,No,0,No,0,Not applicable,0,"The study focused on the reverse transcriptase (RT) region (codons around positions 64/65, 70, 210, 219 and the K65R mutation).",1,Not specified,0,No,0,Pol,0
Human Answer,23749954,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not reported — the paper does not describe any sequencing methodology for newly generated sequences.,1,No,1,No,1,Not reported,1
Human Answer,23749954,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,No new patient-derived samples were sequenced; the study used laboratory-generated NL4-3 mutant viruses and analyses of public database sequence alignments.,1,No,1,No,1,Not reported,1
Human Answer,23749954,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — the study did not obtain or report sequences from individuals with virological failure.,1,No,1,No,1,Not reported,1
Human Answer,23749954,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No — there were no patients enrolled in this study; experiments used laboratory viruses and database sequences.,1,No,1,No,1,Not reported,1
Human Answer,23749954,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper does not report sequences from treated individuals; it analyzes laboratory-generated clones and database consensus sequences.,1,No,1,No,1,Not reported,1
Human Answer,23749954,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — there were no individuals sampled in this study.,1,NRTI,0,No,1,Not reported,1
Human Answer,23749954,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no human participants or their prior drug exposures were part of this study.,1,"Tenofovir, didanosine, stavudine, apricitabine, and abacavir",0,No,1,Not reported,1
Human Answer,24227862,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,24227862,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,24227862,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (no public sequence deposition is reported).,1,No,1,No,1,No,1
Human Answer,24227862,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,24227862,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,None — no patient-derived samples were sequenced.,1,0,1,0,1,Not reported,1
Human Answer,24227862,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — no patient-derived samples; laboratory materials and CBMCs (obtained in Montreal, Canada) were used.",1,No,1,No,1,Not reported,1
Human Answer,24227862,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no calendar years of sample collection or patient-derived sequences are reported.,1,No,1,No,1,Not reported,1
Human Answer,24227862,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Yes — site-directed cloning was performed to generate recombinant NL4.3 clones prior to sequencing for verification.,0,No,1,No,1,Not reported,1
Human Answer,24227862,9,Which HIV genes were reported to have been sequenced?,List,RT,,No,0,No,0,Not applicable,0,The reverse transcriptase (RT) coding sequences were sequenced/genotyped.,1,"Reverse transcriptase, RT",1,RT,1,RT,1
Human Answer,24227862,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,DNA sequencing (method not specified).,0,No,1,No,1,Not reported,1
Human Answer,24227862,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Laboratory-derived recombinant HIV-1 NL4.3 proviral clones and viruses harvested from cell culture (in vitro selections); genotyping was performed on virus-containing culture media.,0,PBMC,0,No,1,Not reported,1
Human Answer,24227862,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,No,1,No,1,Yes,0
Human Answer,24227862,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No — there were no patients enrolled in this study.,1,No,1,No,1,Not reported,1
Human Answer,24227862,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,Yes,0,No,1,Yes,0
Human Answer,24227862,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — there were no individual patient samples; the study used RT inhibitors (NRTIs and NNRTIs) in vitro.,1,NNRTI,0,No,1,"NRTI, NNRTI, PI",0
Human Answer,24227862,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — no individuals received drugs in this study; experimentally used drugs included ETR, RPV, NVP, EFV, and zidovudine (ZDV) among others.",1,"Nevirapine (NVP), Etravirine (ETR), Rilpivirine (RPV)",0,No,1,"ETR, RPV",0
Human Answer,25637519,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No — the study did not report sequencing of patient-derived HIV samples; it used an infectious plasmid and site-directed mutants for in vitro work.,1,No,1,Yes,0,Yes,0
Human Answer,25637519,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — the paper reports in vitro phenotypic drug susceptibility data for mutant and wild-type viruses.,1,Yes,1,Yes,1,Yes,1
Human Answer,25637519,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report depositing sequences or providing public accession numbers.,1,No,1,No,1,No,1
Human Answer,25637519,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,25637519,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,Not reported,1,No individuals' samples were sequenced in this study (0); the work used a previously constructed infectious plasmid and plasmid-derived mutants.,1,0,1,0,1,Not reported,1
Human Answer,25637519,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,China,0,Not applicable / not reported — the paper does not specify the country of origin for any sequenced patient samples.,1,China,0,No,1,Not reported,1
Human Answer,25637519,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not reported / not applicable — the paper does not provide years for any sequenced samples.,1,No,1,No,1,Not reported,1
Human Answer,25637519,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Yes — plasmid clones (constructs) were generated and positive clones were identified and sequenced.,0,Yes,0,No,1,Not reported,1
Human Answer,25637519,9,Which HIV genes were reported to have been sequenced?,List,RT,,No,0,No,0,Not applicable,0,The reverse transcriptase (RT) gene/region (including the connection subdomain) was sequenced/analysed.,1,"Reverse transcriptase, RT",1,RT,1,Pol,0
Human Answer,25637519,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,The paper states DNA sequencing was used to confirm plasmid mutations; no specific sequencing platform or method is specified.,0,No,1,No,1,Sanger sequencing,0
Human Answer,25637519,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not reported,1,"Plasmid DNA from constructed infectious clones/mutant plasmids was sequenced (i.e., plasmid clones), not clinical patient specimens in this study.",0,Other,0,No,1,Plasma,0
Human Answer,25637519,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Yes,0,No sequences from such individuals were obtained in this study; the paper only references (from other studies) that D404N has been found in treatment-failure patients.,1,Yes,0,No,1,Yes,0
Human Answer,25637519,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — there were no patients enrolled or treated in a clinical trial in this study; the work was performed using cell lines and plasmid-derived viruses.,1,No,1,No,1,Not reported,1
Human Answer,25637519,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Yes,0,No — the study itself did not report sequences from individuals with prior ARV exposure; it only cites other reports where D404N was found in ART-experienced patients.,1,Yes,0,No,1,Yes,0
Human Answer,25637519,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not reported,1,Not applicable — no individuals were sampled or sequenced in this study. (The study itself tested NNRTIs and NRTIs in vitro.),1,"NRTI, NNRTI",0,No,1,"NRTI, NNRTI",0
Human Answer,25637519,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no study participants or patient-derived samples were sequenced. (The paper notes externally that D404N has been found in patients receiving nevirapine and efavirenz in other studies.),1,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR)",0,No,1,"zidovudine, abacavir, lamivudine, emtricitabine, tenofovir, efavirenz, nevirapine, etravirine, rilpivirine",0
Human Answer,26246578,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,26246578,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,26246578,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No sequences were reported as being made publicly available.,1,No,1,No,1,No,1
Human Answer,26246578,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,26246578,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Zero — no individuals were sampled for sequencing.,1,0,1,0,1,Not reported,1
Human Answer,26246578,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no patient-derived sequences or samples were obtained from any country.,1,No,1,No,1,Not reported,1
Human Answer,26246578,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing of patient samples was performed.,1,No,1,No,1,Not reported,1
Human Answer,26246578,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,"Not applicable — no sequencing was performed; however, engineered plasmid clones were generated by site-directed mutagenesis.",1,No,1,No,1,Not reported,1
Human Answer,26246578,9,Which HIV genes were reported to have been sequenced?,List,IN,,No,0,No,0,Not applicable,0,None — no sequencing was reported; the study focused on the integrase (IN) gene via engineered mutations.,0,No,0,No,0,IN,1
Human Answer,26246578,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing method is described because no sequencing was reported.,1,No,1,No,1,Not reported,1
Human Answer,26246578,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — no sequencing of samples was performed; the study used plasmid constructs, recombinant proteins, and cell-culture–derived viruses.",1,No,1,No,1,Viral samples,0
Human Answer,26246578,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the study did not obtain sequences from any individuals, including those with virological failure.",1,No,1,No,1,Yes,0
Human Answer,26246578,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — there were no patients in this study; it was an in vitro laboratory study.,1,No,1,No,1,No,1
Human Answer,26246578,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper does not report sequences from such individuals.,1,No,1,No,1,Yes,0
Human Answer,26246578,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — there were no individuals or sample sequencing; the study used integrase inhibitors (INSTIs) in in vitro assays.,1,INSTI,0,No,1,INSTI,0
Human Answer,26246578,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — no individuals received drugs and no sample sequencing was done; experimentally, the study used the drugs dolutegravir (DTG), raltegravir (RAL) and elvitegravir (EVG) in vitro.",1,"RAL, EVG, DTG",0,No,1,"RAL, EVG, DTG",0
Human Answer,26311878,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,"No. The paper reports sequences from plasmids and tissue-culture viruses, not from patient samples.",1,No,1,No,1,Yes,0
Human Answer,26311878,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes. The paper reports in vitro susceptibility (IC50) measurements to DTG, RAL, and EVG.",1,Yes,1,Yes,1,Yes,1
Human Answer,26311878,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,"No. The paper does not report any public deposition (e.g., GenBank accession numbers) for sequences generated in this study.",1,No,1,No,1,No,1
Human Answer,26311878,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,26311878,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Zero; no individual/patient samples were sequenced in this study.,1,0,1,0,1,Not reported,1
Human Answer,26311878,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable; sequenced material was laboratory-derived (plasmids and tissue-culture viruses).,1,No,1,No,1,Not reported,1
Human Answer,26311878,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not reported / not applicable.,1,No,1,No,1,Not reported,1
Human Answer,26311878,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Yes. Plasmids bearing the integrase mutations were generated (cloned) by site-directed mutagenesis and verified by sequencing; replication-competent genetically homogeneous viruses were produced from these plasmids.,0,No,1,No,1,Not reported,1
Human Answer,26311878,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,Integrase (IN).,0,Integrase,0,No,1,IN,0
Human Answer,26311878,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,"Viral RNA was extracted and amplified by RT-PCR, and the PCR products were sequenced; plasmids were also verified by sequencing. The specific sequencing technology (e.g., Sanger or NGS) is not specified.",0,No,1,No,1,Not reported,1
Human Answer,26311878,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Sequencing was performed on PCR products derived from viral RNA extracted from tissue-culture supernatants and on plasmid DNA used to generate engineered viruses.,0,Other,0,No,1,Plasma,0
Human Answer,26311878,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No. The study did not sequence samples from individuals with treatment failure; mentions of such individuals refer to prior reports in the literature.,1,No,1,No,1,Yes,0
Human Answer,26311878,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No. The study is an in vitro laboratory study using cell lines, primary cells, and engineered plasmids/viruses, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer,26311878,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No. The paper does not report sequencing of ARV-exposed individuals; it studies laboratory-generated viruses and references ARV-exposed individuals in prior literature.,1,No,1,No,1,Yes,0
Human Answer,26311878,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not applicable—no individuals were sampled in this study. The study used integrase strand transfer inhibitors (INSTIs: RAL, EVG, DTG) in experiments.",1,INSTI,0,No,1,"NRTI, PI, INSTI",0
Human Answer,26311878,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"None. No individuals in the study received drugs prior to sequencing. Experimentally, the study used the drugs raltegravir (RAL), elvitegravir (EVG), and dolutegravir (DTG) in vitro.",1,"RAL, EVG, DTG",0,No,1,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0
Human Answer,26559830,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,26559830,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,26559830,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No public deposition or accession numbers are reported in the paper.,1,No,1,No,1,No,1
Human Answer,26559830,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not reported,1
Human Answer,26559830,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Zero; no patient samples or individuals were sequenced.,1,0,1,0,1,Not reported,1
Human Answer,26559830,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — sequences came from laboratory clones rather than samples from countries; clones were obtained from U.S. research sources.,1,No,1,No,1,Not reported,1
Human Answer,26559830,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not reported / not applicable.,1,No,1,No,1,Not reported,1
Human Answer,26559830,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Yes,0,Yes — sequencing was performed on engineered full-length molecular clones.,0,Yes,0,No,1,Not reported,1
Human Answer,26559830,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,The full-length viral genome was sequenced; protease (within gag-pol) was specifically manipulated and analyzed.,0,Protease,0,Protease,0,"PR, RT",0
Human Answer,26559830,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,The paper states that clones were sequenced but does not specify the sequencing method.,1,No,1,No,1,Not reported,1
Human Answer,26559830,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Full-length plasmid molecular clones (engineered infectious HIV-1 and HIV-2 clones).,0,No,1,No,1,Plasma,0
Human Answer,26559830,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,No,1,No,1,Not reported,1
Human Answer,26559830,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No — there were no patient participants or clinical trial subjects in this study.,1,No,1,No,1,Not reported,1
Human Answer,26559830,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,No,1,No,1,Not reported,1
Human Answer,26559830,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — there were no individuals whose prior drug exposures were relevant to sequencing.,1,PI,0,No,1,Not reported,1
Human Answer,26559830,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no individuals or patient drug histories were involved in the sequencing.,1,"Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Darunavir (DRV), Nelfinavir (NFV)",0,No,1,Not reported,1
Human Answer,27009474,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,27009474,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,27009474,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,27009474,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,KU761565,,KU761565,1,KU761565,1,KU761565,1,KU761565.,1,KU761565,1,KU761565,1,KU761565,1
Human Answer,27009474,5,How many individuals had samples obtained for HIV sequencing?,Number,1,,1,1,1,1,1,1,One individual (a single patient).,1,1,1,1,1,1,1
Human Answer,27009474,6,From which countries were the sequenced samples obtained?,List,No,,No,1,United States,0,Not reported,1,Not specified in the paper.,1,No,1,USA,0,Not reported,1
Human Answer,27009474,7,From what years were the sequenced samples obtained?,List,No,,No,1,2014,0,2014,0,2014 (patient sample) and 2015 (clones created/characterized).,0,2014,0,2014,0,2014,0
Human Answer,27009474,8,Were samples cloned prior to sequencing?,Boolean,Yes,,No,0,No,0,Not reported,0,"Yes, infectious molecular clones and a recombinant infectious molecular clone from the patient's sample were created.",1,Yes,1,Yes,1,Not reported,0
Human Answer,27009474,9,Which HIV genes were reported to have been sequenced?,List,IN,,"Integrase, IN",1,IN,1,IN,1,Integrase was sequenced and reported; reverse transcriptase and protease regions were also genotyped (mutations reported).,1,"Integrase, IN",1,"PR, RT, IN",1,Pol,0
Human Answer,27009474,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,The specific sequencing method is not specified in the paper.,1,No,1,No,1,Not reported,1
Human Answer,27009474,11,What type of samples were sequenced?,List,No,,No,1,Plasma,0,Not reported,1,Plasma-derived samples (patient's plasma sample) were used.,0,Plasma,0,Plasma,0,Plasma,0
Human Answer,27009474,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — the patient whose sample was sequenced was virologically suppressed (plasma HIV-1 RNA <50 copies/ml) on therapy.,1,No,1,No,1,No,1
Human Answer,27009474,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No; the report describes a single clinical case and does not indicate participation in a clinical trial.,1,No,1,No,1,Not reported,1
Human Answer,27009474,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,The primary sequence in this study was from a treatment-naive individual with transmitted resistance; the paper also references GenBank sequences from raltegravir-experienced individuals.,1,Yes,1,Yes,1,Yes,1
Human Answer,27009474,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, INSTI",,"NRTI, INSTI",1,"NRTI, INSTI",1,"NRTI, INSTI",1,The reported patient was treated with an INSTI-containing regimen and NRTIs (tenofovir and emtricitabine); cobicistat was included as a pharmacoenhancer.,1,"INSTI, NRTI",1,"NRTI, INSTI",1,"INSTI, NRTI",1
Human Answer,27009474,16,Which drugs were received by individuals in the study before sample sequencing?,List,"Tenofovir, Emtricitabine, Elvitegravir",,"Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",1,"Tenofovir (TFV), Emtricitabine (FTC), Elvitegravir (EVG), Cobicistat",1,"Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",1,"Tenofovir, emtricitabine, elvitegravir, and cobicistat.",1,"Tenofovir, Emtricitabine, Elvitegravir, Cobicistat",1,"Tenofovir (TFV), Emtricitabine (FTC), Elvitegravir (EVG)",1,"Tenofovir, emtricitabine, elvitegravir, cobicistat",1
Human Answer,27124362,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,27124362,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,27124362,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No sequences or accession numbers are reported in the paper.,1,No,1,No,1,No,1
Human Answer,27124362,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,27124362,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,None — no patient sequencing was reported.,1,0,1,0,1,Not reported,1
Human Answer,27124362,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no patient-derived sequences were reported.,1,No,1,No,1,Not reported,1
Human Answer,27124362,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no patient-derived sequencing or sample collection years are reported.,1,No,1,No,1,Not reported,1
Human Answer,27124362,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — sequencing of patient samples was not reported.,1,No,1,No,1,Not reported,1
Human Answer,27124362,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,The paper reports mutations and analyses of the HIV-1 reverse transcriptase (RT) gene.,0,No,1,No,1,Pol,0
Human Answer,27124362,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing method for patient-derived sequences is described in the paper.,1,No,1,No,1,Not reported,1
Human Answer,27124362,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — the study tested laboratory HIV-1 vectors and cell-culture selected viral mutants rather than sequencing clinical samples.,1,No,1,No,1,Plasma,0
Human Answer,27124362,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — sequences were not obtained from such individuals in this study.,1,No,1,No,1,Yes,0
Human Answer,27124362,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — the study did not include patients or a clinical trial.,1,No,1,No,1,Not reported,1
Human Answer,27124362,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper does not report sequencing of individuals with prior ARV exposure.,1,No,1,No,1,Yes,0
Human Answer,27124362,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — no individuals were sequenced; however, the paper discusses cART regimens that include NRTIs (e.g., 3TC or FTC) and NNRTIs (RPV).",1,NNRTI,0,No,1,NNRTI,0
Human Answer,27124362,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no patient sequencing was reported; the paper references 3TC or FTC as common regimen components and discusses RPV as an NNRTI.,1,"RPV, DOR",0,No,1,"DOR, RPV",0
Human Answer,28559249,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,No.,0,No,0,No,0,Yes,1
Human Answer,28559249,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,28559249,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report that sequences were made publicly available.,1,No,1,No,1,No,1
Human Answer,28559249,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in this paper.,1,No,1,No,1,Not reported,1
Human Answer,28559249,5,How many individuals had samples obtained for HIV sequencing?,Number,1,,0,0,0,0,Not reported,0,The paper reports isolates from 10 HIV-1 and 14 HIV-2 strains (24 isolates total) derived from individuals.,0,0,0,0,0,Not reported,0
Human Answer,28559249,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not fully specified; the paper indicates West Africa/Senegal involvement but does not provide a full country list for isolates.,1,No,1,No,1,Not reported,1
Human Answer,28559249,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not reported.,1,No,1,No,1,Not reported,1
Human Answer,28559249,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Some viral strains used in the study were derived from full-length molecular clones and site-directed/recombinant clones were constructed.,0,No,1,No,1,Not reported,1
Human Answer,28559249,9,Which HIV genes were reported to have been sequenced?,List,RT,,No,0,RT,1,Not reported,0,The paper does not report sequencing of genes; it reports analysis of reverse transcriptase (RT) (part of pol) mutations and states pol gene origin for one recombinant.,0,No,0,No,0,RT,1
Human Answer,28559249,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not reported — no sequencing methods are described in this paper.,1,No,1,No,1,Not reported,1
Human Answer,28559249,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not reported,1,"The study used viral isolates derived from patient samples (clinical isolates) and molecular clones; however, no sequencing of those samples is reported.",1,No,1,No,1,Not reported,1
Human Answer,28559249,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,Not applicable,1,"The paper used a recombinant clone derived from a patient receiving antiretroviral therapy (AZT, 3TC, ritonavir-boosted lopinavir), but it does not state sequencing was performed on that patient's virus within this report.",0,No,1,No,1,Yes,0
Human Answer,28559249,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,No indication that the patients providing isolates for this study were participants in a clinical trial.,0,No,1,No,1,Not reported,1
Human Answer,28559249,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Not applicable,0,"Yes — the paper includes a recombinant clone (4.7a) derived from a patient who had received ARV drugs (AZT, lamivudine/3TC, and ritonavir-boosted lopinavir), though sequence data are not presented in this paper.",0,No,0,No,0,Yes,1
Human Answer,28559249,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI",,NRTI,0,NRTI,0,,0,Nucleoside reverse transcriptase inhibitors (NRTIs) and a protease inhibitor (boosted lopinavir).,1,No,0,No,0,Not reported,0
Human Answer,28559249,16,Which drugs were received by individuals in the study before sample sequencing?,List,"AZT, 3TC, LPV",,No,0,No,0,Not applicable,0,"AZT (zidovudine), lamivudine (3TC), and ritonavir-boosted lopinavir.",1,No,0,No,0,Not reported,0
Human Answer,29373677,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,29373677,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,29373677,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported in the paper,0,Yes,0,No,1,No,1
Human Answer,29373677,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported,1,No,1,No,1,Not reported,1
Human Answer,29373677,5,How many individuals had samples obtained for HIV sequencing?,Number,1,,0,0,1,1,1,1,One individual (a single patient case),1,1,1,1,1,1,1
Human Answer,29373677,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not specified in the paper,1,No,1,No,1,Not reported,1
Human Answer,29373677,7,From what years were the sequenced samples obtained?,List,2008-2015,,2008-2015,1,No,0,2008–2014,0,"Samples and genotypic analyses relate to the period 2008–2015, with key events in 2014–2015 (dolutegravir introduced in 2014 and virological failure observed five months later).",1,No,0,No,0,Not reported,0
Human Answer,29373677,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No cloning prior to sequencing is described in the paper,1,No,1,No,1,Not reported,1
Human Answer,29373677,9,Which HIV genes were reported to have been sequenced?,List,IN,,"Integrase, IN",1,IN,1,IN,1,Integrase (IN) gene,1,"Integrase, IN",1,IN,1,IN,1
Human Answer,29373677,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,The paper does not specify a sequencing method; it refers to 'integrase genotypic analysis' on PBMC DNA and plasma RNA but gives no sequencing technique details.,1,No,1,No,1,Not reported,1
Human Answer,29373677,11,What type of samples were sequenced?,List,"PBMC, Plasma",,PBMC,0,"Plasma, PBMC",1,Plasma,0,DNA from PBMCs and plasma RNA,1,PBMC,0,PBMC,0,PBMC,0
Human Answer,29373677,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,29373677,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No, the report describes an individual patient case, not a clinical trial",1,No,1,No,1,Not reported,1
Human Answer,29373677,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,29373677,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"INSTI, NRTI",,"INSTI, NRTI",1,"NRTI, INSTI",1,"NRTI, INSTI",1,Integrase strand-transfer inhibitors (INSTIs) and nucleos(t)ide reverse transcriptase inhibitors (NRTIs),1,INSTI,0,INSTI,0,INSTI,0
Human Answer,29373677,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TFV, FTC, RAL, DTG",,"Raltegravir, Tenofovir, Emtricitabine",0,"Raltegravir (RAL), Tenofovir (TFV), Emtricitabine (FTC), Dolutegravir (DTG)",1,"Raltegravir, Tenofovir, Emtricitabine",0,"Raltegravir, tenofovir/emtricitabine (Truvada), and later dolutegravir (monotherapy)",1,"Dolutegravir (DTG), Raltegravir (RAL)",0,"Raltegravir, Dolutegravir",0,"Raltegravir, dolutegravir",0
Human Answer,30053052,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,30053052,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,30053052,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No GenBank accession numbers provided in the paper.,1,No,1,No,1,No,1
Human Answer,30053052,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,30053052,5,How many individuals had samples obtained for HIV sequencing?,Number,51,,51,1,51,1,24,0,51 samples were initially selected (42 therapy-naive and 9 treatment-failure); 27 replication-competent viruses were ultimately obtained (24 from treatment-naive and 3 from treatment-failure individuals).,1,51,1,51,1,51,1
Human Answer,30053052,6,From which countries were the sequenced samples obtained?,List,Sweden,,Sweden,1,Sweden,1,Sweden,1,"Sweden (samples from the HIV cohort at Karolinska University Hospital, Stockholm, Sweden).",1,Sweden,1,Sweden,1,Sweden,1
Human Answer,30053052,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Sampling years are not specified in the paper.,1,No,1,No,1,Not reported,1
Human Answer,30053052,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Yes,0,Yes. Patient-derived fragments were cloned (gag-pol into pNL43; RT subunits into expression vectors).,0,Yes,0,Yes,0,Not reported,1
Human Answer,30053052,9,Which HIV genes were reported to have been sequenced?,List,"Full length Genome, Gag, Pol, RT",,"Reverse transcriptase, RT",0,"Full length Genome, Gag, Pol, RT",1,Pol,0,gag-pol (HXB2: 0702-5798) including reverse transcriptase (RT); near full-length sequencing was also referenced.,0,Capsid,0,"Gag, Pol",0,"Gag, Pol",0
Human Answer,30053052,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,"A previously published near full-length sequencing protocol was used; viral RNA was extracted, PCR amplified and cloned (specific sequencing platform/technology is not stated).",0,No,1,No,1,Not reported,1
Human Answer,30053052,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma samples (viral RNA extracted from plasma).,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,30053052,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes. Sequences (viruses) were obtained from therapy-failure patients (3 viruses), and their drug resistance mutations are reported.",1,Yes,1,Yes,1,Yes,1
Human Answer,30053052,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,"No. Patients were sampled from an observational HIV cohort, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer,30053052,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. Sequences from individuals with virological treatment failure (indicating prior ARV exposure) were reported and mutations associated with ARV resistance are listed.,1,Yes,1,Yes,1,Yes,1
Human Answer,30053052,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI",0,No,1,Not reported,1,Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) (inferred from reported resistance mutations); specific classes beyond RT inhibitors are not detailed for patients.,0,"NNRTI, NRTI",0,"NRTI, NNRTI",0,Not reported,1
Human Answer,30053052,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Specific prior antiretroviral drugs received by individual patients are not reported in the paper; only resistance-associated mutations and genotype-based predicted resistance to drug names/classes are provided.,1,"Nevirapine, Efavirenz, Etravirine, Rilpivirine, Tenofovir alafenamide",0,"Tenofovir, Lamivudine, Nevirapine, Efavirenz, Etravirine, Rilpivirine",0,Not reported,1
Human Answer,30803972,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No — the paper does not report sequencing of patient-derived HIV sequences.,1,No,1,No,1,Yes,0
Human Answer,30803972,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,30803972,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report making sequences publicly available.,1,No,1,No,1,No,1
Human Answer,30803972,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,30803972,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,Not reported,1,Not applicable — no patient-derived sequencing was performed.,1,0,1,0,1,Not reported,1
Human Answer,30803972,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not Reported,1,Not applicable — no sequences were reported and no country-of-origin for sequenced samples is provided.,1,No,1,No,1,Not reported,1
Human Answer,30803972,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,"Not applicable — no sequencing was reported, so no sample years are provided.",1,No,1,No,1,Not reported,1
Human Answer,30803972,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not Reported,1,"Not applicable — sequencing was not performed; however, the study used molecular clones and constructed site-directed mutants.",1,No,1,No,1,Not reported,1
Human Answer,30803972,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,IN,0,Not applicable,1,No genes were reported as sequenced; the study focused on the integrase-encoding region (integrase in pol) for site-directed mutagenesis and phenotypic testing.,1,No,1,No,1,Integrase,0
Human Answer,30803972,10,What method was used for sequencing?,List,No,,No,1,No,1,Not Reported,1,Not applicable — the paper does not report any sequencing methods.,1,No,1,No,1,Not reported,1
Human Answer,30803972,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not Reported,1,Not applicable — no samples were sequenced in this study.,1,No,1,No,1,Plasma,0
Human Answer,30803972,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — the study did not obtain or report sequences from individuals with virological failure on treatment.,1,No,1,No,1,Not reported,1
Human Answer,30803972,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not Reported,1,"No — the paper reports in vitro experiments with virus isolates and clones, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer,30803972,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the isolates tested in this study were from ART-naive individuals.,1,No,1,No,1,Not reported,1
Human Answer,30803972,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,,0,Not applicable — individuals were ART-naive and no sequencing was performed.,1,INSTI,0,No,1,Not reported,1
Human Answer,30803972,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,None — the individuals were ART-naive; no sequencing was performed.,1,Bictegravir,0,No,1,Not reported,1
Human Answer,31988104,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,Yes,0,No,1,Yes.,0,No,1,Yes,0,Yes,0
Human Answer,31988104,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,31988104,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No evidence of public deposition is reported.,1,No,1,No,1,No,1
Human Answer,31988104,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,The paper does not report GenBank accession numbers for the study's sequenced HIV isolates.,1,No,1,No,1,Not reported,1
Human Answer,31988104,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,Not reported,1,14 patient-derived isolates were used.,0,0,1,0,1,Not reported,1
Human Answer,31988104,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not specified in the paper.,1,No,1,No,1,Not reported,1
Human Answer,31988104,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not specified in the paper.,1,No,1,No,1,Not reported,1
Human Answer,31988104,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Yes,0,"Yes, patient-derived fragments were cloned into plasmid backbones to create recombinant viruses.",0,No,1,No,1,Not reported,1
Human Answer,31988104,9,Which HIV genes were reported to have been sequenced?,List,RT,,No,0,RT,1,Not applicable,0,The reverse transcriptase (RT) region of the pol gene was targeted.,1,No,0,No,0,"Pol, RT",1
Human Answer,31988104,10,What method was used for sequencing?,List,No,,No,1,No,1,Not Reported,1,The sequencing method is not specified in the paper.,1,No,1,No,1,Sanger sequencing,0
Human Answer,31988104,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not Reported,1,Patient-derived clinical isolates from ART-experienced patients.,0,No,1,No,1,Plasma,0
Human Answer,31988104,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,Not specified.,0,No,1,No,1,Yes,0
Human Answer,31988104,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No—patient-derived isolates were used for in vitro experiments; clinical trials mentioned are separate referenced studies.,1,No,1,No,1,Not reported,1
Human Answer,31988104,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer,31988104,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not reported,1,NRTIs (nucleoside/nucleotide reverse transcriptase inhibitors) are implicated based on the mutations described.,0,"NRTI, NNRTI, PI, INSTI",0,No,1,"NRTI, NNRTI, INSTI",0
Human Answer,31988104,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not explicitly specified; mutations suggest prior exposure to thymidine analogs (e.g., zidovudine/stavudine) and lamivudine/emtricitabine.",0,"Abacavir (ABC), Zidovudine (AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir (EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,1,"TAF, TDF, AZT, FTC",0
Human Answer,32601157,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer,32601157,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,32601157,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (no public sequence accession information is provided),1,No,1,No,1,No,1
Human Answer,32601157,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported,1,No,1,No,1,Not reported,1
Human Answer,32601157,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,None (0 individuals),1,0,1,0,1,Not reported,1
Human Answer,32601157,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable / None reported,0,No,1,No,1,Not reported,1
Human Answer,32601157,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable / None reported,0,No,1,No,1,Not reported,1
Human Answer,32601157,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Yes (cloned as plasmid constructs prior to sequencing),0,No,1,No,1,No,1
Human Answer,32601157,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,Integrator (IN) coding sequence (HIV-1 integrase gene),0,No,1,No,1,IN,0
Human Answer,32601157,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not specified beyond 'sequencing' (method/platform not stated),0,No,1,No,1,Not reported,1
Human Answer,32601157,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Plasmid DNA constructs containing mutant IN coding sequences (cloned IN ORFs),0,No,1,No,1,Viral RNA,0
Human Answer,32601157,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,No,1
Human Answer,32601157,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No (no patients were enrolled; study used in vitro constructs),1,No,1,No,1,No,1
Human Answer,32601157,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,No,1
Human Answer,32601157,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable / None reported,0,INSTI,0,No,1,Not reported,1
Human Answer,32601157,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable / None reported,0,"Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,1,Not reported,1
Human Answer,33855437,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,33855437,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,33855437,3,Were sequences from the paper made publicly available?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,33855437,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,"MW484894, MW484895, MW484893, DQ380549, AF492618",,"MW484894, MW484895, MW484893, DQ380549, AF492618",1,"MW484894, MW484895, MW484893, DQ380549, AF492618, MW48492, AF324493",1,"MW484894, MW484895, MW484893, DQ380549, MW48492, AF324493",0,"MW484894, MW484895, MW484893, DQ380549, AF492618, MW48492 (as printed), AF324493 (pNL4.3)",0,"MW484894, MW484895, MW484893, DQ380549, AF492618, MW48492, AF324493",1,"MW484894, MW484895, MW484893, DQ380549, AF492618, MW48492, AF324493",1,"MW484894, MW484895, MW484893, DQ380549",0
Human Answer,33855437,5,How many individuals had samples obtained for HIV sequencing?,Number,6 or 7,,6,1,6,1,6,1,Six individuals (three subtype B and three non-B clinical isolates),0,6,1,0,0,6,1
Human Answer,33855437,6,From which countries were the sequenced samples obtained?,List,"Canada, Ethiopia",,"Canada, Ethiopia",1,"Canada, Ethiopia, United States",1,Ethiopia,0,Explicitly stated: Ethiopia (isolate 4742); others obtained from Clinique Actuel (location not specified in the paper) and from the National Institutes of Health (USA).,0,Ethiopia,0,"Canada, Ethiopia",1,Not Reported,0
Human Answer,33855437,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not reported in the paper.,1,No,1,No,1,Not Reported,1
Human Answer,33855437,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No evidence of cloning prior to sequencing; genotypic analyses were performed on viral RNA and amplified viruses from culture supernatants.,1,No,1,No,1,Not Reported,1
Human Answer,33855437,9,Which HIV genes were reported to have been sequenced?,List,RT,,No,0,RT,1,Not reported,0,The reverse transcriptase (RT) region (pol gene/RT) was sequenced or genotyped to monitor NNRTI/NRTI-associated mutations.,1,No,0,RT,1,"PR, RT",1
Human Answer,33855437,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,Not specified beyond 'genotypic analyses' of extracted viral RNA and re-genotyping; no sequencing platform or method (e.g. Sanger or NGS) is reported.,1,No,1,No,1,Not Reported,1
Human Answer,33855437,11,What type of samples were sequenced?,List,No,,PBMC,0,No,1,Plasma,0,Viral RNA from cultured virus—aliquots of cell culture supernatant from serially passaged patient-derived viral isolates (CBMC cultures) were used for genotypic analyses.,0,PBMC,0,No,1,Clinical isolates,0
Human Answer,33855437,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No clear evidence of sequences from individuals with virological failure; most isolates were from drug‑naive individuals, although one isolate (96USSN20) harboured baseline thymidine analogue mutations.",1,No,1,No,1,No,1
Human Answer,33855437,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1
Human Answer,33855437,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,"Mostly no — isolates were from drug‑naive individuals; however, one isolate (96USSN20) carried baseline thymidine analogue mutations consistent with prior NRTI exposure.",0,No,1,No,1,No,1
Human Answer,33855437,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,,0,Thymidine analogue NRTIs (inferred for isolate 96USSN20); most other individuals were drug‑naive and had not received ARVs.,0,NNRTI,0,No,1,Not Reported,1
Human Answer,33855437,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not specified by drug name; only thymidine-analogue resistance mutations (D67N, T69D, K70R) are reported for one isolate, indicating exposure to thymidine-analogue NRTIs, but specific drug names are not provided.",0,"Doravirine, Rilpivirine",0,No,1,Not Reported,1
Human Answer,34516245,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No.,1,No,1,No,1,Yes,0
Human Answer,34516245,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,34516245,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer,34516245,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,OK263149 to OK263162,,OK263149 to OK263162,1,OK263149 to OK263162,1,OK263149 to OK263162,1,OK263149 to OK263162.,1,No,0,OK263149 to OK263162,1,OK263149 to OK263162,1
Human Answer,34516245,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,Not reported,1,None (0 individuals); sequences were from laboratory virus stocks and culture supernatants.,1,0,1,0,1,Not reported,1
Human Answer,34516245,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not applicable — samples were laboratory-derived (no country of origin for patient samples reported).,1,No,1,No,1,Not reported,1
Human Answer,34516245,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not reported / not applicable.,1,No,1,No,1,Not reported,1
Human Answer,34516245,8,Were samples cloned prior to sequencing?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Not reported,0
Human Answer,34516245,9,Which HIV genes were reported to have been sequenced?,List,RT,,"Reverse transcriptase, RT",1,RT,1,RT,1,The full-length reverse transcriptase (RT) gene.,1,"Reverse transcriptase, RT",1,RT,1,RT,1
Human Answer,34516245,10,What method was used for sequencing?,List,No,,Sanger sequencing,0,Sanger sequencing,0,Not reported,1,"Population (double-stranded) sequencing of RT PCR products submitted to ACGT, Inc., and clonal sequencing of RT inserts after cloning into pGEM-T (Sanger-style sequencing).",0,No,1,Sanger sequencing,0,Not reported,1
Human Answer,34516245,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not reported,1,"Viral RNA purified from cell culture supernatants (passaged virus), converted to cDNA, PCR-amplified, and cloned PCR products.",0,No,1,No,1,Plasma/Serum,0
Human Answer,34516245,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,34516245,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No (no patients were involved).,1,No,1,No,1,Not reported,1
Human Answer,34516245,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,34516245,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not reported,1,Not applicable—there were no individual patients; the study used laboratory viral strains (no drug exposure history of patients).,1,NRTI,0,No,1,Not reported,1
Human Answer,34516245,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not applicable—no individuals received drugs; experimental viruses were exposed in vitro to EFdA and mutants were tested for susceptibility to EFdA, TDF, and FTC.",1,EFdA,0,No,1,Not reported,1
Human Answer,35730213,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,35730213,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,35730213,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,"NRTI, NNRTI",0,No,1,No (not applicable).,1,No,1,No,1,No,1
Human Answer,35730213,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported / Not applicable.,1,No,1,No,1,Not reported,1
Human Answer,35730213,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,None; the paper did not obtain samples for HIV sequencing.,1,0,1,0,1,1228,0
Human Answer,35730213,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed; the study was conducted in Lesotho.,1,No,1,No,1,Lesotho,0
Human Answer,35730213,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing; study enrolment and follow-up occurred in 2020–2021.,1,No,1,No,1,2020,0
Human Answer,35730213,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed.,1,No,1,No,1,Not reported,1
Human Answer,35730213,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,None — no HIV genes were reported as being sequenced.,1,No,1,No,1,Not reported,1
Human Answer,35730213,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing methods were reported.,1,No,1,No,1,Not reported,1
Human Answer,35730213,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no samples were sequenced. The study used questionnaire data and routine clinical measurements (including viral load data).,1,No,1,No,1,Plasma,0
Human Answer,35730213,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,"No — no sequences were obtained; additionally, virological failure was rare in this cohort.",1,No,1,No,1,No,1
Human Answer,35730213,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — they were enrolled in a prospective, registered cohort study (DO-REAL).",1,No,1,No,1,Yes,0
Human Answer,35730213,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,No,1,No,1,Yes,0
Human Answer,35730213,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NNRTI, INSTI",0,No,1,"NRTI, NNRTI",0,"The paper does not explicitly name drug classes; it reports specific drugs in prior regimens (TDF, 3TC, EFV).",0,"NNRTI, INSTI",0,No,1,"NNRTI, INSTI",0
Human Answer,35730213,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Efavirenz (EFV), Dolutegravir (DTG)",0,No,1,"TDF, 3TC, EFV, DTG",0,"Participants were receiving tenofovir disoproxil fumarate (TDF), lamivudine (3TC), and efavirenz (EFV) prior to switching to DTG-based therapy.",0,"EFV, DTG",0,No,1,"EFV, DTG",0
Human Answer,35913500,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,No,0,No,0,"No — the paper does not report HIV nucleotide sequences; it reports clinical resistance testing results (eg, an N155H mutation) but does not present sequence data.",0,No,0,No,0,Yes,1
Human Answer,35913500,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report any in vitro drug susceptibility assay data.,1,No,1,No,1,No,1
Human Answer,35913500,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not indicate that any sequences were deposited or made publicly available.,1,No,1,No,1,No,1
Human Answer,35913500,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported / not applicable.,1,No,1,No,1,Not reported,1
Human Answer,35913500,5,How many individuals had samples obtained for HIV sequencing?,Number,51,,0,0,0,0,0,0,Not specified / sequencing not reported; resistance testing was performed as clinically indicated and one baseline resistance mutation is reported.,0,0,0,0,0,Not reported,0
Human Answer,35913500,6,From which countries were the sequenced samples obtained?,List,US,,No,0,No,0,Not applicable,0,"Not applicable — no sequences were reported. The study population was from a single clinic in San Francisco, United States.",0,No,0,No,0,USA,0
Human Answer,35913500,7,From what years were the sequenced samples obtained?,List,2021-2022,,No,0,No,0,Not applicable,0,Not applicable — sequencing dates are not reported. Clinical activity and sample collection occurred between early 2021 and April 2022.,0,No,0,No,0,2021-2022,1
Human Answer,35913500,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / not reported — the paper does not describe any cloning or sequencing methods.,0,No,1,No,1,Not reported,1
Human Answer,35913500,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",,No,0,No,0,Not applicable,0,Not applicable — the paper does not report sequencing of genes; it discusses resistance mutations related to integrase and rilpivirine (NNRTI) without presenting gene sequence data.,0,No,0,No,0,"Pol, IN",0
Human Answer,35913500,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not reported / not applicable — the paper does not describe any sequencing methods.,0,No,1,No,1,Not reported,1
Human Answer,35913500,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — sequencing is not reported; however, the paper indicates blood work was obtained for resistance testing and viral load measurements (ie, plasma/blood samples).",0,No,1,No,1,"Plasma, PBMC",0
Human Answer,35913500,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,No,0,Not applicable,0,"The paper does not report sequences, but it does report resistance testing and a baseline N155H mutation in a patient with detectable viremia; resistance testing was planned for those with persistent detectable viral load.",0,No,0,No,0,Yes,1
Human Answer,35913500,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this was a demonstration project / observational program, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,35913500,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,No,0,Not applicable,0,"Not applicable — no sequences are reported. The study population included individuals with prior ART exposure and reported resistance mutations (eg, N155H) consistent with prior treatment.",0,No,0,No,0,Yes,1
Human Answer,35913500,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"The manuscript references nucleoside/nucleotide reverse transcriptase inhibitors (eg, tenofovir/emtricitabine), nonnucleoside reverse transcriptase inhibitors (rilpivirine-associated resistance), and integrase strand transfer inhibitors (INSTIs).",0,INSTI,0,No,1,"NRTI, NNRTI, PI, INSTI",0
Human Answer,35913500,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Specific drugs mentioned in the manuscript include tenofovir/emtricitabine (a NRTI combination) and references to rilpivirine (RPV) and cabotegravir (CAB) as the LAI regimen; no other individual prior ARV drugs are enumerated or sequencing-specific drug exposures reported.,0,CAB/RPV-LA,0,No,1,"Cabotegravir, Rilpivirine",0
Human Answer,35945163,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,No,0,Yes — the paper reports HIV resistance-associated mutations detected in patient samples.,1,No,0,No,0,Yes,1
Human Answer,35945163,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro phenotypic drug susceptibility data.,1,No,1,No,1,No,1
Human Answer,35945163,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not indicate that sequences were deposited or made publicly available.,1,No,1,No,1,No,1
Human Answer,35945163,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,35945163,5,How many individuals had samples obtained for HIV sequencing?,Number,6,,0,0,35,0,0,0,Not explicitly reported — the paper does not state the number of individuals who underwent sequencing.,0,0,0,0,0,35,0
Human Answer,35945163,6,From which countries were the sequenced samples obtained?,List,"UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, Spain",,No,0,No,0,Not applicable,0,"Samples (participants) were from the UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain.",1,No,0,No,0,"UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain",1
Human Answer,35945163,7,From what years were the sequenced samples obtained?,List,2016-2020,,No,0,2016-2020,1,Not applicable,0,From February 2016 through July 2020.,1,No,0,No,0,2016-2020,1
Human Answer,35945163,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported / No information provided.,0,No,1,No,1,Not reported,1
Human Answer,35945163,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",,No,0,No,0,Not applicable,0,Reverse transcriptase and integrase (mutations in reverse transcriptase/NNRTI-associated sites and integrase were reported).,1,No,0,No,0,Not reported,0
Human Answer,35945163,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not reported.,0,No,1,No,1,Not reported,1
Human Answer,35945163,11,What type of samples were sequenced?,List,Plasma,,No,0,No,0,Not applicable,0,"Not explicitly stated; resistance and viral load data were reported from plasma measurements, so sequencing likely used plasma-derived virus, but the sample type is not explicitly reported.",0,No,0,No,0,Not reported,0
Human Answer,35945163,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,Not applicable,1,Yes — sequences (resistance-associated mutations) were reported from individuals who stopped therapy because of incomplete virological response.,0,No,1,No,1,Yes,0
Human Answer,35945163,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — participants were enrolled in a compassionate use programme, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,35945163,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Not applicable,0,"Yes — many participants had prior ART exposure, and resistance mutations reported relate to prior or study treatment.",1,No,0,No,0,Yes,1
Human Answer,35945163,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"INSTI, NNRTI",,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,Not applicable,0,"Classes explicitly referenced include NNRTIs, integrase strand transfer inhibitors (INSTIs), protease inhibitors (boosted darunavir is mentioned), and nucleoside reverse transcriptase inhibitors (NRTIs).",0,"INSTI, NNRTI",1,No,0,"INSTI, NNRTI",1
Human Answer,35945163,16,Which drugs were received by individuals in the study before sample sequencing?,List,"CAB, RPV",,"cabotegravir, rilpivirine",1,"Cabotegravir (CAB), Rilpivirine (RPV), Darunavir (DRV), Tenofovir (TFV), Emtricitabine (FTC)",1,Not applicable,0,"Drugs specifically mentioned in the text include cobicistat-boosted darunavir, tenofovir alafenamide/emtricitabine, dolutegravir; the study drugs cabotegravir and rilpivirine were also administered as part of the compassionate use programme.",0,"Cabotegravir, Rilpivirine",1,No,0,"Cabotegravir, Rilpivirine",1
Human Answer,36415058,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer,36415058,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,36415058,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not applicable),1,No,1,No,1,Not Reported,1
Human Answer,36415058,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported / Not applicable,1,No,1,No,1,Not reported,1
Human Answer,36415058,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Zero (no samples were obtained for sequencing),1,0,1,0,1,486,0
Human Answer,36415058,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable / Not reported,1,No,1,No,1,Not Reported,1
Human Answer,36415058,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable / Not reported,1,No,1,No,1,2021,0
Human Answer,36415058,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / No cloning reported,1,No,1,No,1,Not Reported,1
Human Answer,36415058,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,None reported,1,No,1,No,1,Not Reported,1
Human Answer,36415058,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable / No sequencing method reported,1,No,1,No,1,Not Reported,1
Human Answer,36415058,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable / No samples sequenced,1,No,1,No,1,Plasma,0
Human Answer,36415058,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,Not Reported,1
Human Answer,36415058,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1
Human Answer,36415058,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,No,1
Human Answer,36415058,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Reported classes include NNRTIs, integrase strand transfer inhibitors (InSTIs), and protease inhibitors; however no sequencing occurred",0,"INSTI, NNRTI, PI",0,No,1,Not Reported,1
Human Answer,36415058,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Specific individual drug names are not reported; only drug classes (e.g., NNRTIs, InSTIs, protease inhibitors) and discussion of long ART exposure are provided",1,"Cabotegravir, Rilpivirine",0,No,1,Not Reported,1
Human Answer,36454248,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36454248,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,Yes,0,"No — the paper reports genotype-based predicted susceptibility, not in vitro phenotypic assays.",1,Yes,0,No,1,No,1
Human Answer,36454248,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36454248,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,OM201778 - OM201846,,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846.,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1,OM201778 -- OM201846,1
Human Answer,36454248,5,How many individuals had samples obtained for HIV sequencing?,Number,76,,76,1,76,1,76,1,76 individuals had plasma samples collected for sequencing; sequences were recovered from 67 of these.,1,76,1,67,0,76,1
Human Answer,36454248,6,From which countries were the sequenced samples obtained?,List,Panama,,Panama,1,Panama,1,Panama,1,Panama.,1,Panama,1,Panama,1,Panama,1
Human Answer,36454248,7,From what years were the sequenced samples obtained?,List,2018-2019,,2018-19,0,2018--2019,1,2018-2019,1,Samples were collected during 2018–2019.,1,2018-2019,1,2018-2019,1,2018-2019,1
Human Answer,36454248,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer,36454248,9,Which HIV genes were reported to have been sequenced?,List,Pol,,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"Protease (PR), reverse transcriptase (RT), and integrase (IN) regions of the pol gene.",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",0,"PR, RT, IN",0,"Pol (PR, RT, IN)",0
Human Answer,36454248,10,What method was used for sequencing?,List,No,,Sanger sequencing,0,Sanger sequencing,0,Not Reported,1,RT-PCR and nested PCR amplification of HIV-1 pol PCR amplicons which were purified and sequenced by Macrogen Inc.; sequences assembled and edited with Lasergene.,0,No,1,Sanger sequencing,0,Not reported,1
Human Answer,36454248,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma samples (HIV-1 RNA extracted from plasma).,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,36454248,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes; sequences were obtained from treated individuals who were in virological failure (VL >50 copies/mL).,1,Yes,1,Yes,1,Yes,1
Human Answer,36454248,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No; patients were under clinical follow-up/clinical monitoring, not enrolled in a clinical trial.",1,No,1,No,1,No,1
Human Answer,36454248,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36454248,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI",,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"Nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside RT inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs).",1,"NRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTIs, NNRTIs, PIs, INSTIs",0
Human Answer,36454248,16,Which drugs were received by individuals in the study before sample sequencing?,List,"3TC, AZT, LPV, EFV, RAL",,"Lamivudine, Zidovudine, Lopinavir/Ritonavir, Efavirenz",0,"Lamivudine (3TC), Zidovudine (AZT), Lopinavir (LPV), Ritonavir (RTV), Efavirenz (EFV), Darunavir (DRV), Raltegravir (RAL), Emtricitabine (FTC), Tenofovir (TFV), Dolutegravir (DTG), Abacavir (ABC), Etravirine (ETR), Rilpivirine (RPV), Nevirapine (NVP), Nelfinavir (NFV), Stavudine (D4T), Didanosine (DDI), Lamivudine (3TC), Zidovudine (ZDV), Doravirine (DOR), Bictegravir (BIC), Cabotegravir (CAB), Elvitegravir (EVG), Raltegravir (RAL)",1,"Lamivudine, Zidovudine, Lopinavir/Ritonavir, Efavirenz",0,"Reported drugs included lamivudine and zidovudine (often combined), lopinavir/ritonavir, efavirenz; tenofovir and emtricitabine (used in combinations), darunavir and raltegravir were used as rescue regimens; prophylaxis included zidovudine and zidovudine+lamivudine (and one case efavirenz+lamivudine).",0,"Lamivudine, Zidovudine, Lopinavir, Ritonavir, Raltegravir",0,"Lamivudine, Zidovudine, Lopinavir/ritonavir, Efavirenz, Raltegravir",1,"Lamivudine, zidovudine, lopinavir/ritonavir, efavirenz",0
Human Answer,36519389,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0
Human Answer,36519389,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report any in vitro drug susceptibility data.,1,No,1,No,1,No,1
Human Answer,36519389,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report any HIV sequences or state that sequences were made publicly available.,1,No,1,No,1,No,1
Human Answer,36519389,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported / Not applicable — no GenBank accession numbers are provided.,1,No,1,No,1,Not reported,1
Human Answer,36519389,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Not applicable / Not reported — the paper does not report any HIV sequencing or number of individuals sequenced.,0,0,1,0,1,172,0
Human Answer,36519389,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — no sequenced samples were reported. Study participants were from South Africa and several neighbouring countries (Zimbabwe, Malawi, Mozambique, and others).",1,South Africa,0,No,1,South Africa,0
Human Answer,36519389,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not applicable / Not reported — no sequencing was performed or dated. Enrollment occurred from July to November 2022.,1,2022,0,No,1,2022,0
Human Answer,36519389,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported / Not applicable — cloning prior to sequencing is not described.,0,No,1,No,1,Not reported,1
Human Answer,36519389,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable / Not reported — no HIV genes or sequencing targets are described.,1,No,1,No,1,Not reported,1
Human Answer,36519389,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable / Not reported — no sequencing methods are provided in the paper.,1,No,1,No,1,Not reported,1
Human Answer,36519389,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,"Not applicable / Not reported — no sequencing was performed, so no sample types for sequencing are given.",1,No,1,No,1,Plasma,0
Human Answer,36519389,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No sequences were reported. The paper does report virologic elevations in some participants but does not report sequencing from those individuals.,1,No,1,No,1,Yes,0
Human Answer,36519389,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — participants were part of the CHARACTERISE study and had previously been part of the randomized ADVANCE trial.,1,Yes,1,Yes,1,Yes,1
Human Answer,36519389,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the paper does not report HIV sequences. Participants had previously received antiretroviral regimens, but no sequences are presented.",1,Yes,0,No,1,Yes,0
Human Answer,36519389,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,NRTI,0,"Not applicable to sequencing (no sequences reported). The participants had received nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), a non-nucleoside reverse transcriptase inhibitor (NNRTI), and an integrase strand transfer inhibitor (INSTI).",1,"INSTI, NRTI, NNRTI",0,No,1,"NRTI, NNRTI, INSTI",0
Human Answer,36519389,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,"TAF, FTC, DTG, TDF, EFV",0,"Not applicable to sequencing (no sequences reported). Participants received tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), lamivudine (3TC), dolutegravir (DTG), and efavirenz (EFV).",1,"Dolutagravir (DTG), Emtricitabine (FTC), Tenofovir (TFV), Efavirenz (EFV)",0,No,1,"TDF, FTC, EFV, DTG",0
Human Answer,36571282,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36571282,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,36571282,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not publicly available).,1,No,1,No,1,No,1
Human Answer,36571282,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported.,1,No,1,No,1,Not reported,1
Human Answer,36571282,5,How many individuals had samples obtained for HIV sequencing?,Number,2705,,2705,1,2705,1,2705,1,"2,705 individuals.",1,2705,1,2705,1,2705,1
Human Answer,36571282,6,From which countries were the sequenced samples obtained?,List,"France, Greece, Italy, Portugal, Spain",,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, and Spain.",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, Spain",1,"France, Greece, Italy, Portugal, and Spain",1
Human Answer,36571282,7,From what years were the sequenced samples obtained?,List,2018-2021,,2018-2021,1,2018-2021,1,2018–2021,1,2018 through 2021.,1,2018-2021,1,2018-2021,1,2018-2021,1
Human Answer,36571282,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No indication that samples were cloned prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer,36571282,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",,"Integrase, IN",0,"RT, IN",1,IN,0,Integrase and reverse transcriptase (RT).,1,"Integrase, Reverse transcriptase",1,"RT, IN",1,Integrase,0
Human Answer,36571282,10,What method was used for sequencing?,List,"Sanger sequencing, NGS",,Sanger sequencing; Next-generation sequencing,0,Sanger sequencing; NGS,1,Sanger sequencing and NGS,1,Sanger sequencing and next-generation sequencing (NGS); for NGS a 20% consensus was generated.,1,"Sanger sequencing, Next-generation sequencing",0,NGS,0,Sanger sequencing and NGS,1
Human Answer,36571282,11,What type of samples were sequenced?,List,Plasma,,No,0,No,0,Not Reported,0,Not specified in the paper.,0,Plasma,1,No,0,Not reported,0
Human Answer,36571282,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,36571282,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer,36571282,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No.,1,Yes,0,No,1,No,1
Human Answer,36571282,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,,0,None; participants were ART-naive.,1,"NRTI, NNRTI, PI, INSTI",0,No,1,Not reported,1
Human Answer,36571282,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,None; participants were ART-naive and had not received antiretroviral drugs.,1,"Abacavir, Zidovudine, Zalcitabine, Didanosine, Lamivudine, Stavudine, Emtricitabine, Tenofovir, Nevirapine, Delavirdine, Efavirenz, Etravirine, Rilpivirine, Doravirine, Amprenavir, Lopinavir, Atazanavir, Derunavir, Raltegravir, Elvitegravir, Dolutagravir, Bictegravir, Cabotegravir, Lenacapavir",0,No,1,Not reported,1
Human Answer,36597160,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. The paper reports patient HIV genotypes (sequence-based resistance testing) obtained from patient samples.,1,No,0,No,0,Yes,1
Human Answer,36597160,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No. The paper does not report in vitro phenotypic drug susceptibility assays; it reports genotypic resistance testing only.,1,No,1,No,1,No,1
Human Answer,36597160,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No. The paper states that data will not be shared publicly.,1,No,1,No,1,No,1
Human Answer,36597160,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported. The paper does not provide any GenBank accession numbers.,1,No,1,No,1,Not reported,1
Human Answer,36597160,5,How many individuals had samples obtained for HIV sequencing?,Number,6,,6,1,6,1,382,0,"The paper reports 152 patients had a pre-switch HIV resistance genotype available, and genotypic resistance at the time of virologic failure was available for six patients.",0,0,0,0,0,382,0
Human Answer,36597160,6,From which countries were the sequenced samples obtained?,List,France,,No,0,France,1,France,1,France (patients were enrolled from clinical centers in the Paris area).,1,No,0,No,0,Not reported,0
Human Answer,36597160,7,From what years were the sequenced samples obtained?,List,2014,,No,0,2014,1,2014–2015,0,Samples (switches) were obtained between February 2014 and August 2015 (with follow-up over the subsequent 48 weeks).,0,No,0,No,0,2014-2015,0
Human Answer,36597160,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No. The paper reports Sanger (population) genotyping and does not mention cloning prior to sequencing.,1,No,1,No,1,Not reported,1
Human Answer,36597160,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",,"Integrase, NRTI",0,"PR, RT, IN",1,Not reported,0,Pol-region genes relevant to NRTI and integrase resistance—specifically reverse transcriptase (NRTI-associated mutations) and integrase (INSTI-associated mutations).,1,No,0,No,0,Pol,0
Human Answer,36597160,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing (genotypic resistance testing by Sanger).,1,No,0,No,0,Sanger sequencing,1
Human Answer,36597160,11,What type of samples were sequenced?,List,Plasma,,No,0,Plasma,1,Not reported,0,Plasma HIV-1 RNA (plasma samples) used for genotypic resistance testing in cases of virologic failure.,1,No,0,No,0,Plasma,1
Human Answer,36597160,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes. Genotypic resistance results at the time of virologic failure were obtained for six patients, and five of those had NRTI and INSTI resistance-associated mutations.",1,Yes,1,No,0,Yes,1
Human Answer,36597160,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No. The study was a retrospective multicenter observational (non-interventional) cohort study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,36597160,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. The cohort comprised ART-experienced patients and many had prior antiretroviral exposure; genotypes reported include pre-switch resistance profiles.,1,Yes,1,No,0,Yes,1
Human Answer,36597160,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI, NNRTI, INSTI",,"NRTI, PI, NNRTI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, PI, INSTI",0,"NRTIs (part of two-NRTI backbones), ritonavir-boosted protease inhibitors (PI/r), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs).",1,"NRTI, NNRTI, PI, INSTI",1,No,0,"NRTIs, NNRTIs, PIs",0
Human Answer,36597160,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF,FTC,EVG",,"Tenofovir disoproxil fumarate, Emtricitabine, Ritonavir-boosted Protease Inhibitors, NNRTIs, Integrase Inhibitors",0,No,0,"Ritonavir-boosted PI, NNRTI, INSTI",0,"The paper reports prior use of drug classes rather than many specific drug names: individuals were on two NRTIs (including agents associated with M184V and TDF resistance such as emtricitabine [FTC] and tenofovir disoproxil fumarate [TDF] as implied by resistance patterns) plus a third agent that was most commonly a ritonavir-boosted protease inhibitor, an NNRTI, or an INSTI. The regimen they switched to was elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF).",0,"Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate",0,No,0,"3TC, FTC, TDF",0
Human Answer,36645792,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes — the paper reports genotypic sequences from patient plasma (baseline GART performed and numbers of successful baseline GART reported).,1,No,0,Yes,1,Yes,1
Human Answer,36645792,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — the paper reports genotypic resistance testing and algorithmic drug susceptibility prediction, not in vitro phenotypic (laboratory) drug susceptibility assays.",1,No,1,No,1,No,1
Human Answer,36645792,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported — the paper does not state that sequences were deposited in a public database.,0,No,1,No,1,No,1
Human Answer,36645792,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,Not reported — no GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not reported,1
Human Answer,36645792,5,How many individuals had samples obtained for HIV sequencing?,Number,"120 * 76% = 95, or 120 or 129",,0,0,6,0,130,0,120 participants had successful baseline genotypic testing (successful baseline GART).,1,0,0,130,0,130,0
Human Answer,36645792,6,From which countries were the sequenced samples obtained?,List,South Africa,,No,0,South Africa,1,South Africa,1,South Africa.,1,No,0,South Africa,1,South Africa,1
Human Answer,36645792,7,From what years were the sequenced samples obtained?,List,No,,No,1,2020-2021,0,2020–2021,0,2020–2021 (participants recruited between 28 August 2020 and 10 November 2021).,0,No,1,2020-2021,0,2020-2021,0
Human Answer,36645792,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported — the paper does not mention cloning of samples prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer,36645792,9,Which HIV genes were reported to have been sequenced?,List,RT,,No,0,IN,0,Not applicable,0,"Regions relevant to NRTI and integrase resistance — i.e., reverse transcriptase (NRTI-associated mutations for tenofovir and lamivudine) and integrase (for dolutegravir) were assessed.",0,No,0,"PR, RT, IN",1,Pol,0
Human Answer,36645792,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,"The paper reports genotypic antiretroviral resistance testing (GART) performed at the National Health Laboratory Service Virology Laboratory and drug susceptibility prediction by the Stanford algorithm; the specific sequencing platform/method (e.g., Sanger or NGS) is not specified.",1,No,1,No,1,Not reported,1
Human Answer,36645792,11,What type of samples were sequenced?,List,Plasma,,No,0,Plasma,1,Plasma,1,Plasma samples collected at enrollment.,1,No,0,Plasma,1,Plasma,1
Human Answer,36645792,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — participants were enrolled because they had virologic failure on first-line tenofovir–emtricitabine (or lamivudine)–efavirenz, and baseline genotypes were obtained for these individuals.",1,Yes,1,Yes,1,Yes,1
Human Answer,36645792,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — this was a randomized, double-blind, placebo-controlled, phase 2 clinical trial (ARTIST), registered as NCT03991013.",1,Yes,1,Yes,1,Yes,1
Human Answer,36645792,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — sequences were obtained from individuals who had been on first-line antiretroviral therapy (tenofovir + emtricitabine/lamivudine + efavirenz) and were experiencing virologic failure.,1,Yes,1,Yes,1,Yes,1
Human Answer,36645792,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI",,NRTI,0,"NRTI, INSTI",0,"NRTI, NNRTI",1,Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and a nonnucleoside reverse transcriptase inhibitor (NNRTI).,1,"NRTI, NNRTI, INSTI",1,"NRTI, NNRTI",1,"NRTIs, NNRTIs",0
Human Answer,36645792,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, EFV",,"Tenofovir, Lamivudine, Efavirenz",1,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG)",0,"Tenofovir, Emtricitabine, Efavirenz",0,"Tenofovir, emtricitabine (or lamivudine), and efavirenz.",1,"Tenofovir, lamivudine, dolutegravir, efavirenz",1,"Tenofovir (TFV), Emtricitabine (FTC), Efavirenz (EFV)",0,"Tenofovir, emtricitabine, efavirenz",0
Human Answer,36659824,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,No,0,Yes,1,Yes — the paper reports that HIV resistance genotyping was performed on patient samples.,1,No,0,No,0,Yes,1
Human Answer,36659824,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro susceptibility testing of patient isolates; it only references a literature value for an in vitro protein-adjusted IC95.,1,No,1,No,1,No,1
Human Answer,36659824,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No — the paper does not state that HIV sequences or sequence accession numbers were deposited in a public database.,1,No,1,No,1,No,1
Human Answer,36659824,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported / Not provided in the paper.,1,No,1,No,1,Not reported,1
Human Answer,36659824,5,How many individuals had samples obtained for HIV sequencing?,Number,14,,0,0,0,0,112,0,Samples for genotyping were collected from the enrolled participants (118 participants were enrolled).,0,0,0,0,0,112,0
Human Answer,36659824,6,From which countries were the sequenced samples obtained?,List,France,,No,0,No,0,France,1,France.,1,No,0,No,0,France,1
Human Answer,36659824,7,From what years were the sequenced samples obtained?,List,2019-2020,,No,0,No,0,2019–2020,1,Samples were obtained between November 2019 and September 2020 (2019–2020).,1,No,0,No,0,2019-2020,1
Human Answer,36659824,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported / No indication of cloning prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer,36659824,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",,No,0,No,0,Not reported,0,At least reverse transcriptase and integrase regions are implicated (evidenced by detection of M184V in RT and E157Q in integrase).,1,No,0,No,0,Not reported,0
Human Answer,36659824,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,"Not specified — the paper refers to HIV resistance genotyping but does not describe the sequencing or genotyping method (e.g., Sanger or NGS).",1,No,1,No,1,Not reported,1
Human Answer,36659824,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not reported,1,"Blood-derived samples (baseline samples collected at the visit; plasma HIV-1 RNA was quantified), i.e. plasma/blood samples.",0,No,1,No,1,Plasma,0
Human Answer,36659824,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,No,0,No,0,Yes — resistance genotyping was performed for individuals with virological non-response and the paper reports that no emergent resistance-associated mutations were detected in those who did not achieve viral suppression.,1,No,0,No,0,Yes,1
Human Answer,36659824,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — this was a registered clinical study (a national, multicentre, prospective, open-label single-arm study) registered on ClinicalTrials.gov (NCT03858478).",1,Yes,1,Yes,1,Yes,1
Human Answer,36659824,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,No,0,No,0,No — the study population was ART-naive and pretreated individuals were protocol violations and excluded from the main ITT analysis; the paper does not report sequence data specifically from previously treated individuals.,0,No,0,No,0,No,0
Human Answer,36659824,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, INSTI",,No,0,No,0,,0,Not reported — the paper does not provide information on antiretroviral drug classes received prior to sequencing for any participants (the study enrolled ART‑naive patients).,0,No,0,No,0,"INSTI, NRTI",1
Human Answer,36659824,16,Which drugs were received by individuals in the study before sample sequencing?,List," BIC, FTC, TAF",,No,0,No,0,Not applicable,0,Not reported / None specified — the paper does not list any specific antiretroviral drugs received prior to sequencing.,0,No,0,No,0,"BIC, FTC, TAF",1
Human Answer,36660819,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,** No,0,Yes — the paper reports genotypic (sequence-based) resistance results from participant samples (resistance-associated mutations).,1,No,0,No,0,Yes,1
Human Answer,36660819,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,** No,1,No — the provided content does not present in vitro drug susceptibility (phenotypic) data or susceptibility assay results.,1,No,1,No,1,No,1
Human Answer,36660819,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,** No,1,No — the provided paper content does not indicate that sequence data were deposited in a public database; data are available on request to the management group.,1,No,1,No,1,No,1
Human Answer,36660819,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,** Not reported,1,None reported in the provided paper content.,1,No,1,No,1,Not reported,1
Human Answer,36660819,5,How many individuals had samples obtained for HIV sequencing?,Number,8 and 10,,0,0,1045,0,** Not reported,0,The paper reports sequencing/genotypic results for participants with confirmed virologic failure — 14 participants with CVF through week 152.,0,0,0,0,0,1045,0
Human Answer,36660819,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,** Not reported,1,Not specified in the provided content.,1,No,1,No,1,Not reported,1
Human Answer,36660819,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,** Not reported,1,Not specified in the provided content (only study timepoints such as week 152 are given).,1,No,1,No,1,Not reported,1
Human Answer,36660819,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,** Not applicable,1,Not reported in the provided content.,0,No,1,No,1,Not reported,1
Human Answer,36660819,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",,No,0,"PR, RT, IN",1,** Not applicable,0,"Reverse transcriptase (RT, associated with rilpivirine resistance) and integrase (INSTI) genes were implicated by the reported resistance mutations.",1,No,0,No,0,Not reported,0
Human Answer,36660819,10,What method was used for sequencing?,List,No,,No,1,No,1,** Not applicable,1,Not reported in the provided content.,1,No,1,No,1,Not reported,1
Human Answer,36660819,11,What type of samples were sequenced?,List,No,,No,1,PBMC,0,** Not reported,1,Peripheral blood mononuclear cells (baseline PBMCs) and samples from suspected virologic failure (SVF) were used for detection of resistance mutations.,0,No,1,No,1,Plasma,0
Human Answer,36660819,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,** Not applicable,0,Yes — sequences (genotypic resistance data) were obtained from individuals with confirmed virologic failure (CVF) and from suspected virologic failure samples.,1,No,0,No,0,Yes,1
Human Answer,36660819,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,** Yes,1,"Yes — patients were participants in the phase 3b randomized, open-label ATLAS-2M clinical trial.",1,Yes,1,No,0,Yes,1
Human Answer,36660819,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,** Yes,1,"Yes — the study included participants with prior CAB+RPV exposure, and baseline pro-viral RPV resistance-associated mutations were assessed.",1,No,0,No,0,Yes,1
Human Answer,36660819,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NNRTI, INSTI",,No,0,"NRTI, NNRTI, INSTI",1,"** ART-experienced (CAB, RPV)",0,Integrase strand transfer inhibitors (INSTIs) — cabotegravir — and non-nucleoside reverse transcriptase inhibitors (NNRTIs) — rilpivirine — were received by participants prior to sequencing.,1,"INSTI, NNRTI",1,No,0,"NRTIs, INSTIs",0
Human Answer,36660819,16,Which drugs were received by individuals in the study before sample sequencing?,List,"CAB, RPV",,No,0,"CAB, RPV",1,"** CAB, RPV",1,Cabotegravir (CAB) and rilpivirine (RPV) were received by participants prior to the sequencing of resistance mutations.,1,"Cabotegravir (CAB), Rilpivirine (RPV)",1,No,0,"Cabotegravir, rilpivirine",1
Human Answer,36694270,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36694270,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — only genotypic resistance analysis was reported, not in vitro phenotypic susceptibility testing.",1,No,1,No,1,No,1
Human Answer,36694270,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No clear public sequence repository accession information is provided.,1,No,1,No,1,No,1
Human Answer,36694270,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,36694270,5,How many individuals had samples obtained for HIV sequencing?,Number,62,,62,1,62,1,62,1,62 individuals.,1,62,1,62,1,62,1
Human Answer,36694270,6,From which countries were the sequenced samples obtained?,List,China,,China,1,China,1,China,1,China.,1,China,1,China,1,China,1
Human Answer,36694270,7,From what years were the sequenced samples obtained?,List,2019-2022,,2019-2022,1,2019-2022,1,2019–2022,1,June 2020 to June 2022.,0,2019-2022,1,2019-2022,1,2020-2022,0
Human Answer,36694270,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — cloning is not described; PCR products were directly sequenced.,1,No,1,No,1,Not reported,1
Human Answer,36694270,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease, reverse transcriptase, and integrase.",1,"Protease, Reverse transcriptase, Integrase",1,"PR, RT, IN",1,"Protease, reverse transcriptase, and integrase",1
Human Answer,36694270,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Nested PCR,0,One-step RT-PCR followed by nested PCR (nested PCR amplification of viral RNA) and sequencing of the PCR products; specific sequencing platform is not specified.,0,Sanger sequencing,1,No,0,Not reported,0
Human Answer,36694270,11,What type of samples were sequenced?,List,"Plasma, CSF",,Plasma; Other,0,"CSF, Plasma",1,"CSF, Plasma",1,Matched cerebrospinal fluid (CSF) and plasma samples.,1,"CSF, Plasma",1,"CSF, Plasma",1,CSF and plasma,1
Human Answer,36694270,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,Yes,0,Not explicitly reported / Not stated.,0,No,1,Yes,0,Yes,0
Human Answer,36694270,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,No,0,No,0,No,0,No — this was a retrospective observational study of patients admitted to a hospital.,0,No,0,No,0,Not reported,0
Human Answer,36694270,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36694270,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,NRTI; NNRTI,0,NRTI,0,NRTI,0,"NRTIs (mainly), NNRTIs and PIs (patients received regimens including NRTI, NNRTI, and PI classes).",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,NRTIs,0
Human Answer,36694270,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,3TC; TDF,0,No,1,Not reported,1,"Specific drugs mentioned in the manuscript include NRTIs 3TC and TDF, the NNRTI efavirenz (EFV), and the protease inhibitor lopinavir/ritonavir (LPV/r).",0,"3TC, TDF, EFV, LPV/r",0,No,1,"3TC, TDF",0
Human Answer,36706364,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer,36706364,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,36706364,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported).,1,No,1,No,1,No,1
Human Answer,36706364,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,36706364,5,How many individuals had samples obtained for HIV sequencing?,Number,62 or 3,,0,0,0,0,62,1,"56 participants had resistance results reported (baseline genotyping performed for all 62 participants retrospectively, but results are reported for 56).",0,62,1,0,0,62,1
Human Answer,36706364,6,From which countries were the sequenced samples obtained?,List,South Africa,,South Africa,1,South Africa,1,South Africa,1,South Africa.,1,South Africa,1,No,0,South Africa,1
Human Answer,36706364,7,From what years were the sequenced samples obtained?,List,No,,No,1,2019-2020,0,2019–2020,0,Samples were from participants enrolled between August 2019 and July 2020.,0,2019-2020,0,No,1,2019-2020,0
Human Answer,36706364,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No (not reported).,1,No,1,No,1,No,1
Human Answer,36706364,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",,No,0,No,0,Not applicable,0,Reverse transcriptase (RT) and integrase regions (RT mutations K65R and M184V/I reported; integrase resistance assessed and not detected).,1,No,0,No,0,"Pol, IN",0
Human Answer,36706364,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,The paper reports genotypic resistance testing but does not specify the sequencing method or platform.,1,No,1,No,1,Not reported,1
Human Answer,36706364,11,What type of samples were sequenced?,List,Plasma,,No,0,Plasma,1,Not reported,0,Viral load specimens (plasma) associated with elevated VL; genotypic resistance testing was performed on samples with VL >500 copies/mL and on baseline samples.,1,No,0,No,0,Plasma,1
Human Answer,36706364,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,Yes,1,No,0,Yes,1
Human Answer,36706364,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36706364,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,Yes,1,No,0,Yes,1
Human Answer,36706364,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, INSTI",,"NRTI, NNRTI",0,"NRTI, NNRTI",0,NRTI,0,Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).,0,"NRTI, NNRTI",0,No,0,"NRTI, NNRTI, INSTI",1
Human Answer,36706364,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, FTC, EFV, NVP, DTG",,"Tenofovir, Lamivudine, Emtricitabine, NNRTI (Efavirenz or Nevirapine)",0,"Tenofovir (TFV), Lamivudine (3TC), Emtricitabine (FTC), Efavirenz (EFV), Nevirapine (NVP), Dolutegravir (DTG)",1,"Tenofovir, Lamivudine, Emtricitabine",0,"Tenofovir, lamivudine or emtricitabine (XTC), and efavirenz or nevirapine.",0,"Tenofovir, lamivudine/emtricitabine, efavirenz, nevirapine",0,No,0,"Tenofovir, lamivudine, efavirenz, dolutegravir",0
Human Answer,36738248,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36738248,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1
Human Answer,36738248,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,Not reported,1,Not reported as publicly deposited; sequences were stored in internal databases (SwissHIVGenomeDB and SHCS Drug Resistance Database).,1,No,1,No,1,Not Reported,1
Human Answer,36738248,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not Reported,1
Human Answer,36738248,5,How many individuals had samples obtained for HIV sequencing?,Number,527,,527,1,527,1,527,1,527 individuals contributed the 594 SS/NGS sample pairs included in the analysis.,1,527,1,527,1,527,1
Human Answer,36738248,6,From which countries were the sequenced samples obtained?,List,Switzerland,,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1,Switzerland,1
Human Answer,36738248,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not specifically reported; counts and cohort status are given 'as of August 2021' but specific sample collection years are not detailed.,1,2002-2021,0,No,1,Not Reported,1
Human Answer,36738248,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No — cloning prior to sequencing is not described.,1,No,1,No,1,Not Reported,1
Human Answer,36738248,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"pol region (protease [PR], reverse transcriptase [RT], and integrase [IN]); NGS also produced near-whole-genome reads.",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN, Near full length genome",0,Pol,0
Human Answer,36738248,10,What method was used for sequencing?,List,"Sanger sequencing, NGS",,Illumina sequencing,0,Sanger sequencing; NGS,1,Sanger and NGS,0,Sanger sequencing (SS) and Illumina next-generation sequencing (MiSeq or HiSeq) were used.,1,Illumina sequencing,0,Sanger sequencing; Illumina sequencing,0,Sanger sequencing and next-generation sequencing (NGS),0
Human Answer,36738248,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma (viral RNA from blood/plasma samples) was sequenced.,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,36738248,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not reported,1,Not explicitly reported; virological failure status is not described.,0,Yes,0,No,1,Yes,0
Human Answer,36738248,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,"No — patients were enrolled in observational cohort studies (SHCS and ZPHI), not a clinical trial.",1,No,1,No,1,Not Reported,1
Human Answer,36738248,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36738248,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI, PI",0,No,1,Not reported,1,"Protease inhibitors (PIs), nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs), non-nucleoside reverse-transcriptase inhibitors (NNRTIs), and integrase inhibitors (INSTIs) are referenced.",0,"NRTI, NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI",0,Not Reported,1
Human Answer,36738248,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Specific individual ARV drug names received by participants are not listed in the manuscript text.,1,"Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,1,Not Reported,1
Human Answer,36751650,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,** Yes.,1,Yes.,1,Yes,1,Yes,1,Yes.,1
Human Answer,36751650,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,** No.,1,No.,1,No,1,No,1,No.,1
Human Answer,36751650,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,** No.,1,Not reported / No evidence of public deposition in the paper.,0,No,1,No,1,No.,1
Human Answer,36751650,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,** Not reported.,1,Not reported.,1,No,1,No,1,Not reported.,1
Human Answer,36751650,5,How many individuals had samples obtained for HIV sequencing?,Number,1653,,1653,1,1653,1,** 1653.,1,1653 individuals (samples) were sequenced.,1,1653,1,1653,1,1653.,1
Human Answer,36751650,6,From which countries were the sequenced samples obtained?,List,China,,China,1,China,1,** China.,1,"China (Guangxi, China).",1,China,1,China,1,China.,1
Human Answer,36751650,7,From what years were the sequenced samples obtained?,List,2016-2020,,2016-2020,1,2016-2020,1,** 2016–2020.,1,From January 2016 to December 2020 (2016–2020).,1,2016-2020,1,2016-2020,1,2016-2020.,1
Human Answer,36751650,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,** No.,1,No (no cloning step described).,1,No,1,No,1,Not reported.,1
Human Answer,36751650,9,Which HIV genes were reported to have been sequenced?,List,Pol,,"Protease, RT",0,"PR, RT",0,** Pol.,1,A fragment of the pol gene (encoding protease and the first 299 residues of reverse transcriptase).,1,"Protease, Reverse transcriptase",0,"PR, RT",0,Pol.,1
Human Answer,36751650,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,** Sanger sequencing.,1,Sanger sequencing of nested PCR products.,1,No,0,Sanger sequencing,1,Sanger sequencing.,1
Human Answer,36751650,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,** Plasma.,1,Plasma-derived viral RNA from peripheral blood samples.,1,Plasma,1,Plasma,1,Plasma.,1
Human Answer,36751650,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,** No.,1,No.,1,No,1,No,1,No.,1
Human Answer,36751650,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,** No.,1,No (they were recruited from voluntary counseling and testing centers; no clinical trial is reported).,1,No,1,No,1,Not reported.,1
Human Answer,36751650,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,** No.,1,No.,1,No,1,No,1,Yes.,0
Human Answer,36751650,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI, PI, INSTI",0,No,1,** None.,1,None; participants had not received antiretroviral therapy.,1,"NNRTI, PI, NRTI",0,No,1,"NNRTI, PI, INSTI, NRTI.",0
Human Answer,36751650,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,** Not applicable.,1,None; no antiretroviral drugs were received prior to sequencing.,1,"Fosamprenavir, Nelfinavir, Tipranavir, Abacavir, Zidovudine, Stavudine, Emtricitabine, Lamivudine, Tenofovir disoproxil fumarate, Doravirine, Efavirenz, Etravirine, Nevirapine, Rilpivirine, Bictegravir, Dolutegravir, Elvitegravir, Raltegravir",0,No,1,Not reported.,1
Human Answer,36779485,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36779485,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No (the paper reports genotypic predictions rather than in vitro phenotypic susceptibility assays).,1,No,1,No,1,No,1
Human Answer,36779485,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / not specified in this paper.,0,No,1,No,1,Yes,0
Human Answer,36779485,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,36779485,5,How many individuals had samples obtained for HIV sequencing?,Number,1649,,1649,1,1649,1,1649,1,Genotypic sequence data were reported from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure (total 1649 individuals).,1,1649,1,1649,1,1649 (277 + 1372),0
Human Answer,36779485,6,From which countries were the sequenced samples obtained?,List,South Africa,,South Africa,1,South Africa,1,South Africa,1,South Africa.,1,South Africa,1,South Africa,1,South Africa,1
Human Answer,36779485,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not specified in this paper.,1,No,1,No,1,Not reported,1
Human Answer,36779485,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported / no indication that samples were cloned prior to sequencing.,1,No,1,No,1,Not reported,1
Human Answer,36779485,9,Which HIV genes were reported to have been sequenced?,List,Pol,,"Reverse transcriptase, RT",0,Pol,1,Not reported,0,pol (HIV pol gene).,1,"Protease, Reverse transcriptase, Integrase",0,"PR, RT, IN",0,Pol,1
Human Answer,36779485,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,Not specified in this paper (referred to as genotypic sequence data; methods described previously).,1,No,1,No,1,Not reported,1
Human Answer,36779485,11,What type of samples were sequenced?,List,Plasma,,No,0,No,0,Not reported,0,"Not explicitly specified (sequences derive from viremic patients, including those failing NNRTI-based ART).",0,Plasma,1,No,0,Not reported,0
Human Answer,36779485,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36779485,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No; this was a retrospective analysis of a South African cohort, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer,36779485,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes; sequences include individuals failing NNRTI-based ART who had prior ARV exposure.,1,Yes,1,Yes,1,Yes,1
Human Answer,36779485,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI",,NNRTI,0,"NRTI, NNRTI",1,Not reported,0,Non-nucleoside reverse transcriptase inhibitors (NNRTIs) — specifically patients failing NNRTI-based ART.,0,NNRTI,0,NNRTI,0,NNRTI,0
Human Answer,36779485,16,Which drugs were received by individuals in the study before sample sequencing?,List,RPV,,Rilpivirine,1,Rilpivirine,1,Not applicable,0,Specific drug names are not reported in this paper; only that patients were on NNRTI-based regimens.,0,Rilpivirine,1,NNRTI,0,Not reported,0
Human Answer,36795586,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,36795586,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,36795586,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — no sequence data were reported or made available.,1,No,1,No,1,No,1
Human Answer,36795586,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported / Not applicable.,1,No,1,No,1,Not reported,1
Human Answer,36795586,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Not reported / Not specified.,0,0,1,0,1,9419,0
Human Answer,36795586,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,"Not reported; study COEs were located in Botswana, Eswatini, Lesotho, Malawi, Tanzania (Mbeya and Mwanza) and Uganda.",1,"Botswana, Eswatini, Lesotho, Malawi, Tanzania, Uganda",0,No,1,"Botswana, Eswatini, Lesotho, Malawi, Tanzania, Uganda",0
Human Answer,36795586,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not reported; the study period was January 2017 to December 2020.,1,2017-2020,0,No,1,2017-2020,0
Human Answer,36795586,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported / No information provided.,1,No,1,No,1,Not reported,1
Human Answer,36795586,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,Not reported / Not specified.,1,No,1,No,1,Not reported,1
Human Answer,36795586,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not reported / Not specified.,1,No,1,No,1,Not reported,1
Human Answer,36795586,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not reported / Not specified.,1,No,1,No,1,Plasma,0
Human Answer,36795586,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,Yes — targeted HIV genotype testing was sporadically available for CALHIV failing second-line ART.,0,No,1,No,1,Yes,0
Human Answer,36795586,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this was a retrospective cohort (real-world) study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,36795586,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No sequences are reported; however, genotype testing was sporadically performed on ART-experienced (failing second-line) individuals.",1,Yes,0,No,1,Yes,0
Human Answer,36795586,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI, PI",0,No,1,Not applicable,1,"Nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).",0,"INSTI (Integrase Inhibitor), including Dolutagravir (DTG)",0,No,1,Not reported,1
Human Answer,36795586,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Abacavir, tenofovir, zidovudine (as NRTI backbones), lamivudine (as part of TLD), and patients previously received NNRTI- and PI-based regimens (specific NNRTI/PI drugs not detailed).",0,Dolutagravir (DTG),0,No,1,Not reported,1
Human Answer,36851704,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36851704,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No; the paper reports genotypic resistance predictions from sequences, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer,36851704,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report public sequence deposition; data are available on request from the corresponding author.,1,No,1,No,1,No,1
Human Answer,36851704,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,36851704,5,How many individuals had samples obtained for HIV sequencing?,Number,206,,206,1,206,1,206,1,206 individuals had samples obtained; genotyping success rates were 204/206 for protease and reverse transcriptase and 205/206 for integrase.,1,206,1,206,1,206,1
Human Answer,36851704,6,From which countries were the sequenced samples obtained?,List,Uruguay,,Uruguay,1,Uruguay,1,Uruguay,1,Samples were obtained from participants in Uruguay; plasma specimens were shipped to Mexico for testing.,1,Uruguay,1,Uruguay,1,Uruguay,1
Human Answer,36851704,7,From what years were the sequenced samples obtained?,List,2018-2019,,2018-2019,1,2018-2019,1,2018–2019,1,Samples were obtained from October 2018 to October 2019.,1,2018-2019,1,2018-2019,1,2018-2019,1
Human Answer,36851704,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — samples were PCR amplified and Sanger sequenced; cloning is not described.,1,No,1,No,1,Not reported,1
Human Answer,36851704,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"Protease, Reverse transcriptase, Integrase",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease, reverse transcriptase, and integrase genes were sequenced.",1,"Protease, Reverse transcriptase, Integrase",1,"PR, RT, IN",1,"Protease, reverse transcriptase, and integrase",1
Human Answer,36851704,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing was used (performed on an Applied Biosystems 3730xl Genetic Analyser).,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,36851704,11,What type of samples were sequenced?,List,Whole Blood,,Whole Blood,1,Plasma,0,Plasma,0,Plasma specimens (HIV RNA extracted from 1 mL of plasma) derived from whole blood were sequenced.,0,Plasma,0,Plasma,0,Plasma,0
Human Answer,36851704,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,No,1,No — participants were adults initiating or reinitiating ART (not described as experiencing on-treatment virological failure); all had viral load >1000 copies/mL at enrolment.,1,No,1,No,1,Yes,0
Human Answer,36851704,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the study was a nationally representative cross-sectional survey, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer,36851704,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — 35.6% of participants reported previous exposure to antiretroviral drugs, and sequences include participants with and without prior exposure.",1,Yes,1,Yes,1,Yes,1
Human Answer,36851704,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI",,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,Not reported,0,"The paper does not provide a comprehensive list of ARV drug classes previously received; prior exposures are described as prior ART (unspecified), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), and prevention of mother-to-child transmission (PMTCT). It also notes that those with INSTI resistance did not report receiving INSTI-based ART.",0,"NRTI, NNRTI, PI, INSTI",1,No,0,NNRTI,0
Human Answer,36851704,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Efavirenz (EFV), Nevirapine (NVP), Tenofovir disoproxil fumarate (TDF)",0,"TDF, FTC, 3TC, DTG, ATV/r, LPV/r",0,Not applicable,1,"The paper does not list specific drug names received prior to sequencing; it classifies prior exposures (prior ART, PrEP, PEP, PMTCT) but does not provide a comprehensive list of specific drugs administered before sampling.",1,"Abacavir, Zidovudine, Lamivudine, Emtricitabine, Tenofovir, Nevirapine, Efavirenz, Raltegravir, Elvitegravir, Dolutagravir",0,No,1,Not reported,1
Human Answer,36851760,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36851760,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — only genotypic (sequence-based) resistance analysis was reported; no phenotypic in vitro susceptibility assays are described.,1,No,1,No,1,No,1
Human Answer,36851760,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36851760,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,OQ435656-OQ435729,,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656–OQ435729.,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1,OQ435656-OQ435729,1
Human Answer,36851760,5,How many individuals had samples obtained for HIV sequencing?,Number,107,,107,1,107,1,107,1,DBSs were obtained from 107 HIV-1-infected children; sequencing was successful for 75 of those samples.,1,107,1,107,1,107,1
Human Answer,36851760,6,From which countries were the sequenced samples obtained?,List,"Mali, Benin",,"Mali, Benin",1,"Benin, Mali",1,"Mali, Benin",1,Benin and Mali.,1,"Benin, Mali",1,"Benin, Mali",1,"Mali, Benin",1
Human Answer,36851760,7,From what years were the sequenced samples obtained?,List,2015-2020,,2015-2020,1,2015-2020,1,2015–2020,1,"Samples were collected between 2015–2016 (Benin, ART-treated children) and 2018–2020 (Mali, ART-naïve children).",1,"2015-2016, 2018-2020",0,"2015-2016, 2018-2020",0,2015-2020,1
Human Answer,36851760,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No evidence of cloning; samples were amplified by RT-PCR and nested PCR and directly Sanger-sequenced.,1,No,1,No,1,Not Reported,1
Human Answer,36851760,9,Which HIV genes were reported to have been sequenced?,List,IN,,"Integrase, IN",1,IN,1,IN,1,The integrase gene of HIV-1.,1,Integrase,1,IN,1,IN,1
Human Answer,36851760,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing following RT-PCR and nested PCR.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,36851760,11,What type of samples were sequenced?,List,DBS,,Other,0,DBS,1,DBS,1,Dried blood spots (DBSs) collected on Whatman 903 filter paper.,1,DBS,1,DBS,1,DBS,1
Human Answer,36851760,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — sequences include samples from ART-treated children with virological failure.,1,Yes,1,Yes,1,Yes,1
Human Answer,36851760,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No indication that patients were enrolled in a clinical trial; samples were collected during a study and routine early diagnosis/follow-up activities.,1,No,1,No,1,Not Reported,1
Human Answer,36851760,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36851760,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NNRTI, NRTI, PI",,"NNRTI, NRTI, PI",1,"NRTI, NNRTI, PI",1,NNRTI,0,Primarily non-nucleoside reverse transcriptase inhibitors (NNRTIs); some received nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs) in combination.,1,"NRTI, NNRTI, PI",1,No,0,"NNRTI, NRTI, PI",1
Human Answer,36851760,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not reported,1,"The paper reports ART regimens by drug class (NNRTIs, NRTIs, PIs) but does not list specific drug names for the participants; all children were INI‑naïve.",1,"Abacavir, Zidovudine, Zalcitabine, Didanosine, Lamivudine, Stavudine, Emtricitabine, Tenofovir, Nevirapine, Delavirdine, Efavirenz, Etravirine, Rilpivirine, Doravirine, Amprenavir, Lopinavir, Atazanavir, Derunavir, Nelfinavir, Raltegravir, Elvitegravir, Dolutagravir, Bictegravir, cabotagravir, Lenacapavir",0,No,1,Not Reported,1
Human Answer,36920025,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer,36920025,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36920025,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,36920025,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,"FJ800379–FJ800386, GQ477441-GQ477451",0
Human Answer,36920025,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,Not reported,1,None (no human individuals); sequencing was performed on laboratory virus cultures.,1,0,1,0,1,Not reported,1
Human Answer,36920025,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not applicable / not reported (samples were laboratory-derived).,1,No,1,No,1,Not reported,1
Human Answer,36920025,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not reported / not applicable,1,No,1,No,1,Not reported,1
Human Answer,36920025,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,"Yes; PCR products were either directly sequenced or cloned prior to sequencing, and Primer ID NGS was also used.",0,No,1,No,1,Yes,0
Human Answer,36920025,9,Which HIV genes were reported to have been sequenced?,List,PR,,No,0,PR,1,"PR, Gag",1,The protease coding domain (PR) and Gag protease cleavage sites were sequenced.,1,Protease,1,PR,1,Pol,0
Human Answer,36920025,10,What method was used for sequencing?,List,Illumina sequencing,,Illumina sequencing,1,NGS,0,NGS,0,Next-generation sequencing using Primer ID on the Illumina MiSeq (300 bp paired-end) and Sanger/clone-based sequencing of PCR products.,1,Illumina sequencing,1,Illumina sequencing,1,Sanger sequencing,0
Human Answer,36920025,11,What type of samples were sequenced?,List,No,,No,1,No,1,Plasma,0,Viral RNA (for Primer-ID MiSeq libraries) and total cellular DNA from infected cell pellets (PCR-amplified protease coding region); PCR products were sometimes cloned prior to sequencing.,0,Plasma,0,Cell culture,0,Plasma,0
Human Answer,36920025,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer,36920025,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer,36920025,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,Yes,0
Human Answer,36920025,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable; no individuals contributed samples (laboratory viruses only).,1,No,1,No,1,"NRTI, PI, INSTI",0
Human Answer,36920025,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable; no human individuals received drugs for this study.,1,No,1,No,1,"Darunavir, Raltegravir",0
Human Answer,36931676,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes.,1,Yes.,1,No,0,No,0,Yes,1
Human Answer,36931676,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No.,1,No — the paper reports predicted phenotypic sensitivity but does not report in vitro phenotypic susceptibility assays.,1,No,1,No,1,No,1
Human Answer,36931676,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No.,1,No — the paper does not state that sequences were made publicly available; data are available only upon reasonable request.,1,No,1,No,1,No,1
Human Answer,36931676,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported.,1,None reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,36931676,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,Not reported.,1,Not specified in the paper.,0,0,1,0,1,Not reported,1
Human Answer,36931676,6,From which countries were the sequenced samples obtained?,List,Sweden,,No,0,Sweden,1,Sweden.,1,Sweden (samples derive from the national InfCareHIV cohort of people with diagnosed HIV in Sweden).,1,No,0,No,0,Sweden,1
Human Answer,36931676,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported.,1,Not specified for sequencing; the cohort was established in 2003 with national coverage since 2008 and data are current to August 2022.,1,No,1,No,1,2003-2022,0
Human Answer,36931676,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable.,1,Not reported.,0,No,1,No,1,Not reported,1
Human Answer,36931676,9,Which HIV genes were reported to have been sequenced?,List,RT,,No,0,Pol,0,Not applicable.,0,pol gene sequences are reported.,0,No,0,No,0,Not reported,0
Human Answer,36931676,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported.,1,Not specified in the paper.,1,No,1,No,1,Not reported,1
Human Answer,36931676,11,What type of samples were sequenced?,List,"Plasma, CSF, PBMC",,No,0,"Plasma, CSF",0,"Plasma, CSF.",0,"Not explicitly specified for sequencing; the paper reports that blood plasma/serum/liquor, PBMCs, HIV isolates and CSF are collected in biobanks and that HIV-RNA (plasma and CSF) data are included.",0,No,0,No,0,"Plasma, CSF",0
Human Answer,36931676,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Not reported.,0,"Yes — the cohort includes sequences associated with acquired drug resistance, implying sequences from individuals with treatment failure.",1,No,0,No,0,Not reported,0
Human Answer,36931676,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported.,1,"No — this is a registry-based cohort study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,36931676,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes.,1,Yes.,1,No,0,No,0,Yes,1
Human Answer,36931676,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI",,No,0,"NRTI, INSTI, PI",0,Not reported.,0,"Nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs; e.g., dolutegravir) are mentioned.",0,No,0,No,0,Not reported,0
Human Answer,36931676,16,Which drugs were received by individuals in the study before sample sequencing?,List,DTG,,No,0,Dolutegravir,1,Not applicable.,0,"Dolutegravir is explicitly named; in addition, individuals received nucleoside reverse transcriptase inhibitor regimens and protease inhibitor-based regimens (specific other drug names are not provided).",1,No,0,No,0,Not reported,0
Human Answer,36961945,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,** Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,36961945,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,** No,1,No — the paper reports genotypic resistance (sequence-based DRMs) but does not report phenotypic/in vitro drug susceptibility assays.,1,No,1,No,1,No,1
Human Answer,36961945,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,** No,1,Not reported / No accession numbers or public deposition are reported in the paper.,1,No,1,No,1,Not Reported,1
Human Answer,36961945,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,** Not reported,1,Not reported.,1,No,1,No,1,Not Reported,1
Human Answer,36961945,5,How many individuals had samples obtained for HIV sequencing?,Number,190,,190,1,190,1,** 190,1,190 individuals.,1,190,1,190,1,190,1
Human Answer,36961945,6,From which countries were the sequenced samples obtained?,List,USA,,No,0,No,0,** Not reported,0,United States (San Diego cohort).,1,No,0,No,0,Not Reported,0
Human Answer,36961945,7,From what years were the sequenced samples obtained?,List,2005-2020,,2005-2020,1,2005-2020,1,** 2005–2020,1,Samples were collected from January 2005 to February 2020.,1,2005-2020,1,2005-2020,1,2005-2020,1
Human Answer,36961945,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,** No,1,No — cloning is not described; PCR and nested PCR were used to generate amplicons for sequencing.,1,No,1,No,1,Not Reported,1
Human Answer,36961945,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"PR, RT, IN",1,"PR, RT, IN",1,** Pol,0,"Protease (PR), reverse transcriptase (RT), and integrase (IN) (partial pol; RT specifically in plasma genotyping).",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,Pol,0
Human Answer,36961945,10,What method was used for sequencing?,List,Illumina sequencing,,Illumina sequencing,1,NGS,0,** NGS,0,Next-Generation Sequencing (deep sequencing / NGS) of proviral DNA and bulk (consensus) genotyping (GeneSeq or ViroSeq) of plasma (standard Sanger-based genotyping).,0,Next-generation sequencing (NGS),0,Next-generation sequencing,0,NGS,0
Human Answer,36961945,11,What type of samples were sequenced?,List,"Plasma, PBMC",,PBMC,0,"Plasma, PBMC",1,"** Plasma, PBMC",1,Peripheral blood mononuclear cells (PBMCs) for proviral DNA (NGS) and blood plasma for bulk HIV RNA genotyping.,1,PBMC; Plasma,1,"PBMC, Plasma",1,PBMC,0
Human Answer,36961945,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,** No,1,No — no participants experienced virologic failure during follow-up after ART initiation.,1,No,1,No,1,Not Reported,1
Human Answer,36961945,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,** Not reported,1,"No — participants were enrolled in the San Diego PIRC cohort (observational study), not described as part of a clinical trial.",1,No,1,No,1,Not Reported,1
Human Answer,36961945,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,** No,1,"No — the study was conducted in antiretroviral (ART)-naïve individuals, so sequences are from ART-naïve persons prior to ART initiation.",1,No,1,No,1,No,1
Human Answer,36961945,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,NRTI,0,No,1,** None,1,None — participants were ART-naïve at the time of sequencing.,1,NRTI,0,No,1,,0
Human Answer,36961945,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Lamivudine (3TC), Emtricitabine (FTC)",0,No,1,** Not applicable,1,None — no antiretroviral drugs were received prior to the baseline sequencing (participants were ART-naïve).,1,Lamivudine (3TC); Emtricitabine (FTC),0,No,1,,0
Human Answer,36967989,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No — the paper did not report new HIV sequences from patient samples; it analyzed existing genotype-phenotype data from a public database.,1,Yes,0,Yes,0,Yes,0
Human Answer,36967989,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,Yes — the paper used phenotypic (in vitro) drug susceptibility data (fold-change and IC50) from the Stanford PhenoSense assay and external datasets.,0,Yes,0,Yes,0,Yes,0
Human Answer,36967989,3,Were sequences from the paper made publicly available?,Boolean,No,,Yes,0,No,1,No,1,"No novel sequences were reported; however, all data and code used in the study were made publicly available on GitHub and Zenodo.",1,Yes,0,No,1,Yes,0
Human Answer,36967989,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,36967989,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,"Not applicable — the authors did not obtain or sequence clinical samples; they analyzed existing genotype-phenotype records (11,803 genotype-phenotype data points, with isolates counts per PI reported).",1,0,1,0,1,Not reported,1
Human Answer,36967989,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,1,No,1,No,1,Not reported,1
Human Answer,36967989,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,1,No,1,No,1,Not reported,1
Human Answer,36967989,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,1,No,1,No,1,Not reported,1
Human Answer,36967989,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,Protease (HIV-1 protease) — the analysis focused on protease gene mutations associated with protease inhibitor susceptibility.,0,Protease,0,PR,0,PR,0
Human Answer,36967989,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable / not reported — the paper did not perform sequencing and thus does not describe any sequencing method.,1,No,1,No,1,Not reported,1
Human Answer,36967989,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable / not directly sequenced; the analysis used genotype-fold change measurements from viral isolates (population-level virus samples) in the Stanford database.,1,No,1,No,1,Not reported,1
Human Answer,36967989,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,Not specified / not reported.,0,No,1,No,1,Yes,0
Human Answer,36967989,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,No — the study did not involve patients in a clinical trial; it analyzed retrospective genotype-phenotype data from public databases.,1,No,1,No,1,Not reported,1
Human Answer,36967989,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,Not specified / not reported.,0,No,1,No,1,Yes,0
Human Answer,36967989,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not reported.,0,PI,0,No,1,PI,0
Human Answer,36967989,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not reported.,0,"ATV, DRV, FPV, IDV, LPV, NFV, SQV, TPV",0,No,1,"ATV, DRV, FPV, IDV, LPV, NFV, SQV, TPV",0
Human Answer,36982978,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,Yes,0,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,36982978,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,Yes — the paper summarizes and reports in vitro susceptibility data from published studies.,0,Yes,0,No,1,Yes,0
Human Answer,36982978,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not present new sequences and does not provide public sequence accession information.,1,No,1,No,1,No,1
Human Answer,36982978,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,36982978,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,None — the paper did not obtain or sequence samples from individuals.,1,0,1,0,1,Not reported,1
Human Answer,36982978,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing of samples was reported in this paper.,1,No,1,No,1,Not reported,1
Human Answer,36982978,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — the paper does not report sequenced samples or sampling years.,1,No,1,No,1,Not reported,1
Human Answer,36982978,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing experiments or cloning are described in this paper.,1,No,1,No,1,Not reported,1
Human Answer,36982978,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,"RT, IN",0,Not applicable,1,None — the paper does not report sequencing of HIV genes in original samples.,1,No,1,No,1,"Pol, IN",0
Human Answer,36982978,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing methods are described in this review.,1,No,1,No,1,Not reported,1
Human Answer,36982978,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — the paper does not report sequencing of any samples.,1,No,1,No,1,"Plasma, PBMC",0
Human Answer,36982978,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,Not applicable,1,No — this paper did not obtain or report original sequences from such individuals.,1,No,1,No,1,Yes,0
Human Answer,36982978,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,Not applicable — this is a review article and does not report enrollment of patients in a trial by the authors.,1,No,1,No,1,No,1
Human Answer,36982978,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,Yes,0,Not applicable,1,No — the paper does not present original HIV sequences from treated individuals.,1,No,1,No,1,Yes,0
Human Answer,36982978,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,"NRTI, PI, INSTI",0,Not applicable,1,Not applicable — no samples were sequenced in this study and no pre-sequencing drug exposures are reported.,1,"NRTI, PI, INSTI, CAI",0,No,1,"NRTI, PI, INSTI",0
Human Answer,36982978,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,"Lamivudine (3TC), Abacavir (ABC), Zidovudine (AZT), Stavudine (D4T), Emtricitabine (FTC), Didanosine (DDI), Tenofovir (TFV), Tenofovir alafenamide (TAF), Darunavir, Saquinavir, Lopinavir",0,Not applicable,1,Not applicable — the paper did not sequence samples and thus does not list individual patients' prior drugs.,1,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Raltegravir (RAL)",0,No,1,"3TC, FTC, AZT, TDF, DRV, RAL",0
Human Answer,37017009,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37017009,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — the paper reports genotypic resistance predictions, not in vitro phenotypic susceptibility testing.",1,No,1,No,1,No,1
Human Answer,37017009,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No evidence of public deposition is provided in the paper.,0,No,1,No,1,No,1
Human Answer,37017009,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,37017009,5,How many individuals had samples obtained for HIV sequencing?,Number,809 or 899,,899,1,809,1,809,1,899 participants had specimens included for analysis; genotyping and sequencing was successful for 809 of these.,1,899,1,899,1,899,1
Human Answer,37017009,6,From which countries were the sequenced samples obtained?,List,South Africa,,South Africa,1,South Africa,1,South Africa,1,South Africa.,1,South Africa,1,South Africa,1,South Africa,1
Human Answer,37017009,7,From what years were the sequenced samples obtained?,List,2017-2019,,2017-2019,1,2017-2019,1,2017–2019,1,Samples were obtained between March 2017 and March 2019.,1,2017-2019,1,2017-2019,1,2017-2019,1
Human Answer,37017009,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — samples were PCR-amplified and libraries prepared for direct sequencing; cloning is not mentioned.,1,No,1,No,1,Not reported,1
Human Answer,37017009,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",,"Protease, RT",1,"PR, RT",1,"PR, RT",1,The protease gene and the first 250 amino acids of the reverse transcriptase gene (a 1.5 kb segment of pol).,1,"Protease, Reverse transcriptase",1,"PR, RT",1,Pol (protease and reverse transcriptase regions),1
Human Answer,37017009,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing",,Illumina sequencing,0,Sanger sequencing; Illumina sequencing,1,NGS,0,Next-generation sequencing on the Illumina MiSeq (MiSeq V3 kit) with Nextera XT library preparation; Sanger sequencing was used for some smaller amplicons when needed.,1,Next-generation sequencing,0,Illumina sequencing,0,NGS (MiSeq platform),0
Human Answer,37017009,11,What type of samples were sequenced?,List,Whole Blood,,Whole Blood,1,Plasma,0,"Plasma, Whole Blood",1,Plasma-derived total nucleic acid from blood samples (viral RNA/DNA extracted from plasma).,0,Whole Blood,1,Plasma,0,Whole blood,1
Human Answer,37017009,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. All sequenced samples came from children on ART with evidence of virological failure (VL 1000 copies/mL).,1,Yes,1,Yes,1,Yes,1
Human Answer,37017009,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No. The study was a cross-sectional, facility-based survey, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer,37017009,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. All participants were on ART for at least one year and the study collected data on current and previous regimens and PMTCT exposure.,1,Yes,1,Yes,1,Yes,1
Human Answer,37017009,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI",,"PI, NNRTI",0,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,"Protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs).",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,PI and NNRTI,0
Human Answer,37017009,16,Which drugs were received by individuals in the study before sample sequencing?,List,"LPV, ATV, EFV, NVP, 3TC, ABC, AZT, FTC, D4T, TDF",,"Ritonavir-boosted lopinavir, Ritonavir-boosted atazanavir, Efavirenz",0,"Lopinavir (LPV), Atazanavir (ATV), Efavirenz (EFV), Nevirapine (NVP), Lamivudine (3TC), Abacavir (ABC), Zidovudine (AZT), Emtricitabine (FTC), Stavudine (D4T), Tenofovir (TFV)",1,"Ritonavir-boosted Lopinavir, Efavirenz",0,"Specific drugs included ritonavir-boosted lopinavir and ritonavir-boosted atazanavir (PIs); efavirenz and nevirapine (NNRTIs); lamivudine, abacavir, zidovudine, emtricitabine, stavudine and tenofovir disoproxil fumarate (NRTIs).",1,"Abacavir, Zidovudine, Lamivudine, Stavudine, Emtricitabine, Tenofovir, Nevirapine, Delavirdine, Efavirenz, Etravirine, Rilpivirine, Doravirine, Amprenavir, Lopinavir, Atazanavir, Derunavir, Raltegravir, Elvitegravir, Dolutagravir, Bictegravir, cabotagravir",1,"Abacavir (ABC), Lamivudine (3TC), Zidovudine (AZT), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Darunavir (DRV)",1,"Ritonavir-boosted lopinavir, ritonavir-boosted atazanavir, efavirenz, and nevirapine",0
Human Answer,37029656,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — the paper reports genotypic resistance testing (sequencing) performed on patient samples.,1,Yes,1,Yes,1,Yes,1
Human Answer,37029656,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,"No — the paper reports genotypic interpretation of resistance, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer,37029656,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported — the paper does not state that sequence data were deposited in public databases.,0,No,1,No,1,No,1
Human Answer,37029656,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37029656,5,How many individuals had samples obtained for HIV sequencing?,Number,1223,,1223,1,1223,1,1223,1,1223 individuals.,1,1223,1,1223,1,1223,1
Human Answer,37029656,6,From which countries were the sequenced samples obtained?,List,Italy,,Italy,1,Italy,1,Italy,1,Samples were obtained in Italy (single-centre study; many participants of Italian origin).,1,Italy,1,No,0,Not reported,0
Human Answer,37029656,7,From what years were the sequenced samples obtained?,List,2009-2019,,2009-2019,1,2009-2019,1,2009–2019,1,Samples were obtained over the period 2009–2019.,1,2009-2019,1,2009-2019,1,2009-2019,1
Human Answer,37029656,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,Not reported; the paper describes direct Sanger sequencing and does not mention cloning.,0,No,1,No,1,Not reported,1
Human Answer,37029656,9,Which HIV genes were reported to have been sequenced?,List,IN,,No,0,IN,1,Not reported,0,"The integrase gene (INSTI-associated mutations) was sequenced; genotypic resistance testing also assessed resistance to NRTI, NNRTI and PI drug classes (implying sequencing of relevant pol regions), but integrase is explicitly reported.",1,Not specified,0,No,0,Not reported,0
Human Answer,37029656,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing using an ABI PRISM 3130xl Genetic Analyzer (Applied Biosystems).,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37029656,11,What type of samples were sequenced?,List,Plasma,,No,0,Plasma,1,Not Reported,0,Clinical pre-ART patient samples used for genotypic resistance testing (immediate pre-ART GRT in newly diagnosed people).,0,No,0,No,0,Not reported,0
Human Answer,37029656,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No — sequences were obtained from ART-naive individuals before initiation of therapy, not from people with virological failure on treatment.",1,No,1,No,1,Not reported,1
Human Answer,37029656,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the study was an observational time-trend, single-centre study of ART-naive people living with HIV.",1,No,1,No,1,Not reported,1
Human Answer,37029656,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper reports sequences from ART-naive individuals who had not previously received antiretroviral therapy.,1,No,1,No,1,No,1
Human Answer,37029656,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI, PI",0,No,1,,0,None — individuals were ART-naive and had not received antiretroviral drug classes prior to sequencing.,1,INSTI,0,No,1,Not reported,1
Human Answer,37029656,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,None — participants were antiretroviral therapy–naive and had not received specific antiretroviral drugs prior to sequencing.,1,Not mentioned,0,No,1,Not reported,1
Human Answer,37039023,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37039023,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37039023,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes (raw reads deposited to SRA under BioProject PRJNA419915).,1,Yes,1,Yes,1,Yes,1
Human Answer,37039023,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,The paper does not report GenBank accession numbers for the study isolates; only the HXB2 reference accession NC_001802 is cited and raw reads were deposited to SRA (PRJNA419915).,1,No,1,No,1,Not reported,1
Human Answer,37039023,5,How many individuals had samples obtained for HIV sequencing?,Number,86,,86,1,86,1,86,1,86 individuals.,1,86,1,86,1,86,1
Human Answer,37039023,6,From which countries were the sequenced samples obtained?,List,Brazil,,Brazil,1,Brazil,1,Brazil,1,"Brazil (specifically Rio de Janeiro, RJ, and Rio Grande do Sul, RS).",1,Brazil,1,Brazil,1,Brazil,1
Human Answer,37039023,7,From what years were the sequenced samples obtained?,List,2016-2018,,2016-2018,1,2016-2018,1,2016–2018,1,Samples from Rio de Janeiro were collected between February 2016 and November 2018; samples from Rio Grande do Sul were collected between August and December 2017.,1,2016-2018,1,2016-2018,1,2016-2018,1
Human Answer,37039023,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer,37039023,9,Which HIV genes were reported to have been sequenced?,List,"NFLG, PR, RT, IN, Env",,"Protease, RT, IN, Envelope",0,Near full length genome,1,"PR, RT, IN, Env",0,"Near full-length genome (NFLG) sequences were obtained; analyses specifically included protease, reverse transcriptase (including RNaseH and connection subdomains), integrase and envelope (env) regions.",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN; Near full length genome",1,"PR, RT, IN, Env",0,"Protease, reverse transcriptase, integrase, and envelope",0
Human Answer,37039023,10,What method was used for sequencing?,List,Illumina sequencing,,Illumina sequencing,1,Illumina sequencing,1,NGS,0,High-throughput sequencing on the Illumina MiSeq platform with Nextera XT library preparation and a paired-end 2×251 protocol.,1,Illumina sequencing,1,Illumina sequencing,1,NGS,0
Human Answer,37039023,11,What type of samples were sequenced?,List,PBMC,,Whole Blood,0,PBMC,1,Whole Blood,0,"DNA from peripheral blood cells containing archived integrated HIV proviral genomes (i.e., proviral DNA from blood cells / PBMC reservoir).",1,PBMC,1,Whole Blood,0,Whole blood,0
Human Answer,37039023,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37039023,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer,37039023,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. All study participants were on antiretroviral therapy (first- or second-line) and had been receiving ART prior to sampling.,1,Yes,1,Yes,1,Yes,1
Human Answer,37039023,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI",,"NRTI, NNRTI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI",1,"Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).",0,"NRTI, NNRTI, PI",1,"NRTI, NNRTI",1,NRTIs and NNRTIs,0
Human Answer,37039023,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, EFV",,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Efavirenz (EFV)",1,"TDF, 3TC, EFV, ATV/r",1,"TDF, 3TC, EFV",1,"Specifically reported drugs include tenofovir disoproxil fumarate (TDF), lamivudine (3TC), efavirenz (EFV); at least one protease inhibitor mentioned in context was atazanavir/ritonavir (ATV/r). Dolutegravir (DTG) is mentioned as a later recommended first-line drug but most patients received TDF+3TC+EFV.",0,"Tenofovir (TFV), Lamivudine (3TC), Efavirenz (EFV), Atazanavir (ATV), Raltegravir (RAL), Dolutagravir (DTG)",1,"Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV)",1,"TDF, 3TC, and EFV",1
Human Answer,37042390,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37042390,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37042390,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (the paper does not report depositing sequences or providing accession numbers).,1,No,1,No,1,No,1
Human Answer,37042390,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,37042390,5,How many individuals had samples obtained for HIV sequencing?,Number,85,,85,1,85,1,85,1,"At baseline, 40 individuals had the integrase gene sequenced and 38 individuals had the protease and reverse transcriptase genes sequenced.",0,87,0,40,0,87,0
Human Answer,37042390,6,From which countries were the sequenced samples obtained?,List,India,,India,1,India,1,India,1,India.,1,India,1,India,1,India,1
Human Answer,37042390,7,From what years were the sequenced samples obtained?,List,2016-2019,,2016-2019,1,2016-2019,1,2016–2019,1,Samples were obtained from patients started on third-line ART between July 2016 and December 2019 (sequencing done at the start of third-line therapy).,1,2016-2019,1,2016-2019,1,2016-2019,1
Human Answer,37042390,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,"No, samples were PCR-amplified, gel-purified and directly sequenced; no cloning step is described.",1,No,1,No,1,Not reported,1
Human Answer,37042390,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"Integrase, IN; Reverse transcriptase, RT; Protease, PR",1,"PR, RT, IN",1,"IN, RT, PR",1,"Integrase (IN), reverse transcriptase (RT) and protease (PR) genes (regions of the pol gene).",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"IN, RT, PR",1
Human Answer,37042390,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing on an Applied Biosystems 3730xl DNA Analyzer following RT-PCR and nested PCR (gel-purified PCR products).,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37042390,11,What type of samples were sequenced?,List,Plasma,,Whole Blood,0,Plasma,1,"Whole Blood, Plasma",1,Plasma-derived viral RNA (plasma separated from whole blood in EDTA tubes) was extracted and sequenced.,1,Whole Blood,0,Plasma,1,Plasma,1
Human Answer,37042390,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes. Genotyping/sequencing was performed for patients who did not attain virological suppression after 12 months; among 13 patients who did not attain suppression, sequencing was done on multiple samples.",1,Yes,1,Yes,1,Yes,1
Human Answer,37042390,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this was a single-centre observational study in programmatic conditions, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,37042390,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37042390,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI, INSTI",,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, PI, INSTI",1,"Nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs); most were integrase inhibitor (INSTI)-naive prior to third-line therapy.",0,"NRTI, NNRTI, PI, INSTI, CAI",1,No,0,"INSTI, PI",0
Human Answer,37042390,16,Which drugs were received by individuals in the study before sample sequencing?,List,"RAL, DRV",,"Individuals in the study received an initial regimen of raltegravir (400 mg), darunavir (600 mg), and ritonavir (100 mg) before sample sequencing.",0,"Raltegravir (RAL), Darunavir (DRV), Ritonavir (RTV), Dolutegravir (DTG)",1,"Raltegravir, Darunavir, Ritonavir",1,"The paper does not list specific prior first- or second-line drug names; it reports drug classes (NRTIs, NNRTIs, PIs) and specifies the standardized third-line regimen used in the programme was raltegravir + darunavir + ritonavir (later raltegravir replaced by dolutegravir).",0,"Raltegravir, Darunavir, Ritonavir",1,No,0,"Raltegravir, darunavir, ritonavir",1
Human Answer,37052343,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No.,1,No,1,No,1,Yes,0
Human Answer,37052343,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37052343,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37052343,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None / Not applicable.,1,No,1,No,1,Not reported,1
Human Answer,37052343,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,4310,0,None / Not applicable.,1,0,1,0,1,4310,0
Human Answer,37052343,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not applicable — no sequences were obtained.,1,No,1,No,1,"Europe, Australia",0
Human Answer,37052343,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,2014–2020,0,Not applicable — no sequences were obtained.,1,No,1,No,1,2014-2020,0
Human Answer,37052343,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not applicable — no sequencing was performed.,1,No,1,No,1,Not reported,1
Human Answer,37052343,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not reported,1,None / Not applicable.,1,No,1,No,1,Not reported,1
Human Answer,37052343,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,Not applicable — no sequencing method reported.,1,No,1,No,1,Not reported,1
Human Answer,37052343,11,What type of samples were sequenced?,List,No,,No,1,No,1,Plasma,0,Not applicable — the paper does not report sequencing; plasma HIV-1 RNA measurements were used for virological outcomes.,1,No,1,No,1,Blood,0
Human Answer,37052343,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not reported,1,No — no sequences were obtained or reported.,1,No,1,No,1,No,1
Human Answer,37052343,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No; they were participants in an observational cohort study (RESPOND).,1,No,1,No,1,Not reported,1
Human Answer,37052343,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,"No — participants were treatment-naive, and the paper does not report sequences.",1,No,1,No,1,No,1
Human Answer,37052343,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,,0,Not applicable — participants were treatment-naive (no prior ARV exposure) and no sequencing was performed.,1,INSTI,0,No,1,Not reported,1
Human Answer,37052343,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — participants were treatment-naive (no prior ARV drugs before baseline sequencing, and no sequencing was performed).",1,"Raltegravir, Elvitegravir, Dolutagravir, Bictegravir, cabotagravir, Lenacapavir",0,No,1,Not reported,1
Human Answer,37071019,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer,37071019,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37071019,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37071019,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported,1,No,1,No,1,Not reported,1
Human Answer,37071019,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,Not reported,1,None (0 individuals),1,0,1,0,1,Not reported,1
Human Answer,37071019,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not applicable — no patient-derived samples or sequences,1,No,1,No,1,Not reported,1
Human Answer,37071019,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not applicable — no patient-derived samples or sequences,1,No,1,No,1,Not reported,1
Human Answer,37071019,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not Reported,1,No (no patient samples); plasmids were generated by site-directed mutagenesis and amplified in bacteria prior to Sanger sequencing,1,No,1,No,1,Not reported,1
Human Answer,37071019,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,IN,0,Not reported,1,Integrase (IN) coding region,0,No,1,No,1,"IN, RT",0
Human Answer,37071019,10,What method was used for sequencing?,List,No,,No,1,Sanger sequencing,0,Not reported,1,Sanger sequencing,0,No,1,No,1,Not reported,1
Human Answer,37071019,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not reported,1,Plasmid DNA from engineered proviral constructs (site-directed mutagenesis products) amplified in bacteria,0,No,1,No,1,Plasma,0
Human Answer,37071019,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer,37071019,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Yes,0,No — there were no patients in this study,1,No,1,No,1,Not reported,1
Human Answer,37071019,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer,37071019,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not reported,1,Not applicable — no individuals were sequenced in this study,0,INSTI,0,No,1,"NRTI, PI, INSTI",0
Human Answer,37071019,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no individuals were sequenced; in vitro the study used dolutegravir (DTG) and bictegravir (BIC),0,"DTG, BIC",0,No,1,"DTG, BIC",0
Human Answer,37085698,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37085698,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37085698,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37085698,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,MW560010 to MW560058,,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1,MW560010 to MW560058,1
Human Answer,37085698,5,How many individuals had samples obtained for HIV sequencing?,Number,49,,49,1,49,1,49,1,49 individuals,1,49,1,49,1,49,1
Human Answer,37085698,6,From which countries were the sequenced samples obtained?,List,Ethiopia,,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia,1
Human Answer,37085698,7,From what years were the sequenced samples obtained?,List,2018,,2018,1,2018,1,2018,1,2018 (June to December 2018),1,2018,1,2018,1,Not reported,0
Human Answer,37085698,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer,37085698,9,Which HIV genes were reported to have been sequenced?,List,IN,,"Integrase, IN",1,IN,1,IN,1,The HIV-1 integrase (IN) gene region (first 263 codons),1,"Integrase, IN",1,IN,1,IN,1
Human Answer,37085698,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger DNA sequencing using the BigDye Terminator v3.1 kit on an ABI PRISM 3500 xL automated Genetic Analyzer,1,No,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37085698,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma-derived viral RNA from EDTA blood samples,1,Plasma,1,Plasma,1,Blood,0
Human Answer,37085698,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37085698,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer,37085698,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37085698,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,,0,None; participants were ARV-naive,1,No,1,No,1,,0
Human Answer,37085698,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,None; participants had not received any antiretroviral drugs,1,No,1,No,1,,0
Human Answer,37104815,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer,37104815,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37104815,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported).,1,No,1,No,1,No,1
Human Answer,37104815,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37104815,5,How many individuals had samples obtained for HIV sequencing?,Number,121 or 10,,121,1,121,1,121,1,Ten individuals (10 VFs).,1,121,1,121,1,121,1
Human Answer,37104815,6,From which countries were the sequenced samples obtained?,List,France,,No,0,France,1,Not reported,0,Not specified in the paper.,0,No,0,No,0,Not reported,0
Human Answer,37104815,7,From what years were the sequenced samples obtained?,List,2017-2019,,No,0,2017-2019,1,2017–2019,1,Samples were collected during the trial period between 2017 and 2019 (screening 7 Sep 2017 to 22 Jan 2018; W48 data up to 4 Apr 2019).,1,No,0,2017-2019,1,2017-2019,1
Human Answer,37104815,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No indication of cloning; cloning is not reported.,0,No,1,No,1,Not reported,1
Human Answer,37104815,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"PR, RT, IN",1,"PR, RT, IN",1,"RT, PR, IN",1,"Reverse transcriptase (RT), protease (PR) and integrase (INT) regions.",1,"Reverse transcriptase, RT; Protease, PR; Integrase, IN",1,"PR, RT, IN",1,HIV-1 genome,0
Human Answer,37104815,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing",,"Sanger sequencing, Illumina sequencing",1,Sanger sequencing; Illumina sequencing,1,Sanger sequencing and NGS (Illumina technology),0,Sanger sequencing and ultra-deep sequencing (UDS) using Illumina technology.,1,Illumina sequencing,0,Sanger sequencing; Illumina sequencing,1,Sanger and ultra-deep sequencing (UDS) using Illumina technology,0
Human Answer,37104815,11,What type of samples were sequenced?,List,"Whole Blood, Semen",,"Whole Blood, Other",0,Plasma; PBMC,0,"Blood plasma, semen",0,Plasma RNA at failure and cellular (HIV) DNA at baseline (D0).,0,Plasma; Semen,0,Plasma; PBMC; Semen,0,"Plasma, semen, and PBMCs",0
Human Answer,37104815,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37104815,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — they were participants in the ANRS 170 QUATUOR Phase III randomized clinical trial.,1,Yes,1,Yes,1,Yes,1
Human Answer,37104815,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37104815,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI",,"INSTI, NNRTI, PI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"Integrase strand transfer inhibitors (INSTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) as backbone (tenofovir/FTC or TAF/FTC, abacavir/lamivudine).",1,INSTI; NNRTI; PI,0,"NRTI, NNRTI, PI, INSTI",1,"INSTIs, NNRTIs, and PIs",0
Human Answer,37104815,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, FTC, ABC, 3TC",,"Tenofovir/emtricitabine, Tenofovir alafenamide/emtricitabine, Abacavir/lamivudine",1,"Tenofovir (TFV), Emtricitabine (FTC), Abacavir (ABC), Lamivudine (3TC), Rilpivirine (RPV), Raltegravir (RAL), Dolutegravir (DTG), Lopinavir (LPV)",1,"Tenofovir/emtricitabine, tenofovir alafenamide/emtricitabine, abacavir/lamivudine",1,"NRTI backbones included tenofovir/emtricitabine or tenofovir alafenamide/emtricitabine and abacavir/lamivudine; third agents included drugs from INSTI and NNRTI classes and some PIs — specific drugs mentioned in the paper include rilpivirine, raltegravir, elvitegravir/cobicistat and dolutegravir (among others).",1,Tenofovir/emtricitabine; Rilpivirine,0,"Abacavir (ABC), Lamivudine (3TC), Tenofovir (TFV), Tenofovir alafenamide (TAF), Emtricitabine (FTC)",1,Not reported,0
Human Answer,37112971,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37112971,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — the paper reports genotypic sequencing and interpretation, not primary in vitro phenotypic susceptibility testing.",1,No,1,No,1,No,1
Human Answer,37112971,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,"No, the sequence data are not publicly available; they are available on request from the corresponding author.",1,No,1,No,1,No,1
Human Answer,37112971,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers for the sequenced isolates are reported.,1,No,1,No,1,Not reported,1
Human Answer,37112971,5,How many individuals had samples obtained for HIV sequencing?,Number,4481,,4481,1,4481,1,4481,1,Samples from 4481 treatment-naïve individuals were obtained; integrase sequences were available for 844 of them.,1,4481,1,4481,1,4481,1
Human Answer,37112971,6,From which countries were the sequenced samples obtained?,List,Russia,,No,0,Russia,1,Russia,1,All sequenced samples were obtained in Russia (from different regions/federal districts of Russia).,1,Russia,1,Russia,1,Russia,1
Human Answer,37112971,7,From what years were the sequenced samples obtained?,List,2006-2022,,2006-2022,1,2006-2022,1,2006–2022,1,Blood sampling years ranged from 2006 to 2022.,1,2006-2022,1,2006-2022,1,2006-2022,1
Human Answer,37112971,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — there is no indication that samples were cloned; sequencing was performed directly from plasma RNA using genotyping kits and Sanger or NGS methods.,1,No,1,No,1,Not reported,1
Human Answer,37112971,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease (PR), part of reverse transcriptase (RT) (PR-RT region), and integrase (INT).",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, INT",0
Human Answer,37112971,10,What method was used for sequencing?,List,"Sanger sequencing, NGS",,Sanger sequencing,0,Sanger sequencing; NGS,1,Sanger sequencing and NGS,1,"Sanger-based or next-generation sequencing (NGS) with a 20% detection threshold, using commercial genotyping kits and in-house methods.",1,Sanger sequencing; Next-generation sequencing (NGS),0,"Sanger sequencing, NGS",1,Sanger-based or NGS-based sequencing,0
Human Answer,37112971,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Blood plasma samples (RNA extracted from blood plasma).,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37112971,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No — all sequences were from treatment-naïve patients, so not from individuals with virological failure on therapy.",1,No,1,No,1,Not reported,1
Human Answer,37112971,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the sequences were obtained from routine HIV DR testing, research and clinical projects, and outbreak investigations; there is no indication patients were enrolled in a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer,37112971,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,"No — the study population consisted of treatment-naïve individuals (i.e., they had not previously received antiretroviral drugs).",1,No,1,No,1,Not reported,1
Human Answer,37112971,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,,0,None — individuals were treatment-naïve and had not received antiretroviral drug classes prior to sampling.,1,No,1,No,1,Not reported,1
Human Answer,37112971,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,None — no specific antiretroviral drugs were received prior to sampling because all participants were treatment-naïve.,1,No,1,No,1,Not reported,1
Human Answer,37147875,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37147875,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,No,0,Yes,1,No (the paper does not present new in vitro susceptibility experiments; it cites prior in vitro work).,0,Yes,1,No,0,Yes,1
Human Answer,37147875,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication that sequences were made publicly available.,0,No,1,No,1,No,1
Human Answer,37147875,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,37147875,5,How many individuals had samples obtained for HIV sequencing?,Number,1,,1,1,1,1,1,1,One individual (a single 22-year-old man).,1,1,1,1,1,1,1
Human Answer,37147875,6,From which countries were the sequenced samples obtained?,List,France,,No,0,France,1,France,1,France.,1,France,1,France,1,France,1
Human Answer,37147875,7,From what years were the sequenced samples obtained?,List,2022,,No,0,2022,1,2022,1,2022 (April 2022).,1,2022,1,No,0,2022,1
Human Answer,37147875,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No indication that samples were cloned prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer,37147875,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"Integrase, RT, PR",1,"PR, RT, IN",1,"RT, PR, IN",1,"Reverse transcriptase (RT), protease, and integrase.",1,"Reverse transcriptase, RT; Protease, PR; Integrase, IN",1,"PR, RT, IN",1,"RT, protease, integrase",1
Human Answer,37147875,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing",,Illumina sequencing,0,Sanger sequencing; NGS,0,"Sanger sequencing, NGS",0,Sanger-based sequencing (SBS) and next-generation sequencing (NGS) using the Illumina MiSeq platform (data analysed with PASeq).,1,Sanger sequencing; Next-generation sequencing,0,"Sanger sequencing, Illumina sequencing",1,"Sanger sequencing, NGS",0
Human Answer,37147875,11,What type of samples were sequenced?,List,Plasma,,No,0,Plasma,1,Plasma,1,Not specified in the paper.,0,Plasma,1,Plasma,1,Plasma,1
Human Answer,37147875,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,Yes,0,No,1,Yes,0,"No — the sequences reported were from a newly infected, treatment-naive individual; sequences were not reported from the partner who had adherence difficulties.",1,Yes,0,No,1,Yes,0
Human Answer,37147875,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this is a case report/research letter, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,37147875,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No — the reported sequences are from an individual who had not yet started antiretroviral therapy prior to sequencing.,1,Yes,0,No,1,Yes,0
Human Answer,37147875,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI",0,No,1,,0,None — the sequenced individual had not received antiretroviral drugs prior to sequencing.,1,INSTI; NRTI,0,No,1,"INSTI, NRTI",0
Human Answer,37147875,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Doravirine, TDF, FTC",0,No,1,"Dolutegravir, Emtricitabine, Tenofovir disoproxil fumarate",0,None — the sequenced individual had not received any specific antiretroviral drugs prior to sequencing.,1,Dolutegravir (DTG); Emtricitabine (FTC); Tenofovir disoproxil fumarate (TDF),0,No,1,"DTG, FTC, TDF",0
Human Answer,37272233,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer,37272233,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37272233,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication of public deposition.,0,No,1,No,1,No,1
Human Answer,37272233,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,37272233,5,How many individuals had samples obtained for HIV sequencing?,Number,248,,0,0,248,1,248,1,248 individuals were included in the analysis (sequencing results reviewed for these patients).,1,0,0,248,1,248,1
Human Answer,37272233,6,From which countries were the sequenced samples obtained?,List,South Korea,,No,0,Korea,0,Korea,0,Korea (patients diagnosed and treated at a Korean hospital).,1,No,0,Korea,0,Not reported,0
Human Answer,37272233,7,From what years were the sequenced samples obtained?,List,2012-2020,,No,0,2010-2020,0,2010–2020,0,From patients diagnosed between January 2010 and December 2020 (study period).,0,No,0,2010-2020,0,2010-2020,0
Human Answer,37272233,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported / No indication of cloning prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer,37272233,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,No,0,"PR, RT, IN",1,"NRTI, NNRTI, PI, INSTI",0,"Genes corresponding to drug targets for NRTI and NNRTI (reverse transcriptase), PI (protease), and INSTI (integrase) were sequenced.",1,No,0,No,0,"NRTI, NNRTI, PI, INSTI",0
Human Answer,37272233,10,What method was used for sequencing?,List,Sanger sequencing,,No,0,Sanger sequencing,1,Sanger sequencing,1,PCR-based sequencing using an AB 3500xL Dx genetic analyzer (Applied Biosystems).,1,No,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37272233,11,What type of samples were sequenced?,List,Plasma,,No,0,Plasma,1,Not Reported,0,Not explicitly specified in the paper (sequencing is described only as HIV drug resistance mutation sequencing from patients).,0,No,0,No,0,Not reported,0
Human Answer,37272233,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,Not clearly reported; the paper does not state sequences were from individuals identified as having virological failure.,0,No,1,No,1,Yes,0
Human Answer,37272233,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37272233,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,Yes,0,Yes,0,Yes — some participants had prior ART exposure and some underwent ART before resistance testing.,0,No,1,No,1,Yes,0
Human Answer,37272233,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,"NRTI, NNRTI",0,Not specified in detail; the paper reports prior ART use generally but does not enumerate which ARV classes individual patients received before sequencing.,0,"NRTI, NNRTI, PI, INSTI",0,No,1,Not reported,1
Human Answer,37272233,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not Reported,1,Not specified in the report.,0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN), GS-CA1, Lenacapavir (GS-6207)",0,No,1,Not reported,1
Human Answer,37279764,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37279764,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper reports genotypic resistance inference rather than in vitro phenotypic susceptibility assays.,1,No,1,No,1,No,1
Human Answer,37279764,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,No,0,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37279764,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,"MW947591–MW957968, OP058117–OP058658",,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,MW947591–MW957968 and OP058117–OP058658.,1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1,"MW947591–MW957968, OP058117–OP058658",1
Human Answer,37279764,5,How many individuals had samples obtained for HIV sequencing?,Number,12320,,12320,1,12320,1,12320,1,"12,320 individuals.",1,12320,1,12320,1,"12,320",0
Human Answer,37279764,6,From which countries were the sequenced samples obtained?,List,China,,China,1,China,1,China,1,China.,1,China,1,China,1,China,1
Human Answer,37279764,7,From what years were the sequenced samples obtained?,List,2011-2019,,2011 to 2019,0,2011-2019,1,2011–2019,1,2011 to 2019.,1,2011-2019,1,2011-2019,1,2011-2019,1
Human Answer,37279764,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No cloning is reported.,1,No,1,No,1,No,1
Human Answer,37279764,9,Which HIV genes were reported to have been sequenced?,List,Pol,,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",0,Pol,1,Pol,1,A partial HIV-1 pol gene.,1,"Protease, Reverse transcriptase, Integrase",0,"PR, RT",0,Pol,1
Human Answer,37279764,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,PCR amplification and sequencing as performed according to previously described methods.,1,No,1,No,1,Not Reported,1
Human Answer,37279764,11,What type of samples were sequenced?,List,Whole Blood,,Whole Blood,1,Plasma,0,Blood,0,Blood samples.,1,Plasma,0,Whole Blood,1,Not Reported,0
Human Answer,37279764,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,37279764,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — they were newly diagnosed patients, not participants in a clinical trial as described.",1,No,1,No,1,No,1
Human Answer,37279764,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,37279764,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,,0,None — participants were treatment naive.,1,No,1,No,1,Not Reported,1
Human Answer,37279764,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,None — participants were treatment naive.,1,No,1,No,1,Not Reported,1
Human Answer,37327289,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37327289,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37327289,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37327289,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,LC723952-LC724015,,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1,The pol sequences were archived in DDBJ under accessions LC723952–LC724015.,1,LC723952-LC724015,1,LC723952-LC724015,1,LC723952-LC724015,1
Human Answer,37327289,5,How many individuals had samples obtained for HIV sequencing?,Number,157,,157,1,64,0,157,1,64 individuals,0,64,0,64,0,64,0
Human Answer,37327289,6,From which countries were the sequenced samples obtained?,List,Kenya,,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1,Kenya,1
Human Answer,37327289,7,From what years were the sequenced samples obtained?,List,2020-2021,,2020-2021,1,2020-2021,1,2020-2021,1,Samples were obtained between November 2020 and April 2021 (2020–2021).,1,2020-2021,1,2020-2021,1,2020-2021,1
Human Answer,37327289,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37327289,9,Which HIV genes were reported to have been sequenced?,List,Pol,,Full genome,0,Pol,1,Pol,1,pol gene (primary); env V3 loop sequences were used for tropism determination (env attempted).,0,"Protease, Reverse transcriptase, Integrase",0,"PR, RT",0,Pol,1
Human Answer,37327289,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,"Sanger sequencing (Thermo Fisher HIV Genotyping kit, run on an Applied Biosystems 3500xL DX genetic analyzer).",1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37327289,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma samples (HIV-1 RNA extracted from plasma).,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37327289,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37327289,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37327289,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37327289,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,,0,None (participants were treatment-naive).,1,No,1,No,1,,0
Human Answer,37327289,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,None (no specific ARV drugs were received; participants were treatment-naive).,1,No,1,No,1,Not applicable,1
Human Answer,37340869,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,No,0,No,0,"Yes — the paper reports genotypic (sequence-based) data from participants (e.g., RPV resistance-associated mutations and HIV-1 subtypes).",1,No,0,No,0,Yes,1
Human Answer,37340869,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not present in vitro drug susceptibility (phenotypic) results in the main text.,1,No,1,No,1,No,1
Human Answer,37340869,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported — the paper does not state that sequence data were deposited in public databases.,0,No,1,No,1,Not reported,1
Human Answer,37340869,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,Not reported — no GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37340869,5,How many individuals had samples obtained for HIV sequencing?,Number,1651,,1651,1,0,0,0,0,"Up to 1,431 participants had complete baseline records (including genotypic factors) used for analyses; BFAs included 1,363 and 1,431 unique participants in the single-regimen and all-regimens models, respectively.",0,0,0,0,0,1651,1
Human Answer,37340869,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Specific countries are not comprehensively listed in the main text; Russia is explicitly mentioned (11 participants with CVF were from Russia).,0,No,1,No,1,Russia,0
Human Answer,37340869,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not reported — the paper does not provide calendar years of sample collection in the main text.,1,No,1,No,1,Not reported,1
Human Answer,37340869,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported — there is no mention in the paper of cloning prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer,37340869,9,Which HIV genes were reported to have been sequenced?,List,RT,,No,0,No,0,Not applicable,0,"Genotypic data pertain to integrase (L74I) and reverse transcriptase (RPV resistance-associated mutations), i.e., integrase and RT regions.",0,No,0,No,0,Not reported,0
Human Answer,37340869,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not specified in the main text; the paper refers to a ""retrospective proviral DNA analysis"" for RPV RAMs and notes that full genotypic/phenotypic methodology has been published separately (Supplementary page 1).",1,No,1,No,1,Not reported,1
Human Answer,37340869,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Proviral DNA (retrospective proviral DNA analysis) was used for identifying RPV RAMs; participants were virologically suppressed (plasma HIV-1 RNA <50 copies/mL) at randomization.,0,No,1,No,1,"Plasma, Proviral DNA",0
Human Answer,37340869,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,"Yes — genotypic/subtype data are reported for participants who experienced confirmed virologic failure (CVF); for example, participants with CVF had RPV RAMs and subtype A6/A1 was observed among CVF cases.",0,No,1,No,1,Yes,0
Human Answer,37340869,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — participants were enrolled in randomized, multicenter, open-label phase 3/3b clinical trials (FLAIR, ATLAS, ATLAS-2M).",1,Yes,1,Yes,1,Yes,1
Human Answer,37340869,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,No,0,Not applicable,0,Yes — the study participants were virologically suppressed on antiretroviral therapy prior to randomization and retrospective proviral DNA analyses (identifying RPV RAMs) reflect prior ARV exposure/history.,1,No,0,No,0,Yes,1
Human Answer,37340869,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,NNRTI,0,No,1,Not applicable,1,The paper references exposure and/or relevance of INSTIs (integrase strand transfer inhibitors) and NNRTIs (non-nucleoside reverse-transcriptase inhibitors); study drugs included an INSTI (cabotegravir) and an NNRTI (rilpivirine).,0,"INSTI, NNRTI",0,No,1,"INSTI, NNRTI",0
Human Answer,37340869,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,Rilpivirine (RPV),0,No,1,Not applicable,1,The paper does not provide a detailed list of specific prior ARV drugs received by participants; it focuses on drug classes and on the study drugs cabotegravir and rilpivirine and reports mutations relevant to rilpivirine (RPV RAMs) and integrase (L74I/K103N mentioned as relevant).,1,"Cabotegravir, Rilpivirine",0,No,1,"Cabotegravir, Rilpivirine",0
Human Answer,37358226,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes.,0
Human Answer,37358226,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No.,1
Human Answer,37358226,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No.,1
Human Answer,37358226,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported.,1
Human Answer,37358226,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,None; the study did not obtain samples for HIV sequencing.,1,0,1,0,1,"14,242.",0
Human Answer,37358226,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequences were obtained; the study population was from Lesotho.,1,Lesotho,0,No,1,Lesotho.,0
Human Answer,37358226,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not applicable — no sequencing was done. The study included transitions to DTG before 30 October 2021 and data closure was 1 May 2023.,1,No,1,No,1,Not reported.,1
Human Answer,37358226,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No — not applicable because no sequencing was performed.,1,No,1,No,1,Not reported.,1
Human Answer,37358226,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,None — no HIV genes were sequenced or reported.,1,No,1,No,1,Not reported.,1
Human Answer,37358226,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed or reported.,1,No,1,No,1,Not reported.,1
Human Answer,37358226,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no samples were sequenced.,1,No,1,No,1,Plasma.,0
Human Answer,37358226,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No; no sequences were obtained. The cohort did include individuals with pretransition viremia (>999 copies/mL).,1,No,1,No,1,Yes.,0
Human Answer,37358226,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No; they were participants in a prospective open cohort (routine care), not a clinical trial.",1,No,1,No,1,No.,1
Human Answer,37358226,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No; the paper does not report HIV sequences, although the cohort consisted of treatment-experienced individuals who had received ARV drugs.",1,Yes,0,No,1,Yes.,0
Human Answer,37358226,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI",0,No,1,Not applicable,1,Participants had received NNRTIs and NRTIs (no sequencing was performed).,0,"NRTI, NNRTI, INSTI",0,No,1,"NNRTIs, NRTIs.",0
Human Answer,37358226,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Efavirenz, Nevirapine, Abacavir, Zidovudine, Tenofovir, Lamivudine",0,No,1,Not applicable,1,"Participants received efavirenz or nevirapine (NNRTIs) and NRTIs including abacavir (ABC), zidovudine (ZDV), tenofovir disoproxil fumarate (TDF) together with lamivudine (3TC); many were on efavirenz-containing ART prior to transition.",0,"Abacavir (ABC), Zidovudine'(AZT), Lamivudine (3TC), Tenofovir (TFV), Nevirapine (NVP), Efavirenz (EFV), Dolutagravir (DTG)",0,No,1,"Efavirenz, nevirapine, abacavir, zidovudine, TDF, 3TC.",0
Human Answer,37376649,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer,37376649,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37376649,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No explicit public sequence deposition is reported.,0,Yes,0,No,1,Not Reported,1
Human Answer,37376649,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None are reported in the paper.,1,No,1,No,1,Not Reported,1
Human Answer,37376649,5,How many individuals had samples obtained for HIV sequencing?,Number,734,,734,1,734,1,734,1,Retrospective proviral DNA testing was performed on baseline samples from 734 participants.,1,734,1,734,1,734,1
Human Answer,37376649,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not specified in the paper.,0,No,1,No,1,Not Reported,1
Human Answer,37376649,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,The years when samples were obtained are not reported in the paper.,0,No,1,No,1,Not Reported,1
Human Answer,37376649,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No indication of cloning; samples were analyzed by NGS without mention of cloning.,0,No,1,No,1,Not Reported,1
Human Answer,37376649,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"RT, IN",0,"PR, RT, IN",1,Not reported,0,The HIV-1 polymerase (pol) region was sequenced.,1,"Reverse transcriptase, RT; Protease, PR; Integrase, IN",1,"PR, RT, IN",1,Pol,0
Human Answer,37376649,10,What method was used for sequencing?,List,Illumina sequencing,,Illumina sequencing,1,NGS,0,NGS,0,Next-generation sequencing (NGS) using the GenoSure Archive assay.,0,Next-generation sequencing (NGS),0,NGS,0,NGS,0
Human Answer,37376649,11,What type of samples were sequenced?,List,Whole Blood,,Whole Blood,1,Whole Blood,1,Whole blood,1,Participants' baseline whole blood samples (proviral DNA) were used.,1,Whole Blood,1,PBMC,0,Whole Blood,1
Human Answer,37376649,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No — participants with prior virologic failure were excluded, and the baseline sequencing was performed in participants without previous virologic failure.",1,No,1,No,1,No,1
Human Answer,37376649,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — they were participants in the randomized TANGO clinical trial (ClinicalTrials.gov, NCT03446573).",1,Yes,1,Yes,1,Yes,1
Human Answer,37376649,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Not reported,0,Yes.,1,No,0,No,0,No,0
Human Answer,37376649,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, INSTI",,"NRTI, NNRTI, PI, INSTI",1,"NRTI, INSTI",1,Not applicable,0,"Participants had prior exposure to NRTIs, NNRTIs, protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs).",0,INSTI,0,No,0,Not Reported,0
Human Answer,37376649,16,Which drugs were received by individuals in the study before sample sequencing?,List,"Lamivudine (3TC), Tenofovir (TAF), Dolutegravir (DTG)",,"Lamivudine (3TC), Tenofovir (TAF), Dolutegravir (DTG)",1,"DTG, 3TC, TAF",1,Not applicable,0,The manuscript primarily reports prior regimens as tenofovir alafenamide (TAF)-based regimens and discusses study drugs dolutegravir (DTG) and lamivudine (3TC); no comprehensive list of all individual prior drugs for participants is provided.,1,"Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,0,Not Reported,0
Human Answer,37381002,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37381002,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,Yes,0,No — the paper reports genotypic resistance analysis/predictions rather than in vitro phenotypic susceptibility testing.,1,No,1,No,1,No,1
Human Answer,37381002,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported in the paper.,0,No,1,No,1,No,1
Human Answer,37381002,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,Not provided / Not reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37381002,5,How many individuals had samples obtained for HIV sequencing?,Number,398,,398,1,398,1,398,1,398 individuals (pol gene sequences successfully sequenced).,1,398,1,398,1,398,1
Human Answer,37381002,6,From which countries were the sequenced samples obtained?,List,China,,No,0,China,1,China,1,China.,1,China,1,China,1,China,1
Human Answer,37381002,7,From what years were the sequenced samples obtained?,List,2017-2020,,2017-2020,1,2017-2020,1,2017–2020,1,From 2017 to 2020.,1,2017-2020,1,2017-2020,1,2017-2020,1
Human Answer,37381002,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — cloning is not described; PCR products were directly sequenced (Sanger) or pooled and NGS-sequenced.,1,No,1,No,1,Not reported,1
Human Answer,37381002,9,Which HIV genes were reported to have been sequenced?,List,"NFLG, Pol",,"Protease, PR; Reverse transcriptase, RT",0,"Near full length genome, PR, RT",1,Pol,0,Partial pol gene (protease and first 300 amino acids of reverse transcriptase) and near full-length genomes covering gag to nef.,1,"Protease, PR; Reverse transcriptase, RT",0,"PR, RT, Near full length genome",1,"Pol, Near full-length genome",1
Human Answer,37381002,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing",,Illumina sequencing,0,Sanger sequencing; NGS,0,NGS,0,Sanger sequencing for the partial pol fragments and next-generation sequencing (Illumina iSeq) for near full-length genomes.,1,Next-generation sequencing (NGS),0,Sanger sequencing; Illumina sequencing,1,"Sanger sequencing, NGS",0
Human Answer,37381002,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma samples (EDTA-anticoagulated blood/plasma).,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37381002,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — sequences were from individuals with antiretroviral therapy (ART) failure (viral load ≥ 1000 copies/ml).,1,Yes,1,Yes,1,Yes,1
Human Answer,37381002,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the study is described as a retrospective observational study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,37381002,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — individuals had received antiretroviral therapy for more than one year prior to being identified as treatment failures.,1,Yes,1,Yes,1,Yes,1
Human Answer,37381002,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI, PI",0,No,1,Not reported,1,Primarily nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs); protease inhibitors (PIs) are also discussed though first-line exposure was mainly NRTI + NNRTI.,0,"NRTI, NNRTI, PI",0,No,1,Not reported,1
Human Answer,37381002,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Abacavir (ABC), Zidovudine (AZT), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TDF)",0,No,1,Not applicable,1,"The paper states the most common first-line drugs/regimen included TDF (tenofovir) or AZT (zidovudine), plus 3TC (lamivudine), and EFV (efavirenz) or NVP (nevirapine).",0,"ABC, AZT, EFV",0,No,1,Not reported,1
Human Answer,37439411,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37439411,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,Yes,0,"No — only genotypic susceptibility interpretations were reported, not in vitro phenotypic assays.",1,No,1,No,1,No,1
Human Answer,37439411,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / Not specified,0,No,1,No,1,Not Reported,1
Human Answer,37439411,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not Reported,1
Human Answer,37439411,5,How many individuals had samples obtained for HIV sequencing?,Number,9387,,9387,1,9387,1,9387,1,"15,369 individuals (5,982 treatment-naïve and 9,387 treatment-experienced)",0,5982 naïve individuals and 9387 treatment-experienced individuals,0,14969,0,5982 naïves and 9387 treatment-experienced PLWH,0
Human Answer,37439411,6,From which countries were the sequenced samples obtained?,List,Italy,,Italy,1,Italy,1,Italy,1,Italy (samples originated from Italian centres); patients included some born outside Italy but sequencing was from Italian cohort centres,1,Italy,1,Italy,1,Italy,1
Human Answer,37439411,7,From what years were the sequenced samples obtained?,List,2000-2020,,2000-2020,1,2000-2020,1,2000-2020,1,2000 to 2020,1,2000-2020,1,2000-2020,1,2000-2020,1
Human Answer,37439411,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported / No indication of cloning prior to sequencing,0,No,1,No,1,Not Reported,1
Human Answer,37439411,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",,"PR, RT",1,"PR, RT",1,Not reported,0,Protease and reverse transcriptase (parts of the pol gene),1,"Protease, Reverse transcriptase",1,"PR, RT",1,Protease and reverse transcriptase,1
Human Answer,37439411,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,Population genotypic sequencing of HIV-1 RNA (genotyping); specific laboratory sequencing platform/method not specified,1,No,1,No,1,Not Reported,1
Human Answer,37439411,11,What type of samples were sequenced?,List,No,,No,1,Plasma,0,Plasma,0,"HIV-1 RNA (viral RNA) samples (i.e., RNA genotypes); biological source (e.g. plasma) not explicitly stated",1,Plasma,0,Plasma,0,Plasma,0
Human Answer,37439411,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer,37439411,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,No,0,No,0,No,0,No — they were part of an observational cohort,0,No,0,No,0,Not Reported,0
Human Answer,37439411,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37439411,15,Which drug classes were received by individuals in the study before sample sequencing?,List,NNRTI,,NNRTI,1,No,0,Not reported,0,NNRTIs are explicitly reported as a prior exposure class; other classes are discussed but prior exposure to other specific classes is not explicitly reported as predictors.,1,NNRTI,1,"NRTI, NNRTI, PI, INSTI",1,"NNRTIs, NRTIs, and PIs",0
Human Answer,37439411,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Nevirapine (NVP), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR)",0,No,1,Not applicable,1,"Specific individual drugs received prior to sequencing are not detailed; only prior exposure to NNRTIs as a class is reported. The paper does discuss NNRTI drugs (e.g., RPV, ETR, NVP, EFV, DOR) when reporting susceptibility but does not specify which of these were received by participants.",1,"Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), and Doravirine (DOR)",0,No,1,"Efavirenz, nevirapine, and rilpivirine",0
Human Answer,37495103,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37495103,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37495103,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No evidence of public deposition,1,No,1,No,1,No,1
Human Answer,37495103,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers reported,1,No,1,No,1,Not reported,1
Human Answer,37495103,5,How many individuals had samples obtained for HIV sequencing?,Number,271,,271,1,271,1,271,1,237 individuals (sequences/subtyping reported for 237 patients),0,271,1,271,1,271,1
Human Answer,37495103,6,From which countries were the sequenced samples obtained?,List,Russia,,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1,Russia,1
Human Answer,37495103,7,From what years were the sequenced samples obtained?,List,2018-2022,,2018-2022,1,2018-2022,1,2018–2022,1,March 2018 through August 2022,1,2018-2022,1,2018-2022,1,2018-2022,1
Human Answer,37495103,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37495103,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,Pol,0,HIV-1 pol gene (specifically the PR-RT fragment: protease and reverse transcriptase),1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT",1,"PR, RT",1
Human Answer,37495103,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,RT-PCR followed by Sanger sequencing on an ABI PRISM 3130xl DNA Analyser,1,No,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37495103,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma (HIV-1 RNA isolated from plasma),1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37495103,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37495103,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37495103,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37495103,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI",,"NRTI, NNRTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI",0,"Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs)",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI",0,"NRTI, NNRTI, INSTI, PI",1
Human Answer,37495103,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, FTC, EFV, ABC, 3TC, DTG, LPV, Elsulfavirine, RAL, DRV, AZT",,"Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV), Abacavir (ABC)",0,"Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV), Abacavir (ABC), Dolutegravir (DTG), Lopinavir (LPV), Raltegravir (RAL), Darunavir (DRV), Elsulfavirine (ESV)",0,"TDF, 3TC, EFV, DTG",0,"Drugs included tenofovir (TDF), lamivudine (3TC), efavirenz (EFV), abacavir (ABC), dolutegravir (DTG), lopinavir/ritonavir (LPV/r), elsulfavirine (ESV), raltegravir (RAL), darunavir/ritonavir (DRV/r), and PhAZT (phosphoside).",0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Tenofovir (TFV), Nevirapine (NVP), Efavirenz (EFV), Lopinavir (LPV), Dolutegravir (DTG)",0,"TDF, 3TC, EFV, ABC, DTG, LPV/r, ETR",0,"TDF, 3TC, EFV, ABC, DTG, LPV/r",0
Human Answer,37498738,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37498738,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37498738,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,Yes,0,Not stated in the main text; data availability is referenced in the Supplementary Appendix 6.,0,No,1,No,1,No,1
Human Answer,37498738,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are provided in the main text.,1,No,1,No,1,Not reported,1
Human Answer,37498738,5,How many individuals had samples obtained for HIV sequencing?,Number,43 or 101,,43,1,43,1,43,1,Sequencing was attempted for 101 participants; consensus sequences were obtained from samples overall and a focused analysis included 43 participants with successful sequences at three time points; single-genome sequencing was performed on 10 participants.,1,43,1,101,1,43,1
Human Answer,37498738,6,From which countries were the sequenced samples obtained?,List,Switzerland,,No,0,Switzerland,1,Switzerland,1,Switzerland.,1,No,0,Switzerland,1,Not reported,0
Human Answer,37498738,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,"Calendar years are not specified; samples are described by study-relative time points (ART start, 1 year after ART start, ESS week 0, ESS week 48).",1,No,1,No,1,Not reported,1
Human Answer,37498738,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No; samples were not cloned—sequencing was performed on near full-length PCR amplicons and single-genome dilutions with whole-genome amplification rather than cloning.,1,No,1,No,1,Not reported,1
Human Answer,37498738,9,Which HIV genes were reported to have been sequenced?,List,NFLG,,"Gag, Pol, Env",0,Near full length genome,1,"Gag, Pol, Env",0,"Near full-length proviral genomes were sequenced, with specific analysis of gag, pol (including protease and reverse transcriptase), env, and integrase.",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN; Envelope",0,Near full length genome,1,Near full-length genome,1
Human Answer,37498738,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing",,Illumina sequencing,0,NGS,0,NGS,0,Near full-length PCR amplification followed by next-generation sequencing (NGS); consensus assembly used SmaltAlign.,0,Next-generation sequencing (NGS),0,Next-generation sequencing (NGS),0,NGS,0
Human Answer,37498738,11,What type of samples were sequenced?,List,PBMC,,PBMC,1,PBMC,1,PBMC,1,Peripheral blood mononuclear cells (PBMCs) or co-culture virus derived from PBMCs.,1,PBMC,1,PBMC,1,PBMC,1
Human Answer,37498738,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No sequences were reported from individuals with virological failure; participants demonstrated sustained virological suppression over 48 weeks.,1,No,1,No,1,No,1
Human Answer,37498738,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes; participants were enrolled in the Early Simplified Study (ESS), a randomized clinical trial (NCT00537966).",1,Yes,1,Yes,1,Yes,1
Human Answer,37498738,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Not reported,0
Human Answer,37498738,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, INSTI",,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI, INSTI",1,Not reported,0,Participants received combination antiretroviral therapy (cART) and dolutegravir (an integrase inhibitor) was used in monotherapy; analyses also reference reverse transcriptase and protease drug-resistance contexts (indicating exposure to RT-targeting and protease-targeting drugs in cART).,0,"NRTI, NNRTI, PI, INST",0,No,0,Not reported,0
Human Answer,37498738,16,Which drugs were received by individuals in the study before sample sequencing?,List,DTG,,No,0,DTG,1,Not applicable,0,Dolutegravir (DTG) is explicitly mentioned; the paper refers generally to combination antiretroviral therapy (cART) but does not list specific other drug names in the main text provided.,1,Dolutegravir (DTG),1,No,0,Not reported,0
Human Answer,37515095,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37515095,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — only genotypic resistance profiling from sequences was reported, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer,37515095,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37515095,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37515095,5,How many individuals had samples obtained for HIV sequencing?,Number,968 or 1004,,1004,1,968,1,1004,1,1004 participants provided blood samples for the study; after processing and removal of duplicates the final sequencing dataset comprised 968 HIV-1 sequences.,1,0,0,968,1,1004,1
Human Answer,37515095,6,From which countries were the sequenced samples obtained?,List,Kazakhstan,,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan.,1,Kazakhstan,1,Kazakhstan,1,Kazakhstan,1
Human Answer,37515095,7,From what years were the sequenced samples obtained?,List,2017-2020,,2017-2020,1,2017-2020,1,2017–2020,1,2017 to 2020.,1,2017-2020,1,2017-2020,1,2017-2020,1
Human Answer,37515095,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No evidence of cloning; samples were processed by RT-PCR and directly sequenced.,1,No,1,No,1,Not reported,1
Human Answer,37515095,9,Which HIV genes were reported to have been sequenced?,List,Pol,,"Protease, RT",0,"PR, RT",0,Pol,1,Partial pol gene: protease and the 5′-end of reverse transcriptase (positions 2253 to 3337 on HXB2).,1,"Reverse transcriptase, RT",0,"PR, RT",0,Pol (including protease and reverse transcriptase),0
Human Answer,37515095,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,RT-PCR followed by Sanger sequencing,0,RT-PCR followed by Sanger sequencing using the AmpliSens® HIV-Resist-Seq kit and an Applied Biosystems Genetic Analyzer 3130.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37515095,11,What type of samples were sequenced?,List,Whole Blood,,Whole Blood,1,Plasma,0,Blood,0,mRNA purified from blood samples.,0,Plasma,0,Whole Blood,1,Blood,0
Human Answer,37515095,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,Yes,0,Not explicitly reported; virological failure status is not specified in the paper.,0,Yes,0,No,1,Not reported,1
Human Answer,37515095,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,968,0,No,1,Not reported,1
Human Answer,37515095,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — most sequences were from ART-experienced individuals; only 7 individuals were not undergoing ART.,1,Yes,1,Yes,1,Yes,1
Human Answer,37515095,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI",,"NRTI, NNRTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI",1,"Nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs).",0,"NRTI, NNRTI",1,"NRTI, NNRTI",1,Not reported,0
Human Answer,37515095,16,Which drugs were received by individuals in the study before sample sequencing?,List,"3TC, ABC, AZT, D4T, DDI, FTC, TDF, ETR, EFV, NVP, RPV",,"FTC, TDF, EFV",0,"Zidovudine (AZT), Didanosine (DDI), Stavudine (D4T), Lamivudine (3TC), Abacavir (ABC), Tenofovir (TDF), Emtricitabine (FTC), Nevirapine (NVP), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Darunavir (DRV), Lopinavir (LPV)",1,"FTC, TDF, EFV",0,"Reported drugs included AZT (zidovudine), DDI (didanosine), D4T (stavudine), 3TC (lamivudine), ABC (abacavir), TDF (tenofovir), FTC (emtricitabine), NVP (nevirapine), EFV (efavirenz), ETR (etravirine), RPV (rilpivirine), DRV/r and DRV/c (darunavir with ritonavir or cobicistat), LPV/r (lopinavir/ritonavir), and DTG (dolutegravir). The most common regimen was FTC + TDF + EFV.",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR)",1,"Emtricitabine (FTC), Tenofovir (TDF), Efavirenz (EFV)",0,Not reported,0
Human Answer,37515146,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37515146,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37515146,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37515146,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"GenBank MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, MK995397-MK995457",1,"MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457",1
Human Answer,37515146,5,How many individuals had samples obtained for HIV sequencing?,Number,379,,379,1,379,1,379,1,379 individuals,1,379,1,379,1,379,1
Human Answer,37515146,6,From which countries were the sequenced samples obtained?,List,Cameroon,,No,0,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1
Human Answer,37515146,7,From what years were the sequenced samples obtained?,List,2014-2019,,2014-2019,1,2014-2019,1,2014–2019,1,December 2014 to June 2019,1,2014-2019,1,2014-2019,1,2014-2019,1
Human Answer,37515146,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1
Human Answer,37515146,9,Which HIV genes were reported to have been sequenced?,List,Pol,,"Protease, RT",0,"PR, RT",0,"PR, RT",0,pol gene — protease and reverse transcriptase regions,1,"Protease, Reverse transcriptase",0,"PR, RT",0,"PR, RT",0
Human Answer,37515146,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger (capillary) sequencing of PCR-amplified pol region products on an ABI 3500 genetic analyzer following RT‑PCR and semi-nested PCR,1,No,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37515146,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma samples (derived from venous blood),1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37515146,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37515146,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1
Human Answer,37515146,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37515146,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,,0,None — participants were ART‑naive (no prior antiretroviral drug classes received),1,No,1,No,1,,0
Human Answer,37515146,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Individuals in the study did not receive any antiretroviral drugs before sample sequencing, as they were ART-naive participants.",0,No,1,Not applicable,1,None — participants had not received any antiretroviral drugs prior to sampling,1,No,1,No,1,Not Applicable,1
Human Answer,37520425,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37520425,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37520425,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37520425,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,OQ627458-OQ627474,,OQ627458-OQ627474,1,OQ627458-OQ627474,1,OQ627458-OQ627474,1,OQ627458-OQ627474.,1,OQ627458-OQ627474,1,OQ627458-OQ627474,1,OQ627458-OQ627474,1
Human Answer,37520425,5,How many individuals had samples obtained for HIV sequencing?,Number,25 or 30,,25,1,30,1,30,1,Sequences were successfully obtained from 16 individuals.,0,30,1,16,0,Not reported (but at least 30),0
Human Answer,37520425,6,From which countries were the sequenced samples obtained?,List,Tanzania,,No,0,Tanzania,1,Tanzania,1,Tanzania.,1,Tanzania,1,Tanzania,1,Tanzania,1
Human Answer,37520425,7,From what years were the sequenced samples obtained?,List,"2016-2017, 2019-2020",,No,0,"2016-2017, 2019-2020",1,2016–2020,0,Samples derive from patients initiating ART in two time periods: NNRTI cohort 16 December 2016 to 15 December 2017 and DTG cohort 16 March 2019 to 15 September 2020.,1,No,0,2016-2020,0,Not reported,0
Human Answer,37520425,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer,37520425,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"Protease, RT",0,"PR, RT, IN",1,"PR, RT",0,Protease and reverse transcriptase (and testing included integrase/INSTI resistance assessment).,1,"Reverse transcriptase, Protease, INSTI",0,"PR, RT",0,Protease and reverse transcriptase,0
Human Answer,37520425,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Direct Sanger sequencing following RT-PCR amplification using the HIV-1 Genotyping Kit Amplification Module and analysis with BioEdit 7.2.,1,Sanger sequencing,1,Sanger sequencing,1,Not reported,0
Human Answer,37520425,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Blood plasma samples.,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37520425,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,No,0,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37520425,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37520425,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,No,0,No; the study focused on treatment-naive individuals and excluded treatment-experienced patients.,0,Yes,1,No,0,Yes,1
Human Answer,37520425,15,Which drug classes were received by individuals in the study before sample sequencing?,List,INSTI,,NNRTI,0,"NRTI, NNRTI, INSTI",1,,0,"Integrase strand transfer inhibitor (INSTI) via dolutegravir-based regimens, nonnucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside reverse transcriptase inhibitor (NRTI) backbone drugs co-administered with DTG.",0,INSTI,1,No,0,INSTI,1
Human Answer,37520425,16,Which drugs were received by individuals in the study before sample sequencing?,List,DTG,,No,0,"DTG, NRTI, NNRTI",1,Not applicable,0,Dolutegravir (DTG) and NNRTI-based regimens (specific NNRTI drugs not named); participants also received co-administered NRTIs as backbone therapy.,0,Dolutegravir (DTG),1,No,0,Dolutegravir (DTG),1
Human Answer,37537871,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37537871,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — the paper reports genotypic resistance (sequence-based) interpretation, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer,37537871,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No public deposition of patient sequences is reported in the paper.,1,Yes,0,No,1,No,1
Human Answer,37537871,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None are provided in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37537871,5,How many individuals had samples obtained for HIV sequencing?,Number,77,,77,1,77,1,77,1,77 individuals (77 plasma samples).,1,77,1,77,1,77,1
Human Answer,37537871,6,From which countries were the sequenced samples obtained?,List,Hong Kong,,Hong Kong,1,Hong Kong,1,Hong Kong,1,Hong Kong.,1,Hong Kong,1,Hong Kong,1,Hong Kong,1
Human Answer,37537871,7,From what years were the sequenced samples obtained?,List,2002-2014,,2002-2014,1,2002-2014,1,2002–2014,1,Between 2002 and 2014.,1,2002-2014,1,2002-2014,1,2002-2014,1
Human Answer,37537871,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — samples were directly sequenced from viral RNA extracted from plasma (no cloning of patient samples is described).,1,No,1,No,1,No,1
Human Answer,37537871,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"Protease, RT, IN",1,"PR, RT, IN",1,"PR, RT",0,"Protease, reverse transcriptase (RT), and integrase (i.e., the pol region were covered by the long amplicon).",1,"Protease, Reverse transcriptase, Integrase",1,"PR, RT, IN",1,Pol,0
Human Answer,37537871,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing, Oxford nanopore",,Oxford Nanopore sequencing,0,Oxford Nanopore sequencing,0,"Sanger sequencing, Nanopore sequencing",0,"Long-read Oxford Nanopore (ONT) sequencing on GridION was the primary method, with Sanger sequencing and Illumina MiSeq used for comparison/validation.",1,Oxford Nanopore sequencing,0,Oxford Nanopore sequencing,0,NGS,0
Human Answer,37537871,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma samples (viral RNA extracted from plasma).,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37537871,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,No,0,Not reported,0,Not reported / clinical virological failure status was not determined for the sequenced individuals.,0,No,0,No,0,No,0
Human Answer,37537871,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — samples were collected from a hospital cohort and no clinical trial is mentioned.,1,No,1,No,1,No,1
Human Answer,37537871,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,No,0,Not applicable,0,Not specified in the paper.,0,No,0,No,0,No,0
Human Answer,37537871,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not reported / not specified.,0,No,1,No,1,Not reported,1
Human Answer,37537871,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not reported / not specified.,0,No,1,No,1,Not reported,1
Human Answer,37540331,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer,37540331,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37540331,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37540331,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported,1,No,1,No,1,Not reported,1
Human Answer,37540331,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,None (0),1,0,1,0,1,85,0
Human Answer,37540331,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed. The study was conducted in Iran.,1,No,1,No,1,Not reported,1
Human Answer,37540331,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed. The trial was registered in 2019.,1,No,1,No,1,Not reported,1
Human Answer,37540331,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed,1,No,1,No,1,Not reported,1
Human Answer,37540331,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,None — no HIV genes were sequenced or reported,1,No,1,No,1,Not reported,1
Human Answer,37540331,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed. Viral load was measured by PCR.,1,No,1,No,1,Not reported,1
Human Answer,37540331,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed. Clinical laboratory samples (for viral load and CD4) were collected.,1,No,1,No,1,Plasma,0
Human Answer,37540331,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,No,1
Human Answer,37540331,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37540331,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No sequences reported; participants were treatment-experienced and on ART,1,No,1,No,1,Yes,0
Human Answer,37540331,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI",0,No,1,"NRTI, NNRTI",0,Not applicable for sequencing. Participants' baseline regimens mostly included two NRTIs and one NNRTI.,1,"NRTI, NNRTI",0,No,1,"NRTIs, NNRTIs",0
Human Answer,37540331,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not reported,1,"Specific prior drugs are not specified; generally patients were on ART, mostly two NRTIs plus one NNRTI. Study drugs administered during the trial included TAF 25 mg (Altafir®) and dolutegravir 50 mg (Dolutegravir®).",1,"NRTI, NNRTI",0,No,1,Not reported,1
Human Answer,37541705,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,No,0,No,0,No — the paper does not report HIV sequences generated from patient samples.,0,No,0,No,0,Yes,1
Human Answer,37541705,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro phenotypic drug susceptibility data.,1,No,1,No,1,No,1
Human Answer,37541705,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — sequence data were not made publicly available.,1,No,1,No,1,No,1
Human Answer,37541705,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,Not applicable — the paper does not report any GenBank accession numbers.,1,No,1,No,1,Not reported,1
Human Answer,37541705,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,Not reported,1,Not applicable / zero — the study does not report obtaining samples for HIV sequencing.,1,0,1,0,1,57,0
Human Answer,37541705,6,From which countries were the sequenced samples obtained?,List,"Botswana, South Africa, Thailand, and the U.S.",,No,0,No,0,"Botswana, South Africa, Thailand, USA",0,"Not applicable — no sequences were reported; participants were recruited from Botswana, South Africa, Thailand, and the U.S.",0,No,0,No,0,"Botswana, South Africa, Thailand, USA",0
Human Answer,37541705,7,From what years were the sequenced samples obtained?,List,2020-2021,,No,0,No,0,Not reported,0,"Not applicable — no sequencing was reported; study enrollment occurred from September 9, 2020 through June 28, 2021 (last Week 24 visit December 14, 2021).",0,No,0,No,0,2020-2021,1
Human Answer,37541705,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing or cloning methods are reported.,1,No,1,No,1,Not reported,1
Human Answer,37541705,9,Which HIV genes were reported to have been sequenced?,List,RT,,No,0,No,0,Not applicable,0,Not applicable — the paper does not report sequencing of any HIV genes.,0,No,0,No,0,Not reported,0
Human Answer,37541705,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing method is reported.,1,No,1,No,1,Not reported,1
Human Answer,37541705,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was reported; the study collected pharmacokinetic plasma samples and monitored plasma HIV-1 RNA.,1,No,1,No,1,Plasma,0
Human Answer,37541705,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report any sequences from individuals with virologic failure.,1,No,1,No,1,Yes,0
Human Answer,37541705,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — participants were enrolled in an international phase I/II clinical trial (IMPAACT 2019, NCT03760458).",1,Yes,1,Yes,1,Yes,1
Human Answer,37541705,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,No — the paper does not report any HIV sequences; however most participants (95%) were treatment-experienced prior to study entry.,0,No,0,No,0,Yes,1
Human Answer,37541705,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"PI, INSTI",,"PI, INSTI",1,"PI, INSTI",1,Not reported,0,"Protease inhibitor (lopinavir/ritonavir) and integrase strand transfer inhibitors (dolutegravir, raltegravir) were used by participants prior to study entry.",1,"NRTI, NNRTI, PI, INSTI",1,No,0,Not reported,0
Human Answer,37541705,16,Which drugs were received by individuals in the study before sample sequencing?,List,"LPV, DTG, RAL, ABC, 3TC",,"Lopinavir/ritonavir, Dolutegravir, Raltegravir",0,"Lopinavir (LPV), Dolutegravir (DTG), Raltegravir (RAL)",0,Not applicable,0,"Specific drugs reported as prior anchor medications were lopinavir/ritonavir, dolutegravir, and raltegravir.",0,"Dolutegravir, Abacavir, Lamivudine",0,No,0,Not reported,0
Human Answer,37546367,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37546367,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,"No — the paper reports genotypic resistance inference, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer,37546367,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37546367,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,OQ886077 - OQ888150,,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150.,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1,OQ886077 - OQ888150,1
Human Answer,37546367,5,How many individuals had samples obtained for HIV sequencing?,Number,2074,,2074,1,2074,1,2074,1,"Sequences were obtained from 2,074 individuals (out of 3,274 samples collected).",1,2074,1,3274,0,2074,1
Human Answer,37546367,6,From which countries were the sequenced samples obtained?,List,China,,China,1,China,1,China,1,"China (Guangdong Province, China).",1,China,1,China,1,China,1
Human Answer,37546367,7,From what years were the sequenced samples obtained?,List,2011-2022,,2011-2022,1,2011-2022,1,2011–2022,1,Samples were obtained from 2011 to 2022.,1,2011-2022,1,2011-2022,1,2011-2022,1
Human Answer,37546367,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No evidence of cloning; PCR products were purified and directly Sanger-sequenced.,1,No,1,No,1,No,1
Human Answer,37546367,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, Pol",,"PR, RT",0,"PR, RT",0,Pol,0,Partial HIV-1 pol gene (HXB2 nt 2253–3252).,1,"Protease, Reverse transcriptase, Integrase",0,"PR, RT, IN",0,Pol,0
Human Answer,37546367,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing of RT-PCR/nested-PCR amplified products after ultracentrifugation-based concentration of plasma.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37546367,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma samples (derived from EDTA blood) concentrated by ultracentrifugation.,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37546367,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"No — sequences were obtained from ART-experienced individuals with low-level viremia (200–1000 copies/mL), not specifically described as virological failure.",0,No,0,No,0,Yes,1
Human Answer,37546367,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this was a retrospective observational study of routine samples, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,37546367,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — all participants had received antiretroviral therapy for at least 6 months.,1,Yes,1,Yes,1,Yes,1
Human Answer,37546367,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI",,"NRTI, NNRTI, PI",1,No,0,"NRTI, NNRTI, PI",1,"NRTIs (nucleoside reverse-transcriptase inhibitors), NNRTIs (non-nucleoside reverse-transcriptase inhibitors), and PIs (protease inhibitors).",1,"NRTI, NNRTI, PI",1,No,0,Not reported,0
Human Answer,37546367,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Efavirenz (EFV)",0,No,1,Not reported,1,"The paper references common NRTIs (AZT, ABC, FTC, 3TC, TDF, D4T, DDI), NNRTIs (NVP, EFV, ETR, RPV, DOR) and PIs (e.g., NFV/r, DRV/r) in the analyses and discussion, indicating these drugs were relevant to regimens/exposures.",0,"ABC, AZT, 3TC, FTC, EFV",0,No,1,Not applicable,1
Human Answer,37554471,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,No,0,No,0,No.,0,No,0,No,0,Yes,1
Human Answer,37554471,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,Yes — for non-HIV pathogens (MAI) and HBV drug resistance testing; no HIV phenotypic susceptibility data are reported.,0,No,1,No,1,No,1
Human Answer,37554471,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report making any sequences publicly available.,1,No,1,No,1,No,1
Human Answer,37554471,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported / not applicable.,1,No,1,No,1,Not reported,1
Human Answer,37554471,5,How many individuals had samples obtained for HIV sequencing?,Number,1,,0,0,0,0,1,1,None — no HIV sequencing was reported; the paper describes a single patient case.,0,0,0,0,0,1,1
Human Answer,37554471,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not applicable — no sequenced samples were reported.,1,No,1,No,1,Not reported,1
Human Answer,37554471,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not applicable — no sequencing or dates for sequencing are reported.,1,No,1,No,1,Not reported,1
Human Answer,37554471,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing or cloning methods are reported.,1,No,1,No,1,Not reported,1
Human Answer,37554471,9,Which HIV genes were reported to have been sequenced?,List,RT,,No,0,No,0,Not applicable,0,None — no HIV genes were reported as sequenced.,0,No,0,No,0,Not reported,0
Human Answer,37554471,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing method is reported.,1,No,1,No,1,Not reported,1
Human Answer,37554471,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no samples were reported as sequenced.,1,No,1,No,1,Not reported,1
Human Answer,37554471,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — no sequences were obtained or reported.,1,No,1,No,1,Yes,0
Human Answer,37554471,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this report is a single-case clinical report, not a clinical trial participant.",1,Yes,0,No,1,No,1
Human Answer,37554471,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper does not report any HIV sequences; the described patient had prior ARV exposure.,1,Yes,0,No,1,Yes,0
Human Answer,37554471,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NNRTI, INSTI, PI",0,"NRTI, NNRTI, PI, INSTI",0,"NNRTI, PI",0,"Reportedly received antiretroviral agents spanning multiple classes: non-nucleotide reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitor (INSTI), protease inhibitor (with pharmacologic booster), and nucleoside/tide reverse transcriptase inhibitors (NRTIs).",0,"NRTI, NNRTI, PI",0,No,1,"NRTIs, NNRTIs, and PIs",0
Human Answer,37554471,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Etravirine, Dolutegravir, Darunavir, Ritonavir",0,"Etravirine (ETR), Dolutegravir (DTG), Darunavir (DRV), Ritonavir (RTV), Tenofovir (TFV), Lamivudine (3TC), Emtricitabine (FTC), Abacavir (ABC), Efavirenz (EFV)",0,"Etravirine, Dolutegravir, Darunavir, Ritonavir",0,"The patient had been prescribed etravirine, dolutegravir, darunavir and ritonavir; prior resistance testing showed mutations to tenofovir, lamivudine, emtricitabine, abacavir and efavirenz. He later received cabotegravir/rilpivirine long‑acting injections and was started on emtricitabine/tenofovir alafenamide for HBV when reactivation was detected.",0,"Etravirine, Dolutegravir, Darunavir, Ritonavir",0,No,1,"emtricitabine, tenofovir alafenamide, etravirine, dolutegravir, darunavir, and ritonavir",0
Human Answer,37573167,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37573167,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,"No — the paper reports genotypic resistance and genotypic susceptibility scores, not in vitro (phenotypic) susceptibility assays.",1,No,1,No,1,No,1
Human Answer,37573167,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication of public sequence deposition.,0,No,1,No,1,No,1
Human Answer,37573167,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37573167,5,How many individuals had samples obtained for HIV sequencing?,Number,1126,,1126,1,1126,1,1126,1,1126 individuals.,1,1126,1,1126,1,1126,1
Human Answer,37573167,6,From which countries were the sequenced samples obtained?,List,Italy,,Italy,1,Italy,1,Italy,1,Italy.,1,No,0,Italy,1,Italy,1
Human Answer,37573167,7,From what years were the sequenced samples obtained?,List,2010-2021,,2010-2021,1,2010-2021,1,2010-2021,1,From 2010 to 2021.,1,2010-2021,1,2010-2021,1,2010-2021,1
Human Answer,37573167,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No — the study used standard Sanger sequencing without mention of cloning.,1,No,1,No,1,Not reported,1
Human Answer,37573167,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,Not reported,0,Protease/reverse transcriptase (PR/RT) and integrase.,1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,Pol (including protease and reverse transcriptase),0
Human Answer,37573167,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37573167,11,What type of samples were sequenced?,List,PBMC,,PBMC,1,PBMC,1,"Whole blood, PBMC",1,HIV-1 DNA extracted from whole blood and lymphomonocytic cells (PBMCs) separated from peripheral blood.,1,PBMC,1,PBMC,1,Whole-blood and lymphomonocytic cells,0
Human Answer,37573167,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — sequences were obtained from virologically suppressed individuals at the time of sampling.,1,No,1,No,1,Yes,0
Human Answer,37573167,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the samples and testing were from routine clinical practice, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer,37573167,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — the cohort consists of drug-experienced individuals, many with prior ARV exposure.",1,Yes,1,Yes,1,Yes,1
Human Answer,37573167,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI",,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,Not reported,0,"NRTIs, NNRTIs, PIs, and INSTIs (antiretroviral classes).",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTIs, NNRTIs, PIs, and INSTIs",0
Human Answer,37573167,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Specific individual drug names are not reported; only antiretroviral drug classes and regimen types are described.,1,No,1,No,1,Not reported,1
Human Answer,37574435,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes — the paper reports HIV genotypic resistance data (mutations) from patient samples.,1,No,0,Yes,1,Yes,1
Human Answer,37574435,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro (phenotypic) drug susceptibility assays.,1,No,1,No,1,No,1
Human Answer,37574435,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report that sequences were deposited or made publicly available.,1,No,1,No,1,No,1
Human Answer,37574435,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,37574435,5,How many individuals had samples obtained for HIV sequencing?,Number,70 or 79,,0,0,0,0,79,1,70 of 79 participants had available genotypic resistance data prior to the switch.,0,0,0,0,0,79,1
Human Answer,37574435,6,From which countries were the sequenced samples obtained?,List,Taiwan,,No,0,Taiwan,1,Taiwan,1,Taiwan (single-center study at National Taiwan University Hospital).,1,No,0,Taiwan,1,Not reported,0
Human Answer,37574435,7,From what years were the sequenced samples obtained?,List,2016-2022,,No,0,2016-2022,1,2016–2022,1,Samples/reports were from the study period between 1 January 2016 and 30 March 2022.,1,No,0,2016-2022,1,2016-2022,1
Human Answer,37574435,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported / not specified.,0,No,1,No,1,No,1
Human Answer,37574435,9,Which HIV genes were reported to have been sequenced?,List,RT,,No,0,No,0,Not reported,0,"Regions associated with NRTI and INSTI resistance — i.e., reverse transcriptase (NRTI-related RAMs) and integrase (INSTI-related RAMs) regions.",0,No,0,"PR, RT, IN",1,Not reported,0
Human Answer,37574435,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,Not specified in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37574435,11,What type of samples were sequenced?,List,No,,No,1,Plasma,0,Plasma,0,"Not explicitly specified; the study references plasma HIV RNA load and genotypic resistance reports, implying plasma-derived viral RNA but the sample type for sequencing is not explicitly stated.",1,No,1,Plasma,0,Plasma,0
Human Answer,37574435,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes — genotypic resistance data were available for participants who had viral rebound (virologic failure) prior to switching regimens.,1,No,0,Yes,1,Yes,1
Human Answer,37574435,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the study was a single-center, retrospective cohort study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,37574435,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes — all participants were antiretroviral-experienced and the paper reports archived resistance mutations from these individuals.,1,No,0,Yes,1,Yes,1
Human Answer,37574435,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, INSTI",,"NRTI, INSTI",1,"NRTI, NNRTI, INSTI",1,"NRTI, INSTI",1,"Classes explicitly mentioned as prior regimens include non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based regimens, first-generation integrase strand-transfer inhibitor (INSTI)-based regimens, and nucleos(t)ide reverse-transcriptase inhibitors (NRTIs).",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1
Human Answer,37574435,16,Which drugs were received by individuals in the study before sample sequencing?,List,"DTG, BIC, FTC, TAF",,No,0,"DTG, FTC, TAF, BIC, NRTI, NNRTI",1,Not reported,0,Specific drugs mentioned as prior exposures include first-generation INSTIs raltegravir and cobicistat-boosted elvitegravir; tenofovir is also mentioned in the context of resistance (K65R).,0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,0,"Bictegravir, dolutegravir, emtricitabine, tenofovir alafenamide, rilpivirine",1
Human Answer,37585352,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37585352,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,No,0,No,0,No,0,No,0,No,0,No,0
Human Answer,37585352,3,Were sequences from the paper made publicly available?,Boolean,No,,Yes,0,No,1,No,1,"Yes, available on request through the PANGEA consortium",0,Yes,0,Yes,0,Yes,0
Human Answer,37585352,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,Not reported / no GenBank accession numbers provided,1,No,1,No,1,Not reported,1
Human Answer,37585352,5,How many individuals had samples obtained for HIV sequencing?,Number,5805,,5805,1,5805,1,5805,1,5805 participants (sequences),1,5805,1,5805,1,5805,1
Human Answer,37585352,6,From which countries were the sequenced samples obtained?,List,Botswana,,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1
Human Answer,37585352,7,From what years were the sequenced samples obtained?,List,2013-2018,,2013-2018,1,2013-2018,1,2013–2018,1,2013,0,2013-2018,1,2013-2018,1,2013-2018,1
Human Answer,37585352,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer,37585352,9,Which HIV genes were reported to have been sequenced?,List,Pol,,Near full length genome,0,Near full length genome,0,Pol,1,The pol gene (near full-length HIV-1 pol sequences),1,"Reverse transcriptase, RT; Integrase, IN",0,"PR, RT, IN",0,Pol,1
Human Answer,37585352,10,What method was used for sequencing?,List,Illumina sequencing,,Illumina sequencing,1,NGS,0,NGS,0,Next-generation sequencing (Illumina MiSeq and HiSeq platforms),1,Illumina sequencing,1,NGS,0,NGS,0
Human Answer,37585352,11,What type of samples were sequenced?,List,No,,Other,0,No,1,Proviral DNA,0,Proviral DNA (from participants),0,PBMC,0,PBMC,0,PBMC,0
Human Answer,37585352,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer,37585352,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes, participants were recruited from a large community HIV incidence trial (the Botswana Combination Prevention Project, registered NCT01965470)",1,No,0,Yes,1,Yes,1
Human Answer,37585352,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37585352,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI",,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,Primarily nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs); very few participants had exposure to integrase strand transfer inhibitors (INSTIs),1,"NNRTI, NRTI",1,NNRTI,0,"NRTI, NNRTI, PI",1
Human Answer,37585352,16,Which drugs were received by individuals in the study before sample sequencing?,List,"EFV, FTC, TDF, 3TC, NVP, AZT",,"Efavirenz, Emtricitabine, Tenofovir, Lamivudine, Nevirapine, Zidovudine",1,"Efavirenz (EFV), Emtricitabine (FTC), Tenofovir (TFV), Lamivudine (3TC), Nevirapine (NVP), Zidovudine (ZDV)",0,"Efavirenz, Emtricitabine, Tenofovir, Lamivudine, Nevirapine, Zidovudine",1,"Reported drugs include efavirenz, emtricitabine, tenofovir, lamivudine, nevirapine and zidovudine; INSTI exposure was very rare",1,"Nevirapine (NVP), Efavirenz (EFV), Lamivudine (3TC), Zidovudine (AZT), Emtricitabine (FTC), Tenofovir (TFV)",1,"Efavirenz (EFV), Nevirapine (NVP), Rilpivirine (RPV)",0,"EFV, FTC, TDF, 3TC, NVP, ZDV",0
Human Answer,37593123,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37593123,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,"No — the study reports genotypic resistance inference, not in vitro phenotypic susceptibility testing.",1,No,1,No,1,No,1
Human Answer,37593123,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Yes — the analysis used sequences obtained from public databases (China CDC records and the Los Alamos HIV sequence database / GenBank annotations).,0,No,1,No,1,Not Reported,1
Human Answer,37593123,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,Not reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37593123,5,How many individuals had samples obtained for HIV sequencing?,Number,57902,,57902,1,57902,1,"57,902",0,"57,902 individuals (ART-naïve).",1,57902,1,57802,0,"57,902",0
Human Answer,37593123,6,From which countries were the sequenced samples obtained?,List,China,,China,1,China,1,China,1,China.,1,China,1,China,1,China,1
Human Answer,37593123,7,From what years were the sequenced samples obtained?,List,2004-2022,,2004-2022,1,2004-2022,1,2004–2022,1,2004 to 2022.,1,2004-2022,1,2004-2022,1,2004-2022,1
Human Answer,37593123,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication of cloning.,0,No,1,No,1,Not Reported,1
Human Answer,37593123,9,Which HIV genes were reported to have been sequenced?,List,Pol,,"Protease, RT",0,"PR, RT",0,Pol,1,"The pol gene region, specifically protease and the initial 238 amino acids of reverse transcriptase.",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",0,"PR, RT",0,Pol,1
Human Answer,37593123,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,Not specified; sequences were obtained from public sequence databases and analyzed computationally (alignment with HIV-Trace and phylogenetics with IQ-Tree).,1,No,1,No,1,Not Reported,1
Human Answer,37593123,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not Reported,1,"Not specified beyond being sequences from ART-naïve HIV-positive individuals; the sample type (e.g., plasma, PBMC) is not reported.",1,No,1,No,1,Plasma,0
Human Answer,37593123,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No. All sequences were from ART-naïve individuals, so none were from persons failing treatment.",1,No,1,No,1,No,1
Human Answer,37593123,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No. The study used surveillance/research sequences from databases and describes observational sampling across PLADs, not enrollment in a clinical trial.",1,No,1,No,1,Not Reported,1
Human Answer,37593123,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No. The sequences were from ART-naïve individuals who had not previously received antiretroviral therapy.,1,No,1,No,1,No,1
Human Answer,37593123,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,NNRTI,0,No,1,,0,None — individuals were ART-naïve and had not received antiretroviral drug classes prior to sampling.,1,No,1,No,1,Not Reported,1
Human Answer,37593123,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Efavirenz, Nevirapine",0,No,1,Not applicable,1,"None — the study population was ART-naïve, so no individual-level prior antiretroviral drugs are reported.",1,No,1,No,1,Not Reported,1
Human Answer,37626789,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer,37626789,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — the paper reports genotypic resistance from sequencing and interpretation via the Stanford HIVDB algorithm, not in vitro phenotypic susceptibility testing.",1,No,1,No,1,No,1
Human Answer,37626789,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report public deposition of sequences.,1,No,1,No,1,No,1
Human Answer,37626789,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37626789,5,How many individuals had samples obtained for HIV sequencing?,Number,551,,551,1,0,0,551,1,Not specified in the paper.,0,551,1,551,1,551,1
Human Answer,37626789,6,From which countries were the sequenced samples obtained?,List,Ethiopia,,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia.,1,Ethiopia,1,Ethiopia,1,Ethiopia,1
Human Answer,37626789,7,From what years were the sequenced samples obtained?,List,2007-2019,,2007-2019,1,2007-2019,1,2017–2019,0,Samples were collected during the 2019 viral load testing period (March to September 2019) with a six-month follow-up for confirmation; the overall cohort follow-up covers 2007,0,2017-2019,0,2017-2019,0,2017-2019,0
Human Answer,37626789,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No cloning prior to sequencing is reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37626789,9,Which HIV genes were reported to have been sequenced?,List,Pol,,"Reverse transcriptase, RT; Protease, PR",0,Pol,1,Pol,1,The pol gene.,1,"Reverse transcriptase, RT; Protease, PR; Integrase, IN",0,"PR, RT, IN",0,Pol,1
Human Answer,37626789,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,An in-house amplification and Sanger sequencing assay using an ABI-3730 DNA genetic analyzer; sequences were edited using the web-based ReCall tool.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37626789,11,What type of samples were sequenced?,List,Plasma,,Whole Blood,0,Plasma,1,"Whole Blood, Plasma",1,Plasma extracted from whole blood samples.,1,Whole Blood,0,Plasma,1,Plasma,1
Human Answer,37626789,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37626789,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No; they were part of an observational longitudinal national cohort study.,1,No,1,No,1,No,1
Human Answer,37626789,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer,37626789,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI",,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI",1,Primarily nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs); protease inhibitors (PIs) were infrequently used.,0,"NRTI, NNRTI",1,"NRTI, NNRTI",1,"NRTI, NNRTI, PI",1
Human Answer,37626789,16,Which drugs were received by individuals in the study before sample sequencing?,List,"AZT, 3TC, NVP, D4T, EFV, ABC, EFV, TDF",,"Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), Efavirenz (EFV)",0,"Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), Efavirenz (EFV)",0,"Zidovudine, Lamivudine, Nevirapine, Stavudine, Efavirenz",0,"Drugs included Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), Efavirenz (EFV), Abacavir (ABC), and Tenofovir (TDF); protease inhibitors such as nelfinavir (NFV) and others are mentioned as second-line options but were infrequently used.",1,"Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), Efavirenz (EFV)",0,"Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP), Stavudine (D4T), Efavirenz (EFV)",0,"AZT, 3TC, NVP, EFV",0
Human Answer,37632026,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37632026,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1
Human Answer,37632026,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37632026,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; OQ985493-OQ985958,,MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; OQ985493-OQ985958,1,MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; OQ985493-OQ985958,1,MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; OQ985493-OQ985958,1,MK580543-MK580618; JF273935-JF273965; JQ796152-JQ796169; MK867721-MK867755; OQ985493-OQ985958,1,"MK580543-MK580618 ; JF273935-JF273965 ; JQ796152-JQ796169, MK867721-MK867755 ; and OQ985493-OQ985958",1,"MK580543-MK580618, JF273935-JF273965, JQ796152-JQ796169, MK867721-MK867755, OQ985493-OQ985958",1,"MK580543-MK580618, JF273935-JF273965, JQ796152-JQ796169, MK867721-MK867755, and OQ985493-OQ985958",1
Human Answer,37632026,5,How many individuals had samples obtained for HIV sequencing?,Number,759,,759,1,759,1,759,1,759 individuals,1,759,1,759,1,759,1
Human Answer,37632026,6,From which countries were the sequenced samples obtained?,List,Cameroon,,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon,1
Human Answer,37632026,7,From what years were the sequenced samples obtained?,List,2011-2019,,2011-2019,1,2011-2019,1,2011–2019,1,November 2011 to August 2019,1,2011-2019,1,2011-2019,1,2011-2019,1
Human Answer,37632026,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1
Human Answer,37632026,9,Which HIV genes were reported to have been sequenced?,List,Pol,,"Protease, RT",0,"PR, RT",0,"PR, RT",0,pol gene: protease and reverse-transcriptase regions,1,"Protease, Reverse transcriptase",0,"PR, RT",0,Pol (protease and reverse transcriptase regions),0
Human Answer,37632026,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,RT-PCR and nested PCR amplification followed by Sanger sequencing on an Applied Biosystems 3500 genetic analyzer; sequence assembly with SeqScape or Recall,1,No,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37632026,11,What type of samples were sequenced?,List,Plasma,,Whole Blood,0,Plasma,1,Plasma,1,Plasma samples (viral RNA extracted from plasma derived from whole blood),1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37632026,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37632026,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37632026,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37632026,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI",,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI",1,"NRTIs (nucleoside/nucleotide RT inhibitors), NNRTIs (non-nucleoside RT inhibitors), and boosted protease inhibitors (PI/r); no integrase inhibitor exposure was reported",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI",1,"NNRTI, PI",0
Human Answer,37632026,16,Which drugs were received by individuals in the study before sample sequencing?,List,"AZT, D4T, XTC, TDF, ATV, LPV, DRV",,No,0,"NRTI (Nucleoside Reverse Transcriptase Inhibitor), including Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Emtricitabine (FTC), Tenofovir (TFV); NNRTI (Non-Nucleosid Reverse Transcriptase Inhibitor), including Nevirapine (NVP), Efavirenz (EFV); PI (Protease Inhibitor), including Lopinavir (LPV), Atazanavir (ATV), Darunavir (DRV)",0,Not reported,0,"Reported drugs included zidovudine (AZT), stavudine (D4T), tenofovir (TDF), lamivudine/emtricitabine (3TC/FTC or XTC), abacavir (ABC), efavirenz (EFV), nevirapine (NVP), boosted protease inhibitors atazanavir/ritonavir (ATV/r), lopinavir/ritonavir (LPV/r), darunavir/ritonavir (DRV/r), and older PIs nelfinavir (NFV) and indinavir (IDV).",1,"TDF, AZT, ABC, EFV, ATV, LPV, DRV",0,"AZT, 3TC, TDF, EFV, NVP, LPV/r, ATV/r",0,Not Reported,0
Human Answer,37632071,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,37632071,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37632071,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — no sequences are reported or deposited.,1,No,1,No,1,No,1
Human Answer,37632071,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None — no GenBank accession numbers are reported.,1,No,1,No,1,Not reported,1
Human Answer,37632071,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,None — the study did not perform HIV sequencing.,1,0,1,0,1,197,0
Human Answer,37632071,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable (no sequencing); the study was conducted in Italy.,1,No,1,No,1,Italy,0
Human Answer,37632071,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable (no sequencing); the clinical study period was 2019–2022.,1,No,1,No,1,2019-2022,0
Human Answer,37632071,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No — cloning and sequencing are not described in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37632071,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,None — no HIV genes were sequenced or reported.,1,No,1,No,1,Not reported,1
Human Answer,37632071,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed or methods reported.,1,No,1,No,1,Not reported,1
Human Answer,37632071,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no samples were sequenced; the study measured plasma HIV RNA (plasma samples).,1,No,1,No,1,Plasma,0
Human Answer,37632071,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — no sequences were obtained; the study largely included individuals with suppressed or low-level viremia prior to switch.,1,No,1,No,1,Yes,0
Human Answer,37632071,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — this was a retrospective cohort study of routine clinical practice.,1,No,1,No,1,No,1
Human Answer,37632071,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper does not report any HIV sequences; the study population were treatment-experienced individuals on antiretroviral therapy.,1,No,1,No,1,Yes,0
Human Answer,37632071,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,INSTI,0,No,1,Not applicable,1,"Not applicable for sequencing, but prior to the switch individuals received NRTIs combined with INSTIs, NNRTIs, or PIs (e.g., 2 NRTI + INSTI, 2 NRTI + NNRTI, 2 NRTI + PI).",1,No,1,No,1,INSTI,0
Human Answer,37632071,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"INSTI (Bictegravir, etc.)",0,No,1,Not applicable,1,"Specific prior drug names are not reported comprehensively; the paper reports the switch regimen (bictegravir, emtricitabine, tenofovir alafenamide) and references lamivudine, TAF, and FTC in discussion, but does not list prior individual drug names for the cohort beyond drug classes.",1,No,1,No,1,"Bictegravir, emtricitabine, and tenofovir alafenamide",0
Human Answer,37649807,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes.,0
Human Answer,37649807,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No.,1
Human Answer,37649807,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report any sequences or GenBank deposits.,1,No,1,No,1,No.,1
Human Answer,37649807,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported.,1
Human Answer,37649807,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Zero — no samples were obtained for sequencing in this study.,1,0,1,0,1,"793,902.",0
Human Answer,37649807,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable (no sequences); the analyzed data derive from Kenya.,1,Kenya,0,No,1,Kenya.,0
Human Answer,37649807,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable (no sequences); the analyzed viral load data span January 2015 to December 2021.,1,2015-2021,0,No,1,2015-2021.,0
Human Answer,37649807,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed.,1,No,1,No,1,Not reported.,1
Human Answer,37649807,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,None — no HIV genes were sequenced or reported.,1,No,1,No,1,Not reported.,1
Human Answer,37649807,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing methods are described.,1,No,1,No,1,Not reported.,1
Human Answer,37649807,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed; viral load testing used plasma samples.,1,Plasma,0,No,1,Plasma.,0
Human Answer,37649807,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — no sequences were obtained; the paper does report virologic failure based on viral load criteria.,1,Yes,0,No,1,Yes.,0
Human Answer,37649807,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not Reported,1,No — patients were part of routine programmatic care and the analysis used retrospective routinely collected data.,1,No,1,No,1,No.,1
Human Answer,37649807,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the paper does not report sequences; however, the cohort included many individuals with prior ARV exposure.",1,Yes,0,No,1,Yes.,0
Human Answer,37649807,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI, INSTI",0,No,1,Not applicable,1,"Not applicable for sequencing; reported antiretroviral classes in the cohort include NRTIs (TDF with 3TC or FTC), NNRTIs, INSTIs (DTG), and protease inhibitors (PIs).",1,"INSTI, NRTI, NNRTI, PI",0,No,1,INSTI.,0
Human Answer,37649807,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Tenofovir disoproxil fumarate (TDF), Lamivudine (3TC), Emtricitabine (FTC), NNRTIs, Dolutegravir (DTG), Protease Inhibitors (PI)",0,No,1,Not applicable,1,"Not applicable for sequencing; the paper reports exposure to tenofovir disoproxil fumarate (TDF), lamivudine (3TC) or emtricitabine (FTC), dolutegravir (DTG), NNRTIs (class reported but individual NNRTI names not specified), and protease inhibitors (PIs).",1,"Dolutegravir (DTG), Tenofovir (TFV), Lamivudine (3TC), Emtricitabine (FTC)",0,No,1,INSTI-based drugs.,0
Human Answer,37662576,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37662576,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37662576,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper used public PDB structures rather than depositing new sequence data.,1,No,1,No,1,No,1
Human Answer,37662576,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,37662576,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,None — no individual patient samples were obtained or sequenced.,1,0,1,0,1,0,1
Human Answer,37662576,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no patient-derived sequences or sample collection locations were reported.,1,No,1,No,1,Not applicable,1
Human Answer,37662576,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing of samples was performed or reported.,1,No,1,No,1,Not applicable,1
Human Answer,37662576,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing or cloning of samples was performed.,1,No,1,No,1,Not applicable,1
Human Answer,37662576,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,None were sequenced; the study analyzed the HIV-1 protease protein (PR) structures.,1,Protease,0,No,1,Not applicable,1
Human Answer,37662576,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing method was used or reported.,1,No,1,No,1,Not applicable,1
Human Answer,37662576,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no samples were sequenced.,1,No,1,No,1,Not applicable,1
Human Answer,37662576,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the study did not obtain or report sequences from individuals, including those with virological failure.",1,No,1,No,1,Not applicable,1
Human Answer,37662576,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No — there were no patients in this study.,1,No,1,No,1,No,1
Human Answer,37662576,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — no individual-derived HIV sequences are reported.,1,No,1,No,1,Not applicable,1
Human Answer,37662576,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no individuals or pre-sequencing drug histories were reported.,1,PI,0,No,1,Not applicable,1
Human Answer,37662576,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no individuals or their prior drug treatments were sampled or sequenced.,1,"Darunavir, Lopinavir",0,No,1,Not applicable,1
Human Answer,37674678,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37674678,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,Yes,0,"No — only genotypic (predicted) resistance analyses were reported, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer,37674678,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,No,0,Yes,1,Not explicitly reported in the manuscript.,0,Yes,1,No,0,No,0
Human Answer,37674678,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37674678,5,How many individuals had samples obtained for HIV sequencing?,Number,1161 or 1393,,1393,1,1161,1,1393,1,"1,161 sequences were successfully obtained and analyzed (from 1,393 enrolled individuals).",1,1161,1,1161,1,"1,393",0
Human Answer,37674678,6,From which countries were the sequenced samples obtained?,List,China,,China,1,China,1,China,1,"China (samples were obtained in Nanjing, China).",1,China,1,China,1,China,1
Human Answer,37674678,7,From what years were the sequenced samples obtained?,List,2019 to 2021,,2019 to 2021,1,2019-2021,0,2019–2021,0,"From 2019 through 2021 (enrolled between January 1, 2019 and November 31, 2021).",1,2019-2021,0,2019-2021,0,2019-2021,0
Human Answer,37674678,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — samples were amplified by nested PCR and PCR products were directly sequenced; no cloning is described.,1,No,1,No,1,Not reported,1
Human Answer,37674678,9,Which HIV genes were reported to have been sequenced?,List,Pol,,"Protease, PR; Reverse transcriptase, RT",0,"PR, RT",0,Pol,1,The pol gene (specifically HXB2 positions 2253–3312).,1,"Reverse transcriptase, RT; Protease, PR",0,Pol,1,Pol,1
Human Answer,37674678,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Nested RT-PCR amplification followed by automatic Sanger sequencing on an ABI 3730XL instrument.,1,No,0,Sanger sequencing,1,Not reported,0
Human Answer,37674678,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma-derived viral RNA from 200 μl plasma samples (plasma isolated from blood).,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37674678,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — all participants were ART-naïve with no history of antiretroviral therapy.,1,No,1,No,1,No,1
Human Answer,37674678,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — patients were enrolled observationally at voluntary counseling and testing clinics, not as part of a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer,37674678,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No — the sequences were from ART-naïve individuals with no history of antiretroviral therapy.,1,No,1,No,1,No,1
Human Answer,37674678,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,,0,None — individuals had not received antiretroviral therapy prior to sampling.,1,"NRTI, NNRTI, PI",0,No,1,Not reported,1
Human Answer,37674678,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,None — no antiretroviral drugs were received by participants prior to sequencing.,1,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV)",0,No,1,Not reported,1
Human Answer,37701387,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,No,0,Yes,1,Yes — the paper reports baseline genotype/mutation data from patient samples.,1,No,0,No,0,Yes,1
Human Answer,37701387,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro phenotypic drug susceptibility data.,1,No,1,No,1,No,1
Human Answer,37701387,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report making sequences publicly available.,1,No,1,No,1,No,1
Human Answer,37701387,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,37701387,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,30,0,30 individuals (the Rainbow study participants).,0,0,1,0,1,30,0
Human Answer,37701387,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Italy,0,Italy.,0,No,1,No,1,Italy,0
Human Answer,37701387,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,2020–2021,0,From 2020 to 2021.,0,No,1,No,1,2020-2021,0
Human Answer,37701387,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication of cloning prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer,37701387,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,Regions corresponding to NRTI-associated sites (reverse transcriptase) and INSTI-associated sites (integrase) were assessed.,0,No,1,No,1,"Pol, Integrase",0
Human Answer,37701387,10,What method was used for sequencing?,List,No,,No,1,No,1,Not Reported,1,Not reported / method not specified in the paper.,1,No,1,No,1,Sanger sequencing,0
Human Answer,37701387,11,What type of samples were sequenced?,List,Whole Blood,,No,0,No,0,Plasma,0,Baseline clinical samples from study participants (baseline genotype was examined); exact specimen type is not specified.,0,No,0,No,0,"Plasma, PBMC",0
Human Answer,37701387,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — sequences were from ART‑naïve individuals and the study reported no virological failure-related ART interruptions.,1,No,1,No,1,Yes,0
Human Answer,37701387,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — the Rainbow component was a phase IV clinical trial.,1,Yes,1,No,0,Yes,1
Human Answer,37701387,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,No,0,Not applicable,0,No — the reported sequences/genotype data are from ART‑naïve individuals.,0,No,0,No,0,Yes,1
Human Answer,37701387,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI, INSTI",,No,0,No,0,,0,None — participants were ART‑naïve prior to sequencing.,0,"INSTI, PI",0,No,0,"NRTI, NNRTI, INSTI",0
Human Answer,37701387,16,Which drugs were received by individuals in the study before sample sequencing?,List,"BIC, FTC, TAF, DRV",,No,0,No,0,Not applicable,0,None — individuals were ART‑naïve before baseline sequencing.,0,"Bictegravir (BIC), Emtricitabine (FTC), Tenofovir (TFV), Darunavir (DRV)",0,No,0,"Bictegravir, Emtricitabine, Tenofovir alafenamide",1
Human Answer,37716367,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,Yes,0,No,1,No,1,No.,1,No,1,No,1,Yes.,0
Human Answer,37716367,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No.,1
Human Answer,37716367,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not applicable).,1,No,1,No,1,No.,1
Human Answer,37716367,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in this paper / Not applicable.,1,No,1,No,1,Not reported.,1
Human Answer,37716367,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Not applicable / none reported.,1,0,1,0,1,Not reported.,1
Human Answer,37716367,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,1,No,1,No,1,Not reported.,1
Human Answer,37716367,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,1,No,1,No,1,Not reported.,1
Human Answer,37716367,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,1,No,1,No,1,Not reported.,1
Human Answer,37716367,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,1,No,1,No,1,Not reported.,1
Human Answer,37716367,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,1,No,1,No,1,Not reported.,1
Human Answer,37716367,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,1,No,1,No,1,Not reported.,1
Human Answer,37716367,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,1,No,1,No,1,Not reported.,1
Human Answer,37716367,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No (the paper is a guideline; it does not report a clinical trial).,1,No,1,No,1,Not reported.,1
Human Answer,37716367,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,0,No,1,No,1,Not reported.,1
Human Answer,37716367,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,0,No,1,No,1,Not reported.,1
Human Answer,37716367,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,0,No,1,No,1,Not reported.,1
Human Answer,37755428,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes.,1
Human Answer,37755428,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — phenotypic in vitro susceptibility testing was not reported; resistance was predicted genotypically.,1,No,1,No,1,No.,1
Human Answer,37755428,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No information provided on public sequence deposition.,0,No,1,No,1,No.,1
Human Answer,37755428,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported.,1
Human Answer,37755428,5,How many individuals had samples obtained for HIV sequencing?,Number,143,,143,1,143,1,143,1,"143 remnant specimens were available for HIVDR testing; 121 and 105 yielded successful genotypes for PR/RT and integrase, respectively.",1,143,1,143,1,143.,1
Human Answer,37755428,6,From which countries were the sequenced samples obtained?,List,Haiti,,Haiti,1,Haiti,1,Haiti,1,Haiti.,1,Haiti,1,Haiti,1,Haiti.,1
Human Answer,37755428,7,From what years were the sequenced samples obtained?,List,2020-2021,,2020-2021,1,2020-2021,1,2020–2021,1,Between April 2020 and March 2021.,1,2020-2021,1,2020-2021,1,2020-2021.,1
Human Answer,37755428,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No — cloning is not reported; Sanger sequencing was performed on extracted nucleic acids.,1,No,1,No,1,Not reported.,1
Human Answer,37755428,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"PR, RT, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,Protease/reverse transcriptase (PR/RT) and integrase regions.,1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,No,0,PR/RT and integrase.,0
Human Answer,37755428,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger-based sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1
Human Answer,37755428,11,What type of samples were sequenced?,List,DBS,,Other,0,DBS,1,DBS,1,Remnant dried blood spot specimens collected at the time of HIV diagnosis.,1,DBS,1,DBS,1,Dried blood spots.,0
Human Answer,37755428,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — sequences were from ART-naive infants; no drug resistance testing was done on the mother's virus despite maternal detectable viral load.,1,No,1,No,1,Yes.,0
Human Answer,37755428,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,"No — the data derive from a national surveillance survey, not a clinical trial.",1,No,1,No,1,Not reported.,1
Human Answer,37755428,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,Yes,0,No,1,"Yes — although infants were ART-naive, the majority had prior exposure to antiretroviral drugs for PMTCT and some infants received postnatal prophylaxis (PNP).",0,Yes,0,No,1,Yes.,0
Human Answer,37755428,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,INSTI,0,"NRTI, INSTI",0,,0,NRTIs and INSTIs (mothers on DTG-based ART); NNRTIs were also referenced as commonly used for PNP historically.,0,"NRTI, INSTI",0,"NRTI, INSTI",0,NRTIs and INSTIs.,0
Human Answer,37755428,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG)",0,Not applicable,1,"Tenofovir/lamivudine/dolutegravir (mother(s)) and zidovudine-based postnatal prophylaxis (infant); the paper also refers to exposure histories involving 3TC/lamivudine, ABC (in resistance context), and historical NNRTIs (efavirenz/nevirapine) in the population.",0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, Lamivudine, Dolutegravir",0,"Tenofovir, lamivudine, and dolutegravir.",0
Human Answer,37775947,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer,37775947,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — the paper reports genotypic predictions (GSS) based on sequence data, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer,37775947,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication in the paper that sequence data were made publicly available.,0,No,1,No,1,Not Reported,1
Human Answer,37775947,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not Reported,1
Human Answer,37775947,5,How many individuals had samples obtained for HIV sequencing?,Number,1380 or 1819,,1380,1,1380,1,1380,1,1819 participants had NGS data at ≥200 read depth; 1380 participants with sequencing and who started ART and had follow-up were included in the main analysis.,1,1380,1,1380,1,1380,1
Human Answer,37775947,6,From which countries were the sequenced samples obtained?,List,"South America, Africa, USA",,"South America, Africa, USA",1,No,0,Not reported,0,"The paper does not list specific countries; samples were from multiple regions including South America, Africa, the USA and Europe.",1,"South America, Africa, USA",1,No,0,Not Reported,0
Human Answer,37775947,7,From what years were the sequenced samples obtained?,List,2009-2013,,2009-2013,1,2009-2013,1,2009–2013,1,Samples were obtained between April 2009 and December 2013.,1,2009-2013,1,2009-2013,1,2009-2013,1
Human Answer,37775947,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — cloning is not reported; samples underwent RNA amplification followed by NGS.,1,No,1,No,1,Not Reported,1
Human Answer,37775947,9,Which HIV genes were reported to have been sequenced?,List,Pol,,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"pol gene covering protease (positions 1–99), reverse transcriptase (positions 100–659), and part of integrase (positions 660–935).",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",0,"PR, RT, IN",0,Pol,1
Human Answer,37775947,10,What method was used for sequencing?,List,Illumina sequencing,,Illumina sequencing,1,Illumina sequencing,1,NGS,0,Next-generation sequencing (NGS) using Illumina MiSeq.,1,Next-generation sequencing (NGS),0,Illumina sequencing,1,NGS,0
Human Answer,37775947,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Stored plasma samples (baseline plasma taken within 60 days before enrolment).,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37775947,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,No,1,No — baseline sequences were obtained from ART‑naïve participants prior to treatment; genotypic tests at time of failure were not conducted.,1,No,1,No,1,Yes,0
Human Answer,37775947,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — they were participants in the START randomized clinical trial.,1,Yes,1,Yes,1,Not Reported,0
Human Answer,37775947,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No — the participants were ART‑naïve at baseline.,1,No,1,No,1,No,1
Human Answer,37775947,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI",0,No,1,,0,None — participants were ART‑naïve before sequencing.,1,"NRTI, NNRTI, PI, INSTI",0,No,1,,0
Human Answer,37775947,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Individuals in the study received a first-line antiretroviral therapy (ART) that included a non-nucleoside reverse transcriptase inhibitor (NNRTI), a boosted protease inhibitor, or an integrase strand transfer inhibitor, with the majority receiving a regimen that included tenofovir/emtricitabine (FTC) combined with efavirenz.",0,No,1,Not applicable,1,None — no antiretroviral drugs were received before baseline sampling because participants were ART‑naïve.,1,"Efavirenz, Tenofovir, Emtricitabine",0,No,1,,0
Human Answer,37817087,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37817087,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37817087,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — sequences are not publicly deposited; they are available from the corresponding author upon reasonable request.,1,Yes,0,No,1,No,1
Human Answer,37817087,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,Not provided in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37817087,5,How many individuals had samples obtained for HIV sequencing?,Number,4559 and 3097,,4559,0,4559,0,4559,0,PR/RT sequences were obtained from 4559 cases; PR/RT/IN sequences were obtained from 3097 cases.,1,4559,0,4559,0,"4559 (PR and RT sequences), 3097 (PR, RT, and IN sequences)",0
Human Answer,37817087,6,From which countries were the sequenced samples obtained?,List,Germany,,No,0,Germany,1,Germany,1,Samples were obtained in Germany (national surveillance of new HIV diagnoses reported to the Robert Koch Institute).,1,Germany,1,Germany,1,Germany,1
Human Answer,37817087,7,From what years were the sequenced samples obtained?,List,2017-2020,,2017-2020,1,2017-2020,1,2017–2020,1,2017–2020.,1,2017-2020,1,2017-2020,1,2017-2020,1
Human Answer,37817087,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37817087,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease (PR), reverse transcriptase (RT) and integrase (IN).",1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN",1
Human Answer,37817087,10,What method was used for sequencing?,List,Illumina sequencing,,Illumina sequencing,1,Illumina sequencing,1,NGS,0,Illumina next-generation sequencing (MiSeq) of PCR amplicons.,1,Illumina sequencing,1,Illumina sequencing,1,NGS (Illumina MiSeq),0
Human Answer,37817087,11,What type of samples were sequenced?,List,"Serum, Plasma, DBS",,Serum,0,Plasma; Serum; DBS,1,"Plasma, Serum",0,"Serum, plasma, or dried serum/plasma spots (spot elution from Whatman 903 filter paper).",0,Plasma; Serum,0,Plasma; Serum,0,"Serum, plasma, or spot elution",0
Human Answer,37817087,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No — sequences were from newly diagnosed cases (primary resistance); the study did not focus on individuals with virological failure on treatment, although the authors note they cannot fully exclude some treated cases diagnosed abroad.",1,No,1,No,1,Not reported,1
Human Answer,37817087,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37817087,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,"Generally no — sequences are from newly diagnosed (presumed treatment-naive) individuals, though the authors acknowledge they cannot completely exclude some cases that were previously treated abroad.",1,No,1,No,1,Not reported,1
Human Answer,37817087,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not reported,1,"Not reported for individual patients; the paper reports resistance categories (NRTI, NNRTI, PI, INI) but does not provide data on which drug classes patients had personally received prior to sequencing.",0,"NRTI, NNRTI, PI, INST",0,No,1,Not reported,1
Human Answer,37817087,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not reported for individual patients.,0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,No,1,Not reported,1
Human Answer,37823653,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37823653,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37823653,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No explicit statement of public deposition,0,No,1,No,1,No,1
Human Answer,37823653,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in the paper,1,No,1,No,1,Not reported,1
Human Answer,37823653,5,How many individuals had samples obtained for HIV sequencing?,Number,6078,,6078,1,6078,1,6030,0,"6,078 participants",1,6078,1,6030,0,"6,078",0
Human Answer,37823653,6,From which countries were the sequenced samples obtained?,List,Botswana,,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1,Botswana,1
Human Answer,37823653,7,From what years were the sequenced samples obtained?,List,2013-2018,,2013-2018,1,2013-2018,1,2013–2018,1,Enrolled between 2013 and 2018,1,2013-2018,1,2013-2018,1,2013-2018,1
Human Answer,37823653,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer,37823653,9,Which HIV genes were reported to have been sequenced?,List,"NFLG, gp120",,Near full length genome,1,Near full length genome,1,gp120,0,gp120 (part of the HIV envelope gene),0,Envelope,0,Envelope,0,gp120,0
Human Answer,37823653,10,What method was used for sequencing?,List,Illumina sequencing,,Illumina sequencing,1,Illumina sequencing,1,NGS,0,Next-generation sequencing (NGS) using Illumina MiSeq and HiSeq after a long-range HIV genotyping PCR,1,Illumina sequencing,1,Illumina sequencing,1,NGS,0
Human Answer,37823653,11,What type of samples were sequenced?,List,No,,No,1,PBMC,0,Not reported,1,Proviral DNA templates (from participants' samples),0,PBMC,0,PBMC,0,Proviral DNA,0
Human Answer,37823653,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37823653,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,No,0,No,0,No,0,"Yes — they were enrolled in the Botswana Combination Prevention Project (BCPP), a registered study (ClinicalTrials.gov NCT01965470)",1,No,0,No,0,Yes,1
Human Answer,37823653,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37823653,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI",,NNRTI,0,"NRTI, NNRTI",1,"NRTI, NNRTI",1,Non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens (efavirenz or nevirapine) and later dolutegravir-based (integrase inhibitor) regimens were mentioned,0,"NNRTI, PI",0,"NNRTI, INSTI",0,"NRTIs, NNRTIs, PIs",0
Human Answer,37823653,16,Which drugs were received by individuals in the study before sample sequencing?,List,"EFV, NVP",,Individuals in the study before sample sequencing primarily received efavirenz (EFV) or nevirapine (NVP) as part of their antiretroviral therapy (ART).,1,"Efavirenz (EFV), Nevirapine (NVP)",1,"Efavirenz, Nevirapine",1,Efavirenz and nevirapine were the predominant drugs; dolutegravir-based regimens are noted as later first-line implementation,1,"Efavirenz, Nevirapine",1,"Efavirenz (EFV), Nevirapine (NVP), Dolutegravir (DTG)",1,"Efavirenz, nevirapine, and other ARV drugs",1
Human Answer,37872202,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,Yes — the paper uses a transmitted/founder Env derived from a participant (patient-derived sequence) and previously reported patient-derived Env plasmids.,0,No,1,Yes,0,Yes,0
Human Answer,37872202,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,No,0,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37872202,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,Yes,0,No — the paper reports deposition of structural data (PDB/EMDB) but does not report deposition of nucleotide sequence data to public sequence databases in the Data availability statement.,1,Yes,0,No,1,Yes,0
Human Answer,37872202,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported in this paper.,1,No,1,No,1,Not reported (as the specific accession numbers are not provided in the text),1
Human Answer,37872202,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,Not reported,1,One individual is explicitly mentioned (participant 40100) as the source of the transmitted/founder T/F100 Env; other Envs used were previously reported plasmids but the paper does not enumerate additional individuals sampled in this study.,0,0,1,0,1,Not reported (as the specific number is not provided in the text),1
Human Answer,37872202,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Thailand,0,Thailand is explicitly mentioned as the source of the transmitted/founder T/F100 Env; other sample origins are not explicitly stated in this paper.,0,No,1,No,1,Not reported (as the specific country is not provided in the text),1
Human Answer,37872202,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,The paper does not report the years when the samples were obtained.,1,No,1,No,1,Not reported (as the specific year range is not provided in the text),1
Human Answer,37872202,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Yes — Env sequences were cloned into expression plasmids and mutations were introduced into Env expressors; the presence of mutations was confirmed by automated DNA sequencing.,0,No,1,No,1,Not reported (as the specific cloning method is not provided in the text),1
Human Answer,37872202,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not reported,1,"Env (gp120/gp41, gp140/SOSIP) sequences were the focus and were sequenced/used.",0,No,1,No,1,Pol,0
Human Answer,37872202,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,Automated DNA sequencing.,0,No,1,No,1,Sanger sequencing,0
Human Answer,37872202,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not reported,1,"Cloned env expression plasmids / Env expressors (engineered plasmid constructs such as codon-optimized JR-FL env, previously reported Env plasmids, and mutated Env expressors) were sequenced.",0,No,1,No,1,Plasma,0
Human Answer,37872202,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — there is no mention of sequences from individuals with virological failure on treatment.,1,No,1,No,1,Yes,0
Human Answer,37872202,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,"No — the paper references a cohort study (RV217 Early Capture HIV Cohort Study), not a clinical trial.",1,No,1,No,1,Yes,0
Human Answer,37872202,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper does not report sequences from individuals with prior antiretroviral treatment.,1,No,1,No,1,Yes,0
Human Answer,37872202,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not reported / none reported.,1,No,1,No,1,"NRTI, PI, INSTI",0
Human Answer,37872202,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not reported / none reported.,1,No,1,No,1,"3TC, FTC, AZT, TDF, abacavir, efavirenz, rilpivirine, doravirine, atazanavir, lopinavir, darunavir, raltegravir, elvitegravir, dolutegravir, bictegravir, cabotegravir, lenacapavir",0
Human Answer,37878637,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes.,1
Human Answer,37878637,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No.,1
Human Answer,37878637,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not explicitly reported (no public sequence accession numbers provided).,1,Yes,0,Yes,0,Yes.,0
Human Answer,37878637,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are provided in the paper.,1,No,1,No,1,Not reported.,1
Human Answer,37878637,5,How many individuals had samples obtained for HIV sequencing?,Number,141,,141,1,141,1,141,1,141 participants.,1,141,1,141,1,141.,1
Human Answer,37878637,6,From which countries were the sequenced samples obtained?,List,Cameroon,,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon.,1,Cameroon,1,Cameroon,1,Cameroon.,1
Human Answer,37878637,7,From what years were the sequenced samples obtained?,List,2018-2020,,2018-2020,1,2018-2020,1,2018–2020,1,2018–2020.,1,2018-2020,1,2018-2020,1,2018-2020.,1
Human Answer,37878637,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No evidence of cloning; PCR products were directly sequenced.,1,No,1,No,1,Not reported.,1
Human Answer,37878637,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",,"Protease, RT",1,"PR, RT",1,"PR, RT",1,Protease and reverse transcriptase regions of the pol gene.,1,"Protease, Reverse transcriptase",1,"PR, RT",1,"PR, RT.",1
Human Answer,37878637,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing of PCR products using an Applied Biosystems 3500 genetic analyzer (population sequencing).,1,No,0,Sanger sequencing,1,Sanger sequencing.,1
Human Answer,37878637,11,What type of samples were sequenced?,List,Plasma,,Whole Blood,0,Plasma,1,"Whole Blood, Plasma",1,Plasma (viral RNA extracted from plasma aliquots).,1,Whole Blood,0,Plasma,1,Plasma.,1
Human Answer,37878637,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes; sequences were obtained from participants experiencing virological failure (PVL ≥ 1000 copies/mL) who were on ART.,1,Yes,1,Yes,1,Yes.,1
Human Answer,37878637,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No; this was a cohort study, not a clinical trial.",1,No,1,No,1,No.,1
Human Answer,37878637,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes; participants were receiving antiretroviral therapy (first- or second-line) for at least six months prior to inclusion.,1,Yes,1,Yes,1,Yes.,1
Human Answer,37878637,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI",,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",1,"NRTI, NNRTI, PI (based on shift to second-line therapy)",0,Reverse transcriptase inhibitors (NRTIs and NNRTIs) and protease inhibitors (ritonavir-boosted PIs).,1,"NRTI, NNRTI",0,No,0,"NRTI, NNRTI, PI.",1
Human Answer,37878637,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, EFV",,"Tenofovir (TDF), Lamivudine (3TC), Efavirenz (EFV)",1,"Tenofovir (TFV), Lamivudine (3TC), Efavirenz (EFV), Lopinavir (LPV), Atazanavir (ATV), Darunavir (DRV)",1,"TDF, 3TC, EFV",1,"Commonly a TDF + 3TC + EFV first-line regimen (tenofovir [TDF], lamivudine [3TC], efavirenz [EFV]) and ritonavir-boosted protease inhibitor regimens for second-line therapy.",1,"Tenofovir (TFV), Lamivudine (3TC), Efavirenz (EFV)",1,No,0,Not reported.,0
Human Answer,37880705,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37880705,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37880705,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,"Yes — sequences were obtained from public repositories (GenBank) when available, and authors were contacted for others.",0,No,1,No,1,Yes,0
Human Answer,37880705,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,Not specified in the provided paper text.,1,No,1,No,1,Not reported,1
Human Answer,37880705,5,How many individuals had samples obtained for HIV sequencing?,Number,1070,,1070,1,1070,1,Not reported,0,1070 individuals (one sequence per individual were included).,1,1070,1,1070,1,1070,1
Human Answer,37880705,6,From which countries were the sequenced samples obtained?,List,Ethiopia,,Ethiopia,1,Ethiopia,1,Ethiopia,1,Ethiopia.,1,Ethiopia,1,Ethiopia,1,Ethiopia,1
Human Answer,37880705,7,From what years were the sequenced samples obtained?,List,2003-2018,,2003-2018,1,2003-2018,1,2003–2018,1,Samples (sequences) were from studies conducted between 2003 and 2018.,1,2003-2018,1,2003-2018,1,2003-2018,1
Human Answer,37880705,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported (no mention of cloning prior to sequencing).,0,No,1,No,1,Not applicable,1
Human Answer,37880705,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",,"PR, RT",1,"PR, RT",1,Pol,0,Full protease (PR) and partial reverse transcriptase (RT) (first 230 codons).,1,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,Pol,0
Human Answer,37880705,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,Not specified in the provided paper text; sequences were retrieved from GenBank (original sequencing methods not reported).,1,No,1,No,1,Not reported,1
Human Answer,37880705,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not reported,1,Not specified in the provided paper text.,1,No,1,No,1,Plasma,0
Human Answer,37880705,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — sequences were from ART-naïve individuals; studies among ART-experienced individuals were excluded.,1,No,1,No,1,No,1
Human Answer,37880705,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication that patients were in a clinical trial.,0,No,1,No,1,Not applicable,1
Human Answer,37880705,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No — the sequences analyzed were from ART-naïve individuals.,1,No,1,No,1,No,1
Human Answer,37880705,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,NNRTI,0,No,1,,0,None — individuals were ART-naïve (no antiretroviral drug classes received prior to sampling).,1,No,1,No,1,Not reported,1
Human Answer,37880705,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Efavirenz, Nevirapine",0,No,1,Not applicable,1,None — participants were ART-naïve and had not received antiretroviral drugs prior to sampling.,1,No,1,No,1,Not reported,1
Human Answer,37896785,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37896785,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37896785,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37896785,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,OQ215322-OQ215382,,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322–OQ215382.,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1,OQ215322-OQ215382,1
Human Answer,37896785,5,How many individuals had samples obtained for HIV sequencing?,Number,61,,61,1,61,1,61,1,61 individuals.,1,61,1,61,1,61,1
Human Answer,37896785,6,From which countries were the sequenced samples obtained?,List,Vietnam,,Vietnam,1,Vietnam,1,Vietnam,1,"Vietnam (Ho Chi Minh City, South Vietnam).",1,Vietnam,1,Vietnam,1,Vietnam,1
Human Answer,37896785,7,From what years were the sequenced samples obtained?,List,2021,,2021,1,2021,1,2021,1,2021.,1,2021,1,2021,1,2021,1
Human Answer,37896785,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not Reported,1
Human Answer,37896785,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,"PR, RT",1,A pol gene fragment encoding the protease (PR) and part of reverse transcriptase (RT).,1,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,Pol,0
Human Answer,37896785,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing (AmpliSens HIVResist-Seq kit) with analysis on an ABI Prism 3500 genetic analyzer.,1,No,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37896785,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Blood plasma samples.,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37896785,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37896785,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not Reported,1
Human Answer,37896785,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37896785,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,Not reported,1,Primarily NRTIs and NNRTIs (first-line regimens); some patients may have received protease inhibitors as second-line therapy.,0,"NRTI, NNRTI, PI",0,No,1,Not Reported,1
Human Answer,37896785,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Stavudine (d4T), Lamivudine (3TC), Zidovudine (AZT), Nevirapine (NVP), Efavirenz (EFV)",0,"Lamivudine (3TC), Emtricitabine (FTC), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Darunavir (DRV), Lopinavir (LPV), Atazanavir (ATV)",0,Not applicable,1,"Drugs mentioned as components of local regimens include stavudine (d4T), lamivudine (3TC), zidovudine (AZT), nevirapine (NVP), efavirenz (EFV); lopinavir/ritonavir is noted as recommended second-line therapy and other PIs (darunavir, fosamprenavir) are discussed in relation to resistance.",0,No,1,No,1,Not Reported,1
Human Answer,37896860,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer,37896860,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,Yes,0,No.,1,No,1,No,1,No,1
Human Answer,37896860,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37896860,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,37896860,5,How many individuals had samples obtained for HIV sequencing?,Number,704,,704,1,106,0,106,0,106 participants had at least one drug resistance test result.,0,704,1,0,0,106,0
Human Answer,37896860,6,From which countries were the sequenced samples obtained?,List,Kenya,,Kenya,1,Kenya,1,Kenya,1,Kenya.,1,Kenya,1,No,0,Kenya,1
Human Answer,37896860,7,From what years were the sequenced samples obtained?,List,2019-2020,,2019-2020,1,2019-2020,1,2019–2020,1,2019–2020.,1,2019-2020,1,No,0,2019-2020,1
Human Answer,37896860,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer,37896860,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,No,0,"PR, RT",0,Not applicable,0,Reverse transcriptase and protease (PI) regions of pol were sequenced; integrase was not routinely evaluated.,0,No,0,No,0,Pol,0
Human Answer,37896860,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing using Applied Biosystems 3130xl and 3730xl Genetic Analyzers.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37896860,11,What type of samples were sequenced?,List,Plasma,,Whole Blood,0,Plasma,1,"Plasma, Whole Blood",1,Plasma samples derived from whole blood.,1,Whole Blood,0,Plasma,1,Plasma,1
Human Answer,37896860,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37896860,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes; participants were enrolled in the Opt4Kids randomized controlled trial.,1,Yes,1,Yes,1,Yes,1
Human Answer,37896860,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37896860,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI, NNRTI, INSTI",,"NRTI, PI",0,"NRTI, NNRTI, PI, INSTI",1,NRTI,0,"NRTIs, NNRTIs, PIs, and INSTIs.",1,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,"NRTIs, PIs, NNRTIs",0
Human Answer,37896860,16,Which drugs were received by individuals in the study before sample sequencing?,List,"3TC, ABC, AZT, LPV, EFV, DTG",,"Lamivudine, Abacavir, Zidovudine, Lopinavir/Ritonavir",0,"Lamivudine (3TC), Abacavir (ABC), Zidovudine (AZT), Lopinavir (LPV), Efavirenz (EFV)",0,"Lamivudine, Abacavir, Zidovudine",0,"Lamivudine, abacavir, zidovudine, lopinavir/ritonavir, efavirenz, and dolutegravir (among others); resistance to drugs such as tenofovir, emtricitabine, rilpivirine, etravirine, and doravirine was also assessed.",1,"Abacavir, Zidovudine, Lamivudine, Nevirapine, Efavirenz, Lopinavir",0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Lopinavir (LPV), Efavirenz (EFV), Dolutegravir (DTG)",1,"Lamivudine, abacavir, zidovudine, lopinavir/ritonavir, efavirenz",0
Human Answer,37910452,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37910452,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37910452,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37910452,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None / Not applicable,1,No,1,No,1,Not reported,1
Human Answer,37910452,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,None / Not applicable,1,0,1,0,1,0,1
Human Answer,37910452,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,None / Not applicable (studies were conducted in Ghana),1,Ghana,0,No,1,Not applicable,1
Human Answer,37910452,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,Not applicable (no sequencing); included studies were conducted between 2013 and 2022,1,2013-2022,0,No,1,Not applicable,1
Human Answer,37910452,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No / Not applicable,1,No,1,No,1,Not applicable,1
Human Answer,37910452,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,None / Not applicable,1,No,1,No,1,Not applicable,1
Human Answer,37910452,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable (no sequencing reported),1,No,1,No,1,Not applicable,1
Human Answer,37910452,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable (no sequencing reported),1,No,1,No,1,Not applicable,1
Human Answer,37910452,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No / Not applicable,1,No,1,No,1,Not applicable,1
Human Answer,37910452,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,Some were — the review included randomized controlled trials among other designs,0,No,1,No,1,Not reported,1
Human Answer,37910452,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,Not applicable,1
Human Answer,37910452,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable; participants were on antiretroviral therapy (ART) but no specific drug classes are reported,1,No,1,No,1,Not applicable,1
Human Answer,37910452,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable; participants received antiretroviral therapy (ART) but no specific drug names are reported,1,No,1,No,1,Not applicable,1
Human Answer,37914679,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37914679,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37914679,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported),1,No,1,No,1,No,1
Human Answer,37914679,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,Not reported,1,No,1,No,1,Not reported,1
Human Answer,37914679,5,How many individuals had samples obtained for HIV sequencing?,Number,76,,76,1,76,1,76,1,76 individuals,1,76,1,76,1,76,1
Human Answer,37914679,6,From which countries were the sequenced samples obtained?,List,No,,No,1,China,0,China,0,China,0,Not specified,0,China,0,China,0
Human Answer,37914679,7,From what years were the sequenced samples obtained?,List,2018 to 2020,,2018 to 2020,1,2018-2020,0,2018-2020,0,"January 1, 2018 to December 31, 2020",1,2018-2020,0,2018-2020,0,2018-2020,0
Human Answer,37914679,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No (not reported),1,No,1,No,1,Not reported,1
Human Answer,37914679,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,RT,0,"PR, RT, IN",1,Not reported,0,Regions encoding drug resistance associated with NNRTI and NRTI (reverse transcriptase) and evidence of PI and INSTI resistance (implying protease and integrase regions) were sequenced (genes not explicitly named).,1,Not specified,0,"PR, RT, IN",1,Not reported,0
Human Answer,37914679,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing",,Illumina sequencing,0,Illumina sequencing,0,NGS (Next-Generation Sequencing),0,MiSeq second-generation sequencing platform (Illumina),0,Illumina sequencing,0,Illumina sequencing,0,NGS (MiSeq),0
Human Answer,37914679,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Baseline plasma samples,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37914679,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,Yes,0,Yes,0,Yes,0,Yes — baseline sequences were obtained from individuals who subsequently were classified as virological failures,0,Yes,0,No,1,Yes,0
Human Answer,37914679,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — this was a retrospective observational study (not a clinical trial),1,No,1,No,1,Not reported,1
Human Answer,37914679,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,Yes,0,No,1,No — the study enrolled ART-naïve patients,1,Yes,0,No,1,No,1
Human Answer,37914679,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI",0,None prior to sequencing — participants were ART-naïve,1,NNRTI,0,No,1,Not reported,1
Human Answer,37914679,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not reported,1,No antiretroviral drugs were received before sequencing (participants were ART-naïve),1,Not specified,0,No,1,Not reported,1
Human Answer,37920909,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,37920909,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer,37920909,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported),1,No,1,No,1,No,1
Human Answer,37920909,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in the paper,1,No,1,No,1,Not reported,1
Human Answer,37920909,5,How many individuals had samples obtained for HIV sequencing?,Number,601 or 629,,629,1,601,1,601,1,629 individuals had samples obtained; sequencing was successful for 601 cases,1,629,1,629,1,629,1
Human Answer,37920909,6,From which countries were the sequenced samples obtained?,List,China,,China,1,China,1,China,1,China,1,China,1,China,1,China,1
Human Answer,37920909,7,From what years were the sequenced samples obtained?,List,2020-2023,,2020-2023,1,2020-2023,1,2020–2023,1,"Between January 1, 2020 and April 1, 2023",1,2020-2023,1,2020-2023,1,2020-2023,1
Human Answer,37920909,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,Not reported (no cloning stated),0,No,1,No,1,Not reported,1
Human Answer,37920909,9,Which HIV genes were reported to have been sequenced?,List,IN,,"Integrase, IN",1,IN,1,IN,1,The HIV-1 integrase gene,1,"Integrase, IN",1,IN,1,IN,1
Human Answer,37920909,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,An in-house genotyping method and standard Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37920909,11,What type of samples were sequenced?,List,Whole Blood,,Whole Blood,1,Plasma,0,Blood,0,Blood-derived RNA (5 mL blood collected from participants),1,Plasma,0,Whole Blood,1,Not reported,0
Human Answer,37920909,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37920909,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer,37920909,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,37920909,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,,0,None (participants were ART-naïve),1,INSTI,0,No,1,,0
Human Answer,37920909,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,None (no specific antiretroviral drugs were received prior to sampling),1,"RAL, EVG, DTG, BIC",0,No,1,Not applicable,1
Human Answer,37938856,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer,37938856,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37938856,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported).,1,No,1,No,1,No,1
Human Answer,37938856,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,37938856,5,How many individuals had samples obtained for HIV sequencing?,Number,820,,820,1,46,0,820,1,46 successful DRM tests (sequenced samples) were obtained.,0,0,0,0,0,820,1
Human Answer,37938856,6,From which countries were the sequenced samples obtained?,List,Kenya,,Kenya,1,Kenya,1,Kenya,1,Kenya.,1,No,0,No,0,Kenya,1
Human Answer,37938856,7,From what years were the sequenced samples obtained?,List,2019-2022,,2019-2022,1,2019-2022,1,2019–2022,1,"Samples were obtained during the intervention enrolment and follow-up period (October 7, 2019 to December 31, 2021).",0,No,0,No,0,2019-2022,1
Human Answer,37938856,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No cloning is reported.,1,No,1,No,1,Not reported,1
Human Answer,37938856,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,No,0,RT,0,Not reported,0,The reverse transcriptase (RT) region (implied by reported NRTI and NNRTI mutations).,0,No,0,No,0,Pol,0
Human Answer,37938856,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,No,0,Sanger sequencing,1
Human Answer,37938856,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not Reported,1,"Samples from participants with viral load ≥1000 copies/ml (i.e., viraemic clinical samples used for DRM testing).",0,No,1,No,1,Plasma,0
Human Answer,37938856,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer,37938856,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No; this was a prospective pre/post-intervention cohort study, not a randomized clinical trial.",1,No,1,No,1,No,1
Human Answer,37938856,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer,37938856,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI",,"NNRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"NRTIs, NNRTIs, protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs).",1,"NRTI, NNRTI, PI, INSTI",1,No,0,"NNRTI, PI, INSTI",0
Human Answer,37938856,16,Which drugs were received by individuals in the study before sample sequencing?,List,"3TC, TDF, EFV, DTG, ATV",,"Lamivudine, Tenofovir, Efavirenz, Dolutegravir",1,"Lamivudine (3TC), Tenofovir (TFV), Efavirenz (EFV), Dolutegravir (DTG), Atazanavir (ATV), Ritonavir (RTV)",1,"Lamivudine, Tenofovir",0,"Lamivudine, tenofovir, efavirenz, dolutegravir, and atazanavir/ritonavir (among others referenced in standard regimens).",1,"Lamivudine, tenofovir, efavirenz, dolutegravir",1,No,0,Not reported,0
Human Answer,37941373,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37941373,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,"No — only genotypic (sequence-based) resistance interpretation was reported, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer,37941373,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — sequences were not publicly deposited; data are available from the first author on request.,1,No,1,No,1,No,1
Human Answer,37941373,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37941373,5,How many individuals had samples obtained for HIV sequencing?,Number,1080 or 1032,,1080,1,1032,1,1032,1,Samples were harvested from 1080 patients; successful IN gene amplification/sequencing was achieved for 1032 samples.,1,1032,1,1032,1,1032,1
Human Answer,37941373,6,From which countries were the sequenced samples obtained?,List,China,,China,1,China,1,China,1,"China (Chongqing, China).",1,China,1,China,1,China,1
Human Answer,37941373,7,From what years were the sequenced samples obtained?,List,2019-2022,,2019-2022,1,2019-2022,1,2019–2022,1,From July 2019 to August 2022.,1,2019-2022,1,2019-2022,1,2019-2022,1
Human Answer,37941373,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — no cloning step is described; nested PCR and Sanger sequencing were used.,1,No,1,No,1,Not reported,1
Human Answer,37941373,9,Which HIV genes were reported to have been sequenced?,List,IN,,"Integrase, IN",1,IN,1,IN,1,The integrase (IN) region of the HIV-1 pol gene.,1,"Integrase, IN",1,IN,1,IN,1
Human Answer,37941373,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger (dideoxy) sequencing following nested RT‑PCR (in-house method).,1,No,0,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37941373,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma samples (HIV-RNA extracted from plasma).,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37941373,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer,37941373,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer,37941373,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37941373,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, INSTI",,"NRTI, NNRTI, INSTI",1,"NRTI, NNRTI, INSTI",1,"NRTI, NNRTI, INSTI",1,"Integrase strand transfer inhibitors (INSTIs), nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), and non-nucleoside reverse transcriptase inhibitors (NNRTIs).",1,"INSTI, NRTI, NNRTI",1,INSTI,0,"INSTIs, NRTIs, NNRTIs",0
Human Answer,37941373,16,Which drugs were received by individuals in the study before sample sequencing?,List,"DTG, RPV, 3TC, TDF, EFV",,"Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Crizaline, Efavirenz",1,"Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Efavirenz",1,"Dolutegravir, rilpivirine, lamivudine, tenofovir, crizaline, efavirenz",1,"Reported drugs included dolutegravir, rilpivirine, lamivudine, tenofovir, crizaline, and efavirenz; the paper also discusses prior use of raltegravir and elvitegravir among INSTI-treated patients.",0,"Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Crizaline, Efavirenz",1,"Dolutegravir, Rilpivirine, Lamivudine, Tenofovir, Crizaline, Efavirenz",1,"Dolutegravir, rilpivirine, lamivudine, tenofovir, crizaline, efavirenz",1
Human Answer,37946329,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37946329,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37946329,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No explicit public deposition is indicated in the paper.,0,No,1,No,1,No,1
Human Answer,37946329,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,Not reported.,1,No,1,No,1,Not reported,1
Human Answer,37946329,5,How many individuals had samples obtained for HIV sequencing?,Number,921,,921,1,921,1,921,1,Partial pol sequences were successfully amplified from 921 individuals; integrase (INT) gene sequences were obtained from 751 individuals.,1,921,1,1078,0,921,1
Human Answer,37946329,6,From which countries were the sequenced samples obtained?,List,China,,China,1,China,1,China,1,China (Henan Province).,1,China,1,China,1,Not reported,0
Human Answer,37946329,7,From what years were the sequenced samples obtained?,List,2018-2022,,2018-2022,1,2018-2022,1,2018–2022,1,From June 2018 to April 2022.,1,2018-2022,1,2018-2022,1,2018-2022,1
Human Answer,37946329,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,Not reported / No evidence of cloning prior to sequencing is provided.,0,No,1,No,1,Not reported,1
Human Answer,37946329,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"Protease, RT, IN",1,"Pol, IN",0,"Pol, IN",0,Partial pol gene and complete integrase (INT) gene.,1,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"Pol, Integrase",0
Human Answer,37946329,10,What method was used for sequencing?,List,No,,No,1,No,1,Not Reported,1,PCR amplification of target gene regions followed by sequencing (genotypic drug resistance testing as described previously); the specific sequencing platform/technique is not specified in the paper.,0,No,1,No,1,Not reported,1
Human Answer,37946329,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma samples.,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37946329,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37946329,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — they were treatment-experienced patients assessed in an observational study, not described as a clinical trial.",1,No,1,No,1,No,1
Human Answer,37946329,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37946329,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI",,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,Not reported,0,"Nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs/INIs).",1,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,Not reported,0
Human Answer,37946329,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"3TC, NVP, ETR, ABC, DTG",0,"NVP, ETR, ABC, 3TC, DTG, ATV, LPV, RAL, SQV",0,Not applicable,1,"Various individual drugs across classes were mentioned, including lamivudine (3TC), abacavir (ABC), tenofovir (TDF), emtricitabine (FTC), stavudine (D4T), nevirapine (NVP), efavirenz (EFV), etravirine (ETR), atazanavir/ritonavir (ATV/r), lopinavir/ritonavir (LPV/r), fosamprenavir/r (FPV/r), saquinavir/r (SQV/r), raltegravir (RAL), dolutegravir (DTG), bictegravir (BIC), cabotegravir (CAB), and elvitegravir (EVG).",0,"Abacavir (ABC), Nevirapine (NVP), Efavirenz (EFV), Raltegravir (RAL)",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",0,Not reported,1
Human Answer,37957382,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37957382,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper reports genotypic susceptibility scoring and ARV drug level testing but does not report in vitro phenotypic drug susceptibility assays.,1,No,1,No,1,No,1
Human Answer,37957382,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37957382,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,The paper provides a GenBank BioProject identifier (PRJNA973660) but does not list individual GenBank accession numbers for specific isolates.,1,No,1,No,1,Not reported,1
Human Answer,37957382,5,How many individuals had samples obtained for HIV sequencing?,Number,8,,8,1,8,1,8,1,Eight participants.,1,8,1,8,1,8,1
Human Answer,37957382,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,"The paper does not explicitly state the countries of origin for the sequenced samples; it reports institutional cohorts (for example, Brigham and Women's Hospital HEAL cohort, ACTG, and the Ragon Institute) but does not list countries.",1,No,1,No,1,Not reported,1
Human Answer,37957382,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,The paper does not report the calendar years when samples were obtained.,1,No,1,No,1,Not reported,1
Human Answer,37957382,8,Were samples cloned prior to sequencing?,Boolean,Yes,,No,0,No,0,No,0,No — sequencing was performed using endpoint dilution single-genome approaches rather than cloning.,0,No,0,No,0,Not reported,0
Human Answer,37957382,9,Which HIV genes were reported to have been sequenced?,List,"Full genome, NFLG",,Full genome; Near full length genome,1,Near full length genome,0,"Pol, Env",0,"Near-full-length proviral genomes were sequenced, including pol and env (pol–env 6.7 kb amplicon); the 5′ leader/gag region was also sequenced, and individual genes (e.g., nef, pol, gag, env) were analyzed.",1,"Protease, Reverse transcriptase, Integrase",0,"Pol, Env",0,Not reported,0
Human Answer,37957382,10,What method was used for sequencing?,List,Illumina sequencing,,Illumina sequencing,1,Illumina sequencing,1,Next-generation sequencing (NGS),0,Single-genome near-full-length PCR (endpoint dilution NFL-seq) with Illumina barcoded library construction and MiSeq sequencing; sequence assembly used UltraCycler and alignments used MAFFT and MEGA.,1,Illumina sequencing,1,Illumina sequencing,1,Not reported,0
Human Answer,37957382,11,What type of samples were sequenced?,List,"Plasma, PBMC",,Plasma,0,Plasma,0,"Plasma, DBS",0,Plasma HIV-1 RNA and proviral DNA extracted from peripheral blood mononuclear cells (PBMCs)/CD4+ T cells.,1,Plasma,0,"Plasma, PBMC",1,Plasma,0
Human Answer,37957382,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Yes,1,Sequences were obtained from individuals on antiretroviral therapy who had persistent low-level (non-suppressible) viremia while on ART; the paper does not characterize these as classic high-level virologic failure but as non-suppressible viremia despite ART.,1,No,0,No,0,Yes,1
Human Answer,37957382,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — the study was observational and used historic comparator cohorts.,1,No,1,No,1,Not reported,1
Human Answer,37957382,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37957382,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI, INSTI",,No,0,"NRTI, INSTI",0,Not reported,0,"Participants received multiple classes including nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase (IN) inhibitors.",1,"NRTI, NNRTI, PI, INSTI",1,No,0,Not reported,0
Human Answer,37957382,16,Which drugs were received by individuals in the study before sample sequencing?,List,"DTG, DRV, TFV, FTC ",,No,0,"Dolutegravir, Darunavir, Tenofovir, Emtricitabine",1,Not applicable,0,"The paper reports specific drugs in participant regimens and testing, including dolutegravir, darunavir (DRV/r), atazanavir/ritonavir (ATV/r), tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), emtricitabine (FTC), and rilpivirine (RPV), among others.",1,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN)",1,No,0,Not reported,0
Human Answer,37966701,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0
Human Answer,37966701,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1
Human Answer,37966701,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — no sequences were made publicly available.,1,No,1,No,1,No,1
Human Answer,37966701,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported — no GenBank accession numbers are provided.,1,No,1,No,1,Not reported,1
Human Answer,37966701,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,None — the study did not obtain or report samples for HIV sequencing.,1,0,1,0,1,321,0
Human Answer,37966701,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,United States,0,Not applicable — no sequencing was performed; the study cohort and data are from the United States.,1,No,1,No,1,United States,0
Human Answer,37966701,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not applicable — no sequencing was performed; study treatment initiation occurred between 21 January 2021 and 28 February 2022 with continuation injections by 15 March 2022.,1,No,1,No,1,2021-2022,0
Human Answer,37966701,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No — samples were not cloned prior to sequencing because no sequencing was performed.,1,No,1,No,1,Not reported,1
Human Answer,37966701,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,None — the paper does not report sequencing of any HIV genes.,1,No,1,No,1,Not reported,1
Human Answer,37966701,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed and no sequencing methods are reported.,1,No,1,No,1,Not reported,1
Human Answer,37966701,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no biological samples were sequenced; the study used routine clinical electronic health record data and viral load measurements.,1,No,1,No,1,Not reported,1
Human Answer,37966701,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — no sequences were obtained; the paper does report four confirmed virologic failures but notes resistance data were not available.,1,No,1,No,1,Yes,0
Human Answer,37966701,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the patients were part of an observational real-world cohort (OPERA) receiving routine clinical care, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,37966701,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the paper does not report HIV sequences from any individuals, though participants had prior antiretroviral exposure (they were initiating CAB + RPV LA, often after stable ART).",1,No,1,No,1,Yes,0
Human Answer,37966701,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not reported,1,Not applicable — no sequencing was performed and the paper does not report prior antiretroviral drug classes; the regimen under study was cabotegravir + rilpivirine LA.,1,INSTI,0,No,1,"INSTI, NNRTI",0
Human Answer,37966701,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — no sequencing was performed; participants received cabotegravir + rilpivirine long-acting injectable as the regimen under study, and prior ART regimens are not specified in the paper.",1,"Cabotegravir, Rilpivirine",0,No,1,"Cabotegravir, Rilpivirine",0
Human Answer,37973713,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — the paper reports HIV sequences (genotyping) from patient samples.,1,No,0,Yes,1,Yes,1
Human Answer,37973713,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro phenotypic drug susceptibility testing data.,1,No,1,No,1,No,1
Human Answer,37973713,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Yes — sequences were submitted to the Stanford University HIV Drug Resistance Database.,0,No,1,No,1,No,1
Human Answer,37973713,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37973713,5,How many individuals had samples obtained for HIV sequencing?,Number,117,,117,1,117,1,117,1,83 individuals had genotyping results (117 recruited minus 34 excluded for missing genotyping results).,0,117,1,0,0,117,1
Human Answer,37973713,6,From which countries were the sequenced samples obtained?,List,"Ukraine, Poland",,"Ukraine, Poland",1,"Poland, Ukraine, Belarus, Georgia, Kazakhstan",1,"Poland, Ukraine",1,"Samples were from Poland and eastern countries including Ukraine, Belarus, Georgia, and Kazakhstan.",0,"Ukraine, Poland",1,"Poland, Ukraine",1,"Poland, Ukraine",1
Human Answer,37973713,7,From what years were the sequenced samples obtained?,List,2020-2022,,2020-2022,1,2020-2022,1,2020–2022,1,Samples were obtained during 2020–2022.,1,2020-2022,1,2020-2022,1,2020-2022,1
Human Answer,37973713,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — the paper describes Sanger population sequencing and does not report cloning prior to sequencing.,1,No,1,No,1,Not reported,1
Human Answer,37973713,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,"PR, RT",1,The protease (PR) and reverse transcriptase (RT) coding regions (parts of pol) were sequenced.,1,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,"PR, RT",1
Human Answer,37973713,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing using the commercially available ViroSeq HIV-1 Genotyping System (Abbott Molecular).,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37973713,11,What type of samples were sequenced?,List,Plasma,,No,0,Plasma,1,Not reported,0,"The paper does not explicitly state the biological sample type used for sequencing (e.g., plasma or whole blood) though viral load was measured in peripheral blood.",0,Plasma,1,No,0,Not reported,0
Human Answer,37973713,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No — sequences were obtained from ART-naïve, newly diagnosed patients, not from individuals with virological failure on treatment.",1,No,1,No,1,Not reported,1
Human Answer,37973713,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"The study was a registered, multi-center prospective observational cross-sectional study (registered on clinicaltrials.gov, NCT04636736), not an interventional randomized clinical trial.",0,Yes,1,No,0,Yes,1
Human Answer,37973713,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No — the paper reports sequences from individuals with no history of antiretroviral therapy (ART-naïve).,1,No,1,No,1,No,1
Human Answer,37973713,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,,0,None — individuals were ART-naïve and had not received antiretroviral drug classes prior to sequencing.,1,"NRTI, NNRTI, PI",0,No,1,Not applicable,1
Human Answer,37973713,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,None — no specific antiretroviral drugs were received before sequencing (participants were ART-naïve).,1,No,1,No,1,Not applicable,1
Human Answer,37976080,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37976080,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,"No — the paper reports genotypic resistance analysis, not in vitro phenotypic drug susceptibility testing.",1,Yes,0,No,1,No,1
Human Answer,37976080,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / Not clearly stated in the paper.,0,No,1,No,1,No,1
Human Answer,37976080,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,37976080,5,How many individuals had samples obtained for HIV sequencing?,Number,2568,,2568,1,2568,1,2568,1,2568 participants had PDR testing / sequencing results.,1,2568,1,2568,1,2568,1
Human Answer,37976080,6,From which countries were the sequenced samples obtained?,List,China,,China,1,China,1,China,1,China.,1,China,1,China,1,China,1
Human Answer,37976080,7,From what years were the sequenced samples obtained?,List,2022,,2022,1,2022,1,2022,1,2022.,1,2022,1,2022,1,2022,1
Human Answer,37976080,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — cloning is not described; PCR amplification followed by Sanger sequencing of the PCR products was used.,1,No,1,No,1,Not reported,1
Human Answer,37976080,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",,"Protease, PR; Reverse transcriptase, RT",1,"PR, RT",1,"PR, RT",1,The pol gene region covering the protease (PR) region and the partial reverse transcriptase (RT) region.,1,"Protease, Reverse transcriptase",1,"PR, RT",1,"Pol (PR, RT)",0
Human Answer,37976080,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37976080,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma samples (viral RNA extracted from 200 µL plasma).,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37976080,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,Not specifically reported; the study sampled individuals starting or restarting ART and reports prior ARV exposure but does not report sequencing from individuals with documented virological failure.,0,No,1,No,1,Yes,0
Human Answer,37976080,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this was a multicenter observational cross-sectional study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,37976080,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — some participants (3.2%, n=81) had prior ARV drug exposure, and they were included in the sequencing/PDR analysis.",1,Yes,1,Yes,1,Yes,1
Human Answer,37976080,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI, PI",0,No,1,Not reported,1,Not specified in the paper.,0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI, PI",0,Not reported,1
Human Answer,37976080,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Efavirenz (EFV), Nevirapine (NVP)",0,No,1,Not applicable,1,"Not reported/specified for the participants; the paper does list the 12 WHO-recommended drugs analyzed for resistance, but it does not state which specific drugs individual participants had received previously.",0,"Abacavir, Zidovudine, Lamivudine, and others",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV)",0,Not reported,1
Human Answer,37976185,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer,37976185,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37976185,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported).,1,No,1,No,1,No,1
Human Answer,37976185,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,0,No,1,No,1,Not reported,1
Human Answer,37976185,5,How many individuals had samples obtained for HIV sequencing?,Number,4246,,4246,1,4246,1,4246,1,"4,246 individuals had a genotype obtained within 30 days of diagnosis and comprised the analytic population.",1,4246,1,4246,1,4246,1
Human Answer,37976185,6,From which countries were the sequenced samples obtained?,List,USA,,No,0,United States,0,USA,1,"United States (New York City, USA).",1,United States,0,United States,0,United States,0
Human Answer,37976185,7,From what years were the sequenced samples obtained?,List,2015-2022,,2015-2022,1,2015-2022,1,2015–2022,1,2015--2022.,1,2015-2022,1,2015-2022,1,2015-2022,1
Human Answer,37976185,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported / No evidence of cloning.,0,No,1,No,1,Not reported,1
Human Answer,37976185,9,Which HIV genes were reported to have been sequenced?,List,RT,,"Reverse transcriptase, RT",1,No,0,RT (reverse transcriptase),1,The paper does not explicitly name a gene; it reports genotypes identifying the M184I/V and K65R resistance-associated mutations.,0,Not specified,0,RT,1,RT,1
Human Answer,37976185,10,What method was used for sequencing?,List,"Sanger sequencing, NGS",,No,0,Sanger sequencing; NGS,1,Sanger sequencing and NGS (next-generation sequencing),0,Sanger sequencing and next-generation sequencing (reported as consensus sequences when NGS was conducted).,1,No,0,No,0,Not reported,0
Human Answer,37976185,11,What type of samples were sequenced?,List,Plasma,,No,0,No,0,Plasma,1,Clinical baseline diagnostic specimens used for HIV genotyping (baseline genotypes obtained within 30 days of diagnosis); plasma viral load is referenced as the specimen source for testing capacity.,1,Plasma,1,No,0,Plasma,1
Human Answer,37976185,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No — sequences were from people with newly diagnosed HIV (baseline genotypes), not described as from individuals with virological failure on ART.",1,No,1,No,1,Yes,0
Human Answer,37976185,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,37976185,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Not applicable,0,Yes — some individuals had prior antiretroviral exposure via PrEP (TDF/TAF with FTC) before diagnosis and sequencing.,1,No,0,No,0,Yes,1
Human Answer,37976185,15,Which drug classes were received by individuals in the study before sample sequencing?,List,NRTI,,No,0,NRTI,1,Not applicable,0,Nucleos(t)ide reverse transcriptase inhibitor drugs used for PrEP (tenofovir disoproxil fumarate or tenofovir alafenamide plus emtricitabine).,1,NRTI,1,NRTI,1,NRTIs,0
Human Answer,37976185,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, FTC",,No,0,"Tenofovir disoproxil fumarate, Tenofovir alafenamide, Emtricitabine",0,Not applicable,0,Tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) with emtricitabine (FTC).,0,"Emtricitabine (FTC), Tenofovir (TFV)",1,"Tenofovir disoproxil fumarate, tenofivir alafenamide fumarate, emtricitabine",0,Tenofovir disoproxil fumarate and emtricitabine,0
Human Answer,37993493,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,37993493,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,Yes,0,No — the paper reports genotypic predictions and genotypic susceptibility scores rather than in vitro phenotypic susceptibility assays.,1,No,1,No,1,No,1
Human Answer,37993493,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report public deposition of sequences; data are available upon request from the authors/DUCS platform.,1,No,1,No,1,No,1
Human Answer,37993493,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,37993493,5,How many individuals had samples obtained for HIV sequencing?,Number,33,,600,0,600,0,33,1,"33 individuals had samples eligible for genotyping; of these, 31/33 were successfully genotyped in at least one region, 23 samples yielded protease/RT sequences and 30 yielded integrase sequences; 22 samples were fully genotyped in all three regions.",1,600,0,0,0,600,0
Human Answer,37993493,6,From which countries were the sequenced samples obtained?,List,Tanzania,,No,0,Tanzania,1,Tanzania,1,Tanzania (Dar es Salaam).,1,Tanzania,1,Tanzania,1,Tanzania,1
Human Answer,37993493,7,From what years were the sequenced samples obtained?,List,2023,,No,0,2023,1,2023,1,Samples were obtained in 2023 (February to May 2023).,1,2023,1,2023,1,2023,1
Human Answer,37993493,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — samples were not cloned; sequencing was performed by Sanger capillary sequencing of PCR products and sequences were assembled and edited with RECall.,1,No,1,No,1,Not reported,1
Human Answer,37993493,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,"Protease, PR; Reverse transcriptase, RT; Integrase, IN",1,"PR, RT, IN",1,"PR, RT, IN",1,"Protease, reverse transcriptase (RT), and integrase.",1,"Protease, Reverse transcriptase, Integrase",1,"PR, RT, IN",1,"Protease, Reverse Transcriptase, Integrase",1
Human Answer,37993493,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,"Sanger-style capillary sequencing using an Applied Biosystems 3500xL genetic analyser, with sequence assembly/editing by RECall and interpretation via Stanford HIVDB.",1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,37993493,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Plasma (derived from venous whole blood) samples.,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,37993493,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — sequences were obtained from individuals with unsuppressed viral load (≥ 1000 copies/mL), i.e., virological failure while on ART.",1,Yes,1,Yes,1,Yes,1
Human Answer,37993493,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — patients were part of a cross-sectional survey of treatment-experienced adults in an urban cohort study, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer,37993493,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — all participants were treatment-experienced and had been receiving antiretroviral therapy for at least one year prior to inclusion.,1,Yes,1,Yes,1,Yes,1
Human Answer,37993493,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, PI, INSTI",,"NRTI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, INSTI",0,"Nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), integrase strand transfer inhibitors (INSTIs, e.g., dolutegravir), and protease inhibitors (PIs) in some patients.",0,"NRTI, NNRTI, INSTI",0,"NRTI, NNRTI, INSTI",0,"NRTIs, INSTIs",0
Human Answer,37993493,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, DTG, ABC, LPV, ATV, EFV",,"Tenofovir, Lamivudine, Dolutegravir, Abacavir, Lopinavir",0,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG), Abacavir (ABC), Lopinavir (LPV), Atazanavir (ATV), Efavirenz (EFV)",1,"TDF, 3TC, DTG",0,"Specific drugs mentioned include tenofovir (TDF), lamivudine (3TC), dolutegravir (DTG), abacavir (ABC), lopinavir/ritonavir (LPV/r), atazanavir/ritonavir (ATV/r), and efavirenz (EFV) as a previously used drug.",1,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG)",0,Dolutegravir,0,"Tenofovir, Lamivudine, Dolutegravir",0
Human Answer,38005921,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,Yes,0,Yes,0,Yes,0,Yes. The study used amino acid sequences of HIV proteins derived from clinical samples (Stanford HIV Drug Resistance Database).,0,No,1,Yes,0,Yes,0
Human Answer,38005921,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,Yes,0,Yes,0,Yes. The datasets include phenotypic resistance measurements determined by the PhenoSense™ test system.,0,Yes,0,Yes,0,No,1
Human Answer,38005921,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. The datasets used for building the models are provided in the Supplementary Materials and the web service is freely available.,1,Yes,1,Yes,1,Yes,1
Human Answer,38005921,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,The paper does not report any GenBank accession numbers.,1,No,1,No,1,Not reported,1
Human Answer,38005921,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,Not reported,1,"The paper does not specify the number of individuals; it reports sample counts per drug class (1958 PI, 1707 NRTI, 1819 NNRTI samples).",0,0,1,0,1,Not reported,1
Human Answer,38005921,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,The paper does not specify the countries of origin for the sequences.,1,No,1,No,1,Not reported,1
Human Answer,38005921,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,The paper does not give exact sample collection years; it uses a publication-year threshold (≤2018 vs >2018) to construct training and test sets.,1,No,1,No,1,Not reported,1
Human Answer,38005921,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported. The paper does not describe any cloning of samples prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer,38005921,9,Which HIV genes were reported to have been sequenced?,List,No,,"Reverse transcriptase, RT; Protease, PR",0,"PR, RT",0,"PR, RT",0,Protease and reverse transcriptase (HIV-1 protease and reverse transcriptase) sequences were used.,0,"Reverse transcriptase, RT; Protease, PR",0,"PR, RT",0,"Protease, reverse transcriptase, and integrase",0
Human Answer,38005921,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,Not applicable / Not reported. The paper used existing amino acid sequence data from the Stanford HIV Drug Resistance Database and does not describe sequencing methods.,1,No,1,No,1,Not reported,1
Human Answer,38005921,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not reported,1,Amino acid sequences of HIV-1 protease and reverse transcriptase derived from clinical samples/isolates (genotype–phenotype datasets).,0,No,1,No,1,Not reported,1
Human Answer,38005921,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not reported,1,Not specified. The paper does not state whether sequences came from individuals with virological failure.,0,No,1,No,1,Yes,0
Human Answer,38005921,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,"No. The paper used sequences compiled from the Stanford HIV Drug Resistance Database and studies, not from a clinical trial conducted by the authors.",1,No,1,No,1,Not reported,1
Human Answer,38005921,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,Not specified. The paper does not explicitly state the prior treatment histories of individuals whose sequences were used.,0,No,1,No,1,Yes,0
Human Answer,38005921,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not specified for individuals; however, the datasets and models encompass protease inhibitors (PI), nucleoside reverse transcriptase inhibitors (NRTI), and non-nucleoside reverse transcriptase inhibitors (NNRTI).",0,No,1,No,1,"Protease inhibitors, reverse transcriptase inhibitors, and integrase inhibitors",0
Human Answer,38005921,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not specified. The paper does not report individual treatment histories, although models and results include many specific drugs (e.g., zidovudine, lamivudine, stavudine, etravirine, rilpivirine, efavirenz, nevirapine, etc.).",0,No,1,No,1,Not reported,1
Human Answer,38020274,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer,38020274,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,38020274,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No evidence of public deposition.,0,No,1,No,1,No,1
Human Answer,38020274,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,38020274,5,How many individuals had samples obtained for HIV sequencing?,Number,311,,311,1,311,1,311,1,"Sequencing was performed on participants with PVL 2,000 copies/ml with sample counts reported as approximately 56 at enrolment (T1), 96 at 6 months (T2), and 60 at 12 months (T3).",0,311,1,311,1,311,1
Human Answer,38020274,6,From which countries were the sequenced samples obtained?,List,Cameroon,,Cameroon,1,Cameroon,1,Cameroon,1,Cameroon.,1,Cameroon,1,Cameroon,1,Cameroon,1
Human Answer,38020274,7,From what years were the sequenced samples obtained?,List,2018-2020,,2018-2020,1,2018-2020,1,2018–2020,1,2018 to 2020.,1,2018-2020,1,2018-2020,1,2018-2020,1
Human Answer,38020274,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No cloning is reported.,0,No,1,No,1,Not reported,1
Human Answer,38020274,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,"PR, RT",0,Pol (indicating it relates to the drug resistance profile),0,HIV-1 polymerase and reverse transcriptase gene regions (pol/RT).,0,"Protease, PR; Reverse transcriptase, RT",0,"PR, RT",0,Pol,0
Human Answer,38020274,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,"An in-house genotypic resistance testing protocol was used; specific sequencing technology (e.g., Sanger or NGS) is not specified.",0,No,1,Sanger sequencing,0,Not reported,1
Human Answer,38020274,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Not reported,0,"Blood-derived plasma samples (blood samples stored at -80°C from participants with plasma viral load ≥1,000 copies/ml).",1,Plasma,1,Plasma,1,Blood,0
Human Answer,38020274,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,38020274,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Yes,0,"No; they were participants in a prospective cohort study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,38020274,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,38020274,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"RTI, PI",,"NRTI, NNRTI",0,"NRTI, NNRTI, PI",0,"NRTI, NNRTI",0,Reverse transcriptase inhibitor-based regimens (NRTIs/NNRTIs) as first-line and ritonavir-boosted protease inhibitors (PI/r) as second-line.,1,"NRTI, NNRTI",0,No,0,"NRTI, NNRTI",0
Human Answer,38020274,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not reported,1,"Reported drugs include TDF, AZT, ABC, 3TC, d4T, NVP (representative NNRTIs), and ritonavir-boosted protease inhibitors LPV/r, ATV/r, and DRV/r; participants were generally not exposed to integrase inhibitors (e.g., Dolutegravir) prior to sequencing.",0,Not specified,0,No,1,Not reported,1
Human Answer,38022124,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0
Human Answer,38022124,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1
Human Answer,38022124,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — sequences were not reported or deposited; no public sequence data are provided.,1,No,1,No,1,No,1
Human Answer,38022124,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,Not applicable / Not reported — no GenBank accession numbers are provided.,1,No,1,No,1,Not reported,1
Human Answer,38022124,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Not applicable / Not reported — sequencing was not performed; the study included 116 patients overall.,1,0,1,0,1,116,0
Human Answer,38022124,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Turkey,0,Not applicable / Not reported — no sequencing was done; the study was conducted in Turkey.,1,No,1,No,1,Turkey,0
Human Answer,38022124,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,2020–2022,0,Not applicable / Not reported — sequencing not performed; the clinical data/samples were from June 2020 to June 2022.,1,No,1,No,1,2020-2022,0
Human Answer,38022124,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not applicable / Not reported — no cloning or sequencing procedures are described.,1,No,1,No,1,Not reported,1
Human Answer,38022124,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable / Not reported — no HIV genes were sequenced in this study.,1,No,1,No,1,Not reported,1
Human Answer,38022124,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,Not applicable / Not reported — no sequencing method is described.,1,No,1,No,1,Not reported,1
Human Answer,38022124,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not reported,1,Not applicable / Not reported — no sequencing was performed; the study reported clinical measures such as HIV-1 RNA (viral load) but did not specify sample types for sequencing.,1,No,1,No,1,Not reported,1
Human Answer,38022124,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / Not reported — no sequences were obtained; the study reports virological suppression outcomes but not sequencing from virological failures.,1,No,1,No,1,No,1
Human Answer,38022124,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the patients were part of a retrospective, real-life observational study rather than a clinical trial.",1,No,1,No,1,No,1
Human Answer,38022124,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Yes,0,"No — the paper does not report HIV sequences from previously treated individuals (sequencing was not performed); however, the cohort did include previously treated patients.",1,No,1,No,1,Yes,0
Human Answer,38022124,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,"NRTI, NNRTI",0,"Sequencing was not performed, but prior regimens reported include integrase inhibitor–containing regimens plus nucleoside reverse transcriptase inhibitor backbones (e.g., EVG/c/FTC/TAF and DTG+TDF/FTC).",1,INSTI,0,No,1,"INSTI, NRTI, PI",0
Human Answer,38022124,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,"EVG/c/FTC/TAF, DTG+TDF/FTC",0,"Sequencing was not performed, but the paper reports prior use of EVG/c/FTC/TAF (elvitegravir/cobicistat/emtricitabine/TAF) in 93.9% of experienced patients and DTG+TDF/FTC (dolutegravir plus tenofovir disoproxil fumarate/emtricitabine) in 4.5%.",1,"Bictegravir (BIC), Emtricitabine (FTC), Tenofovir (TAF)",0,No,1,"EVG, FTC, TAF, DTG, TDF",0
Human Answer,38031075,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer,38031075,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38031075,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38031075,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported,1,No,1,No,1,Not reported,1
Human Answer,38031075,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Zero (no sequencing performed),1,2253,0,0,1,"2,253",0
Human Answer,38031075,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Sierra Leone,0,Not applicable (no sequencing); study samples were from Sierra Leone,1,Sierra Leone,0,No,1,Sierra Leone,0
Human Answer,38031075,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not applicable (no sequencing); samples were collected between August 2022 and January 2023,1,2022-2023,0,No,1,2022-2023,0
Human Answer,38031075,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable (no sequencing performed),1,No,1,No,1,No,1
Human Answer,38031075,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,,0,No,1,No,1,Not reported,1
Human Answer,38031075,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable (no sequencing performed),1,No,1,No,1,RT-PCR,0
Human Answer,38031075,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable (no sequencing performed); blood/plasma samples were collected for viral load testing,1,Plasma,0,No,1,Plasma,0
Human Answer,38031075,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No (no sequences were obtained),1,No,1,No,1,Yes,0
Human Answer,38031075,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38031075,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,Yes,0,No,1,Yes,0
Human Answer,38031075,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, INSTI",0,No,1,Not reported,1,Dolutegravir-based regimens and efavirenz/NNRTI-based regimens (note: no sequencing was performed),0,"NRTI, NNRTI, INSTI",0,No,1,"NRTI, NNRTI, INSTI",0
Human Answer,38031075,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Tenofovir, Lamivudine, Dolutegravir",0,No,1,Not applicable,1,"Tenofovir, lamivudine, dolutegravir, and efavirenz",0,"Tenofovir, Lamivudine, Dolutegravir, Efavirenz",0,No,1,"Tenofovir, lamivudine, dolutegravir",0
Human Answer,38033131,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer,38033131,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38033131,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38033131,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,Not applicable — no sequences reported,1,No,1,No,1,Not reported,1
Human Answer,38033131,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,492,0,Zero — no sequencing was performed,1,0,1,0,1,492,0
Human Answer,38033131,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Ethiopia,0,Not applicable — no sequences; study was conducted in Ethiopia,1,No,1,No,1,Ethiopia,0
Human Answer,38033131,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,2015–2019,0,"Not applicable — no sequences; study data cover January 1, 2015 to December 31, 2019",1,No,1,No,1,2015-2019,0
Human Answer,38033131,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not applicable — no sequencing or cloning reported,1,No,1,No,1,Not reported,1
Human Answer,38033131,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no HIV genes were sequenced or reported,1,No,1,No,1,Not reported,1
Human Answer,38033131,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,Not applicable — no sequencing method reported,1,No,1,No,1,Not reported,1
Human Answer,38033131,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no samples were sequenced,1,No,1,No,1,Plasma,0
Human Answer,38033131,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — no sequences obtained,1,No,1,No,1,Yes,0
Human Answer,38033131,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38033131,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,Yes,0
Human Answer,38033131,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not applicable for sequencing; participants received NNRTI-based ART and prophylactic agents (cotrimoxazole, isoniazid)",1,No,1,No,1,"NNRTI, NRTI",0
Human Answer,38033131,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not applicable for sequencing; drugs received included nevirapine-based ART, cotrimoxazole, and isoniazid (and some had PMTCT history)",1,No,1,No,1,"NVP, NRTI",0
Human Answer,38058846,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,No — the paper reports HIV drug resistance testing results but does not present raw HIV sequences.,0,No,0,No,0,Yes.,1
Human Answer,38058846,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report any in vitro phenotypic drug susceptibility testing.,1,No,1,No,1,No.,1
Human Answer,38058846,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not indicate that sequences were deposited in public repositories.,1,No,1,No,1,No.,1
Human Answer,38058846,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported.,1
Human Answer,38058846,5,How many individuals had samples obtained for HIV sequencing?,Number,3,,0,0,3,1,3,1,Three individuals.,1,0,0,3,1,3.,1
Human Answer,38058846,6,From which countries were the sequenced samples obtained?,List,No,,No,1,South Africa,0,South Africa,0,South Africa.,0,South Africa,0,South Africa,0,South Africa.,0
Human Answer,38058846,7,From what years were the sequenced samples obtained?,List,No,,No,1,2021-2023,0,Not reported,1,Not explicitly stated for the time of sequencing; the paper presents clinical timelines spanning 2018–2023 but does not give explicit calendar years for when resistance tests/sequencing were performed.,1,No,1,"2012, 2020, 2022",0,2012-2020.,0
Human Answer,38058846,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported.,0,No,1,No,1,Not reported.,1
Human Answer,38058846,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT, IN",,No,0,IN,0,Not applicable,0,Not specified in the paper.,0,No,0,No,0,IN.,0
Human Answer,38058846,10,What method was used for sequencing?,List,No,,No,1,No,1,Not Reported,1,Not reported.,0,No,1,No,1,Not reported.,1
Human Answer,38058846,11,What type of samples were sequenced?,List,No,,No,1,Plasma,0,Not Reported,1,Not specified.,0,No,1,No,1,"PBMC, plasma.",0
Human Answer,38058846,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes — resistance testing/sequencing was performed in individuals experiencing virological failure while on ART (notably DTG-containing regimens).,1,Yes,1,Yes,1,Yes.,1
Human Answer,38058846,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — they were managed in clinical care and included in a case series, not enrolled in a clinical trial.",1,No,1,No,1,No.,1
Human Answer,38058846,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes — at least two of the three individuals had prior antiretroviral drug exposure before the resistance testing.,1,Yes,1,Yes,1,Yes.,1
Human Answer,38058846,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI",,"NRTI, PI, INSTI",0,"NRTI, NNRTI, PI, INSTI",1,"NRTI, NNRTI, PI, INSTI",1,"Nucleoside reverse transcriptase inhibitors (NRTIs), non‑nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs) and an integrase strand transfer inhibitor (INSTI; dolutegravir).",1,INSTI,0,No,0,Not reported.,0
Human Answer,38058846,16,Which drugs were received by individuals in the study before sample sequencing?,List,"3TC, ABC, LPV, AZT, DTG, FTC, TDF, DRV, EFV, NVP",,"Lamivudine, Abacavir, Lopinavir, Ritonavir, Zidovudine, Dolutegravir, Tenofovir, Darunavir, Nevirapine",0,"Abacavir (ABC), Zidovudine (AZT), Lamivudine (3TC), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Lopinavir (LPV), Darunavir (DRV), Dolutegravir (DTG)",0,"Lamivudine, Abacavir, Lopinavir, Nevirapine, Dolutegravir",0,"Reported drugs include lamivudine, abacavir, lopinavir/ritonavir, zidovudine, dolutegravir (DTG), emtricitabine, tenofovir, efavirenz, darunavir/ritonavir and combinations thereof (e.g., tenofovir/emtricitabine/efavirenz; tenofovir/emtricitabine/darunavir/ritonavir); TLD (tenofovir/lamivudine/dolutegravir) or equivalent combinations were also used.",0,Dolutegravir (DTG),0,No,0,Not reported.,0
Human Answer,38072961,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1
Human Answer,38072961,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38072961,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported),1,No,1,No,1,No,1
Human Answer,38072961,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported / Not provided,1,No,1,No,1,Not reported,1
Human Answer,38072961,5,How many individuals had samples obtained for HIV sequencing?,Number,1,,1,1,1,1,1,1,One individual,1,1,1,0,0,1,1
Human Answer,38072961,6,From which countries were the sequenced samples obtained?,List,China,,No,0,China,1,China,1,China,1,No,0,No,0,China,1
Human Answer,38072961,7,From what years were the sequenced samples obtained?,List,2022,,No,0,2022,1,Not reported,0,2022,1,No,0,No,0,Not reported,0
Human Answer,38072961,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No (no cloning reported),1,No,1,No,1,Not reported,1
Human Answer,38072961,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",,"Protease, PR; Reverse transcriptase, RT; Nucleoside reverse transcriptase, NRTI",0,"PR, RT",1,"PR, RT",1,Protease and reverse transcriptase (pol region),1,Not specified,0,No,0,"PR, RT, IN",1
Human Answer,38072961,10,What method was used for sequencing?,List,"Sanger sequencing, NGS",,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,Sanger sequencing,0,No,0,No,0,Sanger sequencing,0
Human Answer,38072961,11,What type of samples were sequenced?,List,"CSF, Plasma",,Other,0,"CSF, Plasma",1,"Plasma, CSF",1,Cerebrospinal fluid (CSF) and plasma samples,1,"CSF, Plasma",1,No,0,"CSF, plasma",1
Human Answer,38072961,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1
Human Answer,38072961,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38072961,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1
Human Answer,38072961,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI",,"NRTI, PI",0,"NRTI, NNRTI, PI",1,"NRTI, PI, INSTI",0,"Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitor (NNRTI), and protease inhibitor (PI)",1,"NRTI, PI, INSTI",0,No,0,"PI, NNRTI, NRTI",1
Human Answer,38072961,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, LPV, EFV",,"Tenofovir, Lamivudine, Lopinavir/Ritonavir",0,"Tenofovir (TFV), Lamivudine (3TC), Efavirenz (EFV), Lopinavir (LPV), Zidovudine (AZT), Dolutegravir (DTG)",1,"Tenofovir, Lamivudine, Lopinavir/Ritonavir, Zidovudine, Dolutegravir",0,"Tenofovir, lamivudine, efavirenz, and lopinavir/ritonavir",1,"Tenofovir, Lamivudine, Lopinavir/Ritonavir, Zidovudine, Dolutegravir",0,No,0,"Lopinavir, lamivudine, efavirenz",0
Human Answer,38090027,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes. The paper reports genotypic resistance testing (GRT) results obtained from patient samples (plasma HIV-RNA and PBMC HIV-DNA) in cases of virological failure.,1,No,0,No,0,Yes,1
Human Answer,38090027,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No. The paper reports genotypic resistance testing results but does not present in vitro (phenotypic) drug susceptibility data.,1,No,1,No,1,No,1
Human Answer,38090027,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No. The paper does not report deposition of sequences or provide public accession numbers.,1,No,1,No,1,No,1
Human Answer,38090027,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported. The paper does not provide any GenBank accession numbers.,1,No,1,No,1,Not reported,1
Human Answer,38090027,5,How many individuals had samples obtained for HIV sequencing?,Number,5,,0,0,0,0,1040,0,Five individuals had genotypic resistance testing evaluable at virological failure.,1,0,0,0,0,1040,0
Human Answer,38090027,6,From which countries were the sequenced samples obtained?,List,Italy,,No,0,No,0,Not Reported,0,Italy.,1,No,0,No,0,Not reported,0
Human Answer,38090027,7,From what years were the sequenced samples obtained?,List,2019-2020,,No,0,2019-2022,0,Not reported,0,"Samples/sequencing were obtained during the study period when patients switched to BFTAF from June 2019 to June 2021, with follow-up (and consequent genotypic testing at virological failure) through data freezing on 31 August 2022.",0,No,0,No,0,2019-2021,0
Human Answer,38090027,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No indication of cloning is reported.,0,No,1,No,1,Not reported,1
Human Answer,38090027,9,Which HIV genes were reported to have been sequenced?,List,"RT, IN",,No,0,No,0,Not applicable,0,"Genes corresponding to targets of PIs, NRTIs (reverse transcriptase), and integrase inhibitors were analysed (protease, reverse transcriptase, and integrase regions).",0,No,0,No,0,"Pol, IN",0
Human Answer,38090027,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,"A validated in-house genotypic resistance testing (GRT) method was used to identify resistance-associated mutations on plasma HIV-RNA and PBMC HIV-DNA, with interpretation using the Stanford HIV Drug Resistance Database.",0,No,1,No,1,Not reported,1
Human Answer,38090027,11,What type of samples were sequenced?,List,"Plasma, PBMC",,No,0,"Plasma, PBMC",1,Not reported,0,Plasma HIV-RNA and peripheral blood mononuclear cell (PBMC) HIV-DNA samples were used for genotypic resistance testing/sequencing.,1,No,0,No,0,Plasma,0
Human Answer,38090027,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Not applicable,0,Yes. Genotypic resistance tests were evaluable at virological failure in five patients.,1,No,0,No,0,Yes,1
Human Answer,38090027,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No. The study was a retrospective cohort conducted in clinical practice; although a small number later enrolled in clinical trials, the cohort itself was not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer,38090027,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,"Yes. The cohort consisted of treatment-experienced individuals with long prior ART exposure, and GRTs were performed in some of these individuals.",1,No,0,No,0,Yes,1
Human Answer,38090027,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, NNRTI, PI, INSTI",,"NRTI, INSTI",0,"NRTI, PI, INSTI, NNRTI",1,Not reported,0,"Individuals had previously received integrase strand transfer inhibitor-based regimens (InSTIs), protease inhibitor-based regimens (PIs), non-nucleoside reverse transcriptase inhibitor-based regimens (NNRTIs), and nucleoside reverse transcriptase inhibitors (NRTIs).",1,INSTI,0,No,0,"NRTI, NNRTI, PI, INSTI",1
Human Answer,38090027,16,Which drugs were received by individuals in the study before sample sequencing?,List,"BIC, FTC, TAF, EVG",,"Emtricitabine, Tenofovir Alafenamide, Elvitegravir",0,"Elvitegravir (EVG), Cobicistat (COBI), Emtricitabine (FTC), Tenofovir alafenamide (TAF), Darunavir (DRV), Dolutegravir (DTG), Rilpivirine (RPV)",0,Not applicable,0,"Reported prior drugs/regimens include elvitegravir/cobicistat/FTAF (ECFTAF), other integrase inhibitor regimens, protease inhibitor regimens (e.g., darunavir/cobicistat/FTAF mentioned as a switch), dolutegravir (DTG), rilpivirine (RPV), emtricitabine, and tenofovir alafenamide (TAF).",0,"Bictegravir (BIC), Emtricitabine (FTC), Tenofovir (TFV)",0,No,0,"Bictegravir, emtricitabine, tenofovir alafenamide, elvitegravir",1
Human Answer,38140553,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,38140553,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,38140553,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,38140553,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,K03455,0,GenBank accession numbers for the newly sequenced isolates are not reported; only the HXB-2 reference GenBank accession (K03455) is cited.,1,No,1,No,1,Not reported,1
Human Answer,38140553,5,How many individuals had samples obtained for HIV sequencing?,Number,3178,,3178,1,3178,1,3178,1,3178 individuals.,1,3178,1,3178,1,3178,1
Human Answer,38140553,6,From which countries were the sequenced samples obtained?,List,Russia,,No,0,Russia,1,Russia,1,Russia (Russian Federation).,1,Russia,1,Russia,1,Russia,1
Human Answer,38140553,7,From what years were the sequenced samples obtained?,List,2011-2020,,2011-2020,1,2011 to 2020,0,2011–2020,1,2011 to 2020.,1,2011-2020,1,2011-2020,1,2011-2020,1
Human Answer,38140553,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No evidence of cloning; samples were amplified by nested PCR and sequenced directly by Sanger methods.,1,No,1,No,1,Not reported,1
Human Answer,38140553,9,Which HIV genes were reported to have been sequenced?,List,Pol,,"Protease, PR; Reverse transcriptase, RT",0,"PR, RT",0,"PR, RT",0,The protease (PR) and part of the reverse transcriptase (RT) regions of the pol gene (PR-RT).,1,"Protease, PR; Reverse transcriptase, RT",0,"PR, RT",0,Pol,1
Human Answer,38140553,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Sanger-based (BigDye Terminator v3.1) sequencing of PCR-amplified pol gene fragments; ViroSeq HIV-1 Genotyping System and ViroSeq software were used for some samples.,1,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1
Human Answer,38140553,11,What type of samples were sequenced?,List,Plasma; PBMC; Whole Blood,,Plasma; PBMC; Whole Blood,1,Plasma; PBMC; Whole Blood,1,"Plasma, PBMC, Whole Blood",1,"Blood plasma, peripheral blood mononuclear cells (lymphocytes), and frozen whole blood.",1,Plasma; PBMC; DBS; Whole Blood,1,"Plasma, PBMC, Whole Blood",1,"Plasma, PBMC, Whole Blood",1
Human Answer,38140553,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"Not specifically reported; sequences came from patients both receiving ART and not on ART, but virological failure status is not stated.",0,No,1,No,1,Yes,0
Human Answer,38140553,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,No.,1,No,1,No,1,Not reported,1
Human Answer,38140553,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,"Yes; the study included sequences from individuals receiving ART at the time of sampling, though past treatment histories were not fully known for all patients.",0,Yes,0,No,1,Yes,0
Human Answer,38140553,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI",0,No,1,,0,"Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).",0,"NRTI, NNRTI, PI",0,No,1,Not reported,1
Human Answer,38140553,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"The paper mentions use of efavirenz (EFV) and the NRTIs lamivudine (3TC) and emtricitabine (FTC) as main components of preferred first-line regimens in Russia (i.e., drugs likely received by individuals).",0,"Abacavir (ABC), Zidovudine'(AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine(FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir'(LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Raltegravir (RAL), Elvitegravir(EVG), Dolutagravir (DTG), Bictegravir (BIC), cabotagravir (CAB), Lenacapavir (LEN), GS-CA1, Lenacapavir (GS-6207)",0,No,1,Not reported,1
Human Answer,38140649,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,38140649,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,Yes,0,No.,1,No,1,No,1,No,1
Human Answer,38140649,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,38140649,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,"OR605755-OR606279, OR613869-OR613875",,"OR605755-OR606279, OR613869-OR613875",1,"OR605755-OR606279, OR613869-OR613875, E-MTAB-13563",1,"OR605755-OR606279, OR613869-OR613875",1,OR605755-OR606279 and OR613869-OR613875.,1,OR605755-OR606279 and OR613869-OR613875,1,"OR605755-OR606279, OR613869-OR613875",1,OR605755-OR606279 and OR613869-OR613875,1
Human Answer,38140649,5,How many individuals had samples obtained for HIV sequencing?,Number,270,,270,1,270,1,270,1,270 individuals.,1,270,1,270,1,270,1
Human Answer,38140649,6,From which countries were the sequenced samples obtained?,List,Croatia,,Croatia,1,Croatia,1,Croatia,1,"Croatia (samples collected from patients entering care at the University Hospital for Infectious Diseases, Zagreb, Croatia).",1,Croatia,1,Croatia,1,Croatia,1
Human Answer,38140649,7,From what years were the sequenced samples obtained?,List,2019-2022,,2019-2022,1,2019-2022,1,2019–2022,1,2019 to 2022.,1,2019-2022,1,2019-2022,1,2019-2022,1
Human Answer,38140649,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not Reported,1
Human Answer,38140649,9,Which HIV genes were reported to have been sequenced?,List,Pol,,"Protease, RT, IN",0,"PR, RT, IN",0,"PR, RT, IN",0,"The pol gene: HIV-1 protease (PR), partial reverse transcriptase (RT), and integrase (IN) regions.",1,"Protease, Reverse transcriptase, Integrase",0,"PR, RT, IN",0,"Pol (PR, RT, IN)",0
Human Answer,38140649,10,What method was used for sequencing?,List,"Sanger sequencing, Illumina sequencing",,Illumina sequencing,0,Sanger sequencing; Illumina sequencing,1,Sanger sequencing and NGS (Illumina MiniSeq),0,Sanger sequencing (BigDye Terminator v3.1) for standard genotyping and next-generation sequencing (Illumina MiniSeq) for deep sequencing.,1,Sanger sequencing; Next-generation sequencing (NGS),0,Illumina sequencing,0,Sanger sequencing and NGS,0
Human Answer,38140649,11,What type of samples were sequenced?,List,Plasma,,Plasma,1,Plasma,1,Plasma,1,Patient plasma samples containing HIV-1 RNA.,1,Plasma,1,Plasma,1,Plasma,1
Human Answer,38140649,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,38140649,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not Reported,1
Human Answer,38140649,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,38140649,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,,0,None; individuals were antiretroviral treatment-naïve.,1,"NRTI, NNRTI, PI, INSTI",0,No,1,,0
Human Answer,38140649,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,None; individuals were antiretroviral treatment-naïve.,1,"Abacavir (ABC), Zidovudine (AZT), Zalcitabine (DDC), Didanosine (DDI), Lamivudine (3TC), Stavudine (D4T), Emtricitabine (FTC), Tenofovir (TFV), Nevirapine (NVP), Delavirdine (DLV), Efavirenz (EFV), Etravirine (ETR), Rilpivirine (RPV), Doravirine (DOR), Amprenavir (APV), Lopinavir (LPV), Atazanavir (ATV), Derunavir (DRV), Nelfinavir (NFV), Raltegravir (RAL), Elvitegravir (EVG), Dolutagravir (DTG), Bictegravir (BIC), Cabotagravir (CAB), Lenacapavir (LEN), GS-CA1, Lenacapavir (GS-6207)",0,No,1,Not Applicable,1
Human Answer,38140667,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer,38140667,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer,38140667,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer,38140667,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported,1,No,1,No,1,Not reported,1
Human Answer,38140667,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,146,0,Not reported,1,Not reported / not applicable to this paper,0,0,1,0,1,Not reported,1
Human Answer,38140667,6,From which countries were the sequenced samples obtained?,List,No,,No,1,"Canada, Tanzania, Brazil, Nigeria",0,Not reported,1,"Studies summarized included samples from multiple countries including France, Canada, Spain, Tanzania, Malawi, Brazil, Nigeria, Mozambique, Botswana, South Africa, Italy, Germany, Ukraine, and Poland.",0,No,1,No,1,Not reported,1
Human Answer,38140667,7,From what years were the sequenced samples obtained?,List,No,,No,1,"2012-2014, 2019, 2021, 2018",0,Not reported,1,"Across included studies spanning roughly 2013–2023 (publications and congress data from 2013 to 2023); individual studies reported various years (e.g., 2012–2014, 2019–2022, 2017–2022).",0,No,1,No,1,Not reported,1
Human Answer,38140667,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported,0,No,1,No,1,No,1
Human Answer,38140667,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,IN,0,Not applicable,1,"Primarily the integrase gene (INSTI/integrase) and, in many studies, reverse transcriptase and protease (RT and PR) genes were also reported.",0,No,1,No,1,Not reported,1
Human Answer,38140667,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,Not specified in this review,0,No,1,No,1,Not reported,1
Human Answer,38140667,11,What type of samples were sequenced?,List,No,,No,1,Plasma,0,Not reported,1,Primarily plasma samples (viral RNA/genotypes from viremic individuals) were sequenced in the cited studies.,0,No,1,No,1,Not reported,1
Human Answer,38140667,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Not reported,1
Human Answer,38140667,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,"No — the paper focuses on real-world observational studies and cohorts (though it references some clinical trials elsewhere), and the review itself did not enroll patients in a trial.",1,No,1,No,1,Not reported,1
Human Answer,38140667,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Not reported,1
Human Answer,38140667,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,"NRTI, INSTI",0,"NRTI, PI",0,"Individuals had prior exposure to multiple antiretroviral classes including integrase strand transfer inhibitors (INSTIs), nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).",0,"INSTI, NRTI, NNRTI",0,No,1,Not reported,1
Human Answer,38140667,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG), Rilpivirine (RPV)",0,Not reported,1,"Specific drugs mentioned in the included studies include dolutegravir (DTG), raltegravir (RAL), elvitegravir (EVG), tenofovir disoproxil fumarate (TDF), lamivudine (3TC), abacavir (ABC), emtricitabine (FTC), rilpivirine (RPV), and combinations such as TLD (TDF/3TC/DTG) and DTG/3TC/ABC.",0,"DTG, 3TC, RPV",0,No,1,Not reported,1
Human Answer,38142692,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer,38142692,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,38142692,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,38142692,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None / Not applicable — no sequences were reported.,1,No,1,No,1,Not reported,1
Human Answer,38142692,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Zero — no individuals had samples sequenced for HIV resistance in this study.,1,0,1,0,1,1214,0
Human Answer,38142692,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,None — no sequencing was done. The study population was from South Africa.,1,No,1,No,1,South Africa,0
Human Answer,38142692,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — no sequences were obtained; study participants were switched between Dec 1, 2019, and Nov 30, 2020.",1,No,1,No,1,2019-2020,0
Human Answer,38142692,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed.,0,No,1,No,1,Not reported,1
Human Answer,38142692,9,Which HIV genes were reported to have been sequenced?,List,No,,No,1,No,1,Not applicable,1,None — no HIV genes were sequenced or reported in this study.,1,No,1,No,1,Not reported,1
Human Answer,38142692,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing method was used or reported.,0,No,1,No,1,Not reported,1
Human Answer,38142692,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Not applicable — no samples were sequenced. The study used routine viral load testing data.,0,No,1,No,1,Plasma,0
Human Answer,38142692,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,"No — no sequences were obtained, although the cohort consisted of individuals with virological failure.",1,No,1,No,1,Yes,0
Human Answer,38142692,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this was a retrospective observational cohort study using routine-care data, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,38142692,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the paper does not report HIV sequences from any individuals, including those who had previously received ARV drugs.",1,No,1,No,1,Yes,0
Human Answer,38142692,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, INSTI",0,No,1,Not applicable,1,Participants had received nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs).,0,No,1,No,1,"NRTIs, NNRTIs, and PIs",0
Human Answer,38142692,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Tenofovir (TDF), Emtricitabine (XTC), Efavirenz (EFV), Nevirapine (NVP)",0,No,1,Not applicable,1,"Participants had been receiving tenofovir disoproxil fumarate (TDF), emtricitabine or lamivudine (XTC), efavirenz (EFV), and nevirapine (NVP) as first-line therapy.",0,No,1,No,1,"AZT, 3TC, TDF, EFV, and LPV/r",0
Human Answer,38152686,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,38152686,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,38152686,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not publicly deposited); data are available upon request.,1,No,1,No,1,No,1
Human Answer,38152686,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None reported.,1,No,1,No,1,Not reported,1
Human Answer,38152686,5,How many individuals had samples obtained for HIV sequencing?,Number,1,,0,0,1,1,1,1,One individual (single case report).,1,1,1,1,1,1,1
Human Answer,38152686,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not explicitly stated.,1,No,1,No,1,Not reported,1
Human Answer,38152686,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not stated (no calendar years reported).,1,No,1,No,1,Not reported,1
Human Answer,38152686,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported / not specified.,0,No,1,No,1,Not reported,1
Human Answer,38152686,9,Which HIV genes were reported to have been sequenced?,List,IN,,"Integrase, IN",1,"RT, IN",1,IN,1,Integrase and reverse transcriptase.,0,"Integrase, Reverse transcriptase",1,"IN, RT",1,IN,1
Human Answer,38152686,10,What method was used for sequencing?,List,No,,No,1,No,1,Not reported,1,Only 'genotyping' is reported; the specific sequencing method is not stated.,1,No,1,No,1,Not reported,1
Human Answer,38152686,11,What type of samples were sequenced?,List,Plasma,,No,0,Plasma,1,Not reported,0,Not specified.,0,Plasma,1,Plasma,1,Plasma,1
Human Answer,38152686,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,38152686,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No; this is a single-patient case report, not a clinical trial.",1,No,1,No,1,No,1
Human Answer,38152686,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,38152686,15,Which drug classes were received by individuals in the study before sample sequencing?,List,"NRTI, INSTI",,"NRTI, INSTI",1,"NRTI, NNRTI, INSTI",1,"NRTI, INSTI",1,"Nucleoside reverse transcriptase inhibitors (NRTIs), an integrase strand transfer inhibitor (INSTI), and a non-nucleoside reverse transcriptase inhibitor (NNRTI).",0,"INSTI, NRTI",1,"NRTI, INSTI",1,"NRTI, INSTI",1
Human Answer,38152686,16,Which drugs were received by individuals in the study before sample sequencing?,List,"TDF, 3TC, DTG",,"Tenofovir, Lamivudine, Dolutegravir",1,"Tenofovir (TFV), Lamivudine (3TC), Dolutegravir (DTG), Efavirenz (EFZ)",1,"Tenofovir, Lamivudine, Dolutegravir",1,"Tenofovir (TDF), Lamivudine (3TC), Dolutegravir (DTG), and Efavirenz (EFZ).",0,"Dolutegravir (DTG), Tenofovir (TDF), Lamivudine (3TC)",1,"Tenofovir (TDF), Lamivudine (3TC), Dolutegravir (DTG)",1,"TDF, 3TC, DTG",1
Human Answer,38314093,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer,38314093,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer,38314093,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not explicitly reported / not clearly made publicly available.,0,No,1,No,1,No,1
Human Answer,38314093,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,No GenBank accession numbers are reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer,38314093,5,How many individuals had samples obtained for HIV sequencing?,Number,37,,195,0,37,1,37,1,37 individuals.,1,195,0,37,1,37,1
Human Answer,38314093,6,From which countries were the sequenced samples obtained?,List,China,,No,0,China,1,China,1,China.,1,China,1,China,1,China,1
Human Answer,38314093,7,From what years were the sequenced samples obtained?,List,2008-2019,,2008-2019,1,2008-2019,1,2008–2019,1,Samples were collected between May 2008 and December 2019 (study period).,1,2008-2019,1,2018-2019,0,2008-2019,1
Human Answer,38314093,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No — cloning is not reported.,1,No,1,No,1,Not reported,1
Human Answer,38314093,9,Which HIV genes were reported to have been sequenced?,List,"PR, RT",,"Reverse transcriptase, RT",0,"PR, RT",1,"PR, RT",1,Protease and reverse transcriptase (PR-RT / Pro-RT).,1,No,0,"PR, RT",1,"PR, RT",1
Human Answer,38314093,10,What method was used for sequencing?,List,NGS,,No,0,No,0,NGS,1,PCR amplification of cDNA followed by high-throughput sequencing.,1,No,0,NGS,1,Not reported,0
Human Answer,38314093,11,What type of samples were sequenced?,List,Serum,,Serum,1,Plasma,0,Serum,1,Serum samples.,1,Serum,1,Serum,1,Blood,0
Human Answer,38314093,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Yes,0,No — the sequenced samples were from untreated patients.,1,No,1,No,1,Yes,0
Human Answer,38314093,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer,38314093,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Yes,0,No — the reported sequences were from untreated individuals.,1,No,1,No,1,Yes,0
Human Answer,38314093,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,"NRTI, NNRTI",0,"NRTI, NNRTI",0,"NRTI, NNRTI",0,None — the sequenced individuals were untreated.,1,"NRTIs, NNRTIs",0,No,1,"NRTI, NNRTI",0
Human Answer,38314093,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,"Zidovudine (AZT), Lamivudine (3TC), Efavirenz (EFV), Nevirapine (NVP)",0,"Efavirenz (EFV), Nevirapine (NVP), Zidovudine (AZT), Lamivudine (3TC)",0,"AZT, 3TC, EFV, NVP",0,None — no specific antiretroviral drugs were reported as received prior to sequencing for the sequenced individuals.,1,"AZT, 3TC, EFV, NVP",0,No,1,"AZT, 3TC, EFV, NVP",0
Human Answer,38427738,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,"No. The sequences reported were derived from in vitro–propagated laboratory and primary viral isolates in cell culture, not from patient samples.",1,No,1,No,1,Yes,0
Human Answer,38427738,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,No,0,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer,38427738,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No public sequence accession is reported; sequences are presented in the paper and/or Supplementary Materials and materials are available upon request.,1,No,1,No,1,Not Reported,1
Human Answer,38427738,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,No,,No,1,No,1,Not reported,1,None are provided in the paper; no GenBank accession numbers are reported.,1,No,1,No,1,Not Reported,1
Human Answer,38427738,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,0,1,Zero individuals; sequencing was performed on virus propagated in cell culture rather than samples from human individuals.,1,0,1,0,1,Not Reported,1
Human Answer,38427738,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — sequences were from laboratory and experimentally propagated viral strains in cell culture, not from human subjects in specific countries.",1,No,1,No,1,Not Reported,1
Human Answer,38427738,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not applicable,1,"Not applicable / not reported. The paper reports durations of in vitro passaging (e.g., 'nearly 1 year') but does not report calendar years of sample collection.",1,No,1,No,1,Not Reported,1
Human Answer,38427738,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,"Both approaches were used: bulk sequencing of PCR amplicons from genomic DNA was performed, and env amplicons were cloned into plasmids to construct infectious molecular clones which were then Sanger-sequenced/verified.",0,No,1,No,1,Not Reported,1
Human Answer,38427738,9,Which HIV genes were reported to have been sequenced?,List,"Gag, Pol, Env, Nef, vpu",,"Gag, Pol, Env, Vpu",0,"Gag, Pol, Env, Nef, vpu",1,Not applicable,0,"gag, pol (including RT and IN regions), env, vpu, and nef (regions of Gag, Pol, Env, Vpu, and Nef were amplified/sequenced); specific focus on NC (within Gag), RT, and IN mutations is reported.",1,Envelope; Full genome; Near full length genome,0,"Gag, Pol, Env, Vpu",0,"Env, Gag, IN",0
Human Answer,38427738,10,What method was used for sequencing?,List,No,,No,1,No,1,Not applicable,1,Sanger sequencing of PCR amplicons performed by commercial sequencing providers (Psomagen or Poochon Scientific); constructed plasmids were verified by Sanger DNA sequencing.,0,Sanger sequencing,0,No,1,Not Reported,1
Human Answer,38427738,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not applicable,1,Genomic DNA extracted from infected cell cultures (infected SupT1 or SupT1huR5 cells) and PCR amplicons derived from those cultures; env amplicons were cloned into plasmids and sequenced/verified.,0,Plasma,0,No,1,Not Reported,1
Human Answer,38427738,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No. The study did not report sequencing of samples from individuals with virological failure; analyses were performed on viruses passaged in vitro under drug pressure.,1,No,1,No,1,Not Reported,1
Human Answer,38427738,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No — there were no patients in this study; experiments used cell lines and laboratory/primary viral clones.,1,No,1,No,1,Not Reported,1
Human Answer,38427738,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No. The paper does not report sequences from treated individuals; all sequences were obtained from viruses propagated experimentally under antiretroviral pressure in cell culture.,1,No,1,No,1,Not Reported,1
Human Answer,38427738,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not applicable — there were no human individuals whose drug histories were sequenced. (In the experimental system, cultures were exposed to antiretrovirals, primarily the INSTI dolutegravir (DTG) and the NRTTI EFdA.)",1,INSTI,0,No,1,"INSTI, NRTI",0
Human Answer,38427738,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,"Not applicable for human individuals. In the experimental (cell culture) system, viruses were exposed to antiretroviral drugs including the INSTI dolutegravir (DTG) and the NRTTI islatravir (EFdA); other ARVs (e.g., RAL, CAB, FTC, RPV, EFV, DRV, NFV, T-20, BMS-378806, BI-224436, LEN) were used in drug-sensitivity assays.",1,INSTI,0,No,1,"DTG, EFdA",0
Human Answer,38864613,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer,38864613,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,38864613,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer,38864613,4,What were the GenBank accession numbers for sequenced HIV isolates?,List,PP827803-PP828572,,PP827803 -- PP828572,1,PP827803 - PP828572,1,PP827803 -- PP828572,1,PP827803 -- PP828572,1,No,0,PP827803--PP828572,1,PP827803 -- PP828572,1
Human Answer,38864613,5,How many individuals had samples obtained for HIV sequencing?,Number,0,,0,1,0,1,Not reported,1,0 (no individuals; sequences derived from in vitro experiments),1,0,1,0,1,Not reported,1
Human Answer,38864613,6,From which countries were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not applicable / Not reported,1,No,1,No,1,Not reported,1
Human Answer,38864613,7,From what years were the sequenced samples obtained?,List,No,,No,1,No,1,Not reported,1,Not applicable / Not reported,1,No,1,No,1,Not reported,1
Human Answer,38864613,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer,38864613,9,Which HIV genes were reported to have been sequenced?,List,"RT, CA",,"Capsid, CA; Reverse transcriptase, RT",1,"CA, RT",1,Not reported,0,Capsid (CA) and reverse transcriptase (RT),1,No,0,"CA, RT",1,"CA, RT",1
Human Answer,38864613,10,What method was used for sequencing?,List,Sanger sequencing,,Sanger sequencing,1,Sanger sequencing,1,Sanger sequencing,1,Population-based Sanger sequencing of one-step RT-PCR amplicons (automated population-based full-length sequencing),1,No,0,Sanger sequencing,1,Not reported,0
Human Answer,38864613,11,What type of samples were sequenced?,List,No,,No,1,No,1,Not reported,1,Viral RNA from culture supernatant of wells with viral breakthrough (in vitro cell culture supernatant),0,No,1,Culture supernatant,0,Plasma,0
Human Answer,38864613,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer,38864613,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,No (no patients were involved),1,No,1,No,1,Not reported,1
Human Answer,38864613,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,Yes,0
Human Answer,38864613,15,Which drug classes were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable / None,1,No,1,No,1,"NRTI, INSTI",0
Human Answer,38864613,16,Which drugs were received by individuals in the study before sample sequencing?,List,No,,No,1,No,1,Not applicable,1,Not applicable / None,1,No,1,No,1,"Lenacapavir, Raltegravir",0
Human Answer – Yes/No questions,18715920,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,"No. The sequences reported were derived from in vitro–selected laboratory virus stocks, not from patient samples.",1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,18715920,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,18715920,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No public sequence accession numbers or depositions are reported in the paper.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,18715920,8,Were samples cloned prior to sequencing?,Boolean,No,,Yes,0,No,1,Not applicable,1,"No for the population sequencing of selected viruses — population-based sequencing was used; however, site-directed mutant (SDM) constructs were cloned for recombinant virus studies.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,18715920,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No. The paper did not sequence viruses from individuals with virological failure; sequences were derived from in vitro selections and recombinant constructs.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,18715920,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not Reported,1,No — there were no patients in the study; experiments were in vitro using laboratory viruses and recombinant constructs.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,18715920,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No. The reported sequences were from in vitro–selected viruses and recombinant constructs, not from previously treated individuals.",1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,19104010,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes.,0
Human Answer – Yes/No questions,19104010,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes.,1
Human Answer – Yes/No questions,19104010,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No accession numbers or sequence depositions are reported in the paper.,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,19104010,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Yes.,0,No,1,No,1,Yes.,0
Human Answer – Yes/No questions,19104010,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,No,1,No,1,Not applicable.,1
Human Answer – Yes/No questions,19104010,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No. The study was preclinical and performed in vitro; clinical development was discontinued after pharmacokinetic evaluation in healthy volunteers.,1,No,1,No,1,Not reported.,1
Human Answer – Yes/No questions,19104010,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,Yes,0,No,1,Not applicable.,1
Human Answer – Yes/No questions,21115794,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,21115794,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,21115794,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — GenBank or other public accession numbers are not reported in the paper.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,21115794,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No — PCR products from infected cells were sequenced (no cloning step described for sequencing).,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,21115794,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No sequences from such individuals were reported as being obtained in this paper.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,21115794,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,No — this is a preclinical in vitro study; patients were not enrolled in this study.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,21115794,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the sequenced material derives from in vitro infected cells and laboratory strains, not from ARV-experienced individuals.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,23749954,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No — the study used laboratory-generated NL4-3 clones and public database consensus sequences rather than patient-derived sequences.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,23749954,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,Yes,0,Yes,0,Yes — the paper reports in vitro cell culture drug selection experiments assessing resistance mutation selection under drug pressure.,0,Yes,0,We recently reported the preferential selection of the K65R resistance,0,Yes,0
Human Answer – Yes/No questions,23749954,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported — the paper does not provide GenBank accession numbers or state that newly generated sequences were deposited.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,23749954,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not applicable for patient samples; the authors did generate cloned NL4-3 plasmids with specific mutations in the laboratory.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,23749954,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — the study did not obtain or report sequences from individuals with virological failure.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,23749954,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No — there were no patients enrolled in this study; experiments used laboratory viruses and database sequences.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,23749954,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper does not report sequences from treated individuals; it analyzes laboratory-generated clones and database consensus sequences.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,24227862,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,24227862,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,24227862,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (no public sequence deposition is reported).,1,No,1,No,1,No,1
Human Answer – Yes/No questions,24227862,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Yes — site-directed cloning was performed to generate recombinant NL4.3 clones prior to sequencing for verification.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,24227862,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,24227862,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No — there were no patients enrolled in this study.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,24227862,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,25637519,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No — the study did not report sequencing of patient-derived HIV samples; it used an infectious plasmid and site-directed mutants for in vitro work.,1,No,1,Yes,0,Yes,0
Human Answer – Yes/No questions,25637519,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — the paper reports in vitro phenotypic drug susceptibility data for mutant and wild-type viruses.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,25637519,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report depositing sequences or providing public accession numbers.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,25637519,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Yes — plasmid clones (constructs) were generated and positive clones were identified and sequenced.,0,Yes,0,No,1,Not reported,1
Human Answer – Yes/No questions,25637519,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Yes,0,No sequences from such individuals were obtained in this study; the paper only references (from other studies) that D404N has been found in treatment-failure patients.,1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,25637519,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — there were no patients enrolled or treated in a clinical trial in this study; the work was performed using cell lines and plasmid-derived viruses.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,25637519,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Yes,0,No — the study itself did not report sequences from individuals with prior ARV exposure; it only cites other reports where D404N was found in ART-experienced patients.,1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,26246578,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,26246578,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,26246578,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No sequences were reported as being made publicly available.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,26246578,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,"Not applicable — no sequencing was performed; however, engineered plasmid clones were generated by site-directed mutagenesis.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,26246578,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the study did not obtain sequences from any individuals, including those with virological failure.",1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,26246578,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — there were no patients in this study; it was an in vitro laboratory study.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,26246578,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper does not report sequences from such individuals.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,26311878,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,"No. The paper reports sequences from plasmids and tissue-culture viruses, not from patient samples.",1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,26311878,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes. The paper reports in vitro susceptibility (IC50) measurements to DTG, RAL, and EVG.",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,26311878,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,"No. The paper does not report any public deposition (e.g., GenBank accession numbers) for sequences generated in this study.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,26311878,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Yes. Plasmids bearing the integrase mutations were generated (cloned) by site-directed mutagenesis and verified by sequencing; replication-competent genetically homogeneous viruses were produced from these plasmids.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,26311878,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No. The study did not sequence samples from individuals with treatment failure; mentions of such individuals refer to prior reports in the literature.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,26311878,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No. The study is an in vitro laboratory study using cell lines, primary cells, and engineered plasmids/viruses, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,26311878,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No. The paper does not report sequencing of ARV-exposed individuals; it studies laboratory-generated viruses and references ARV-exposed individuals in prior literature.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,26559830,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,26559830,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,26559830,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No public deposition or accession numbers are reported in the paper.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,26559830,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Yes,0,Yes — sequencing was performed on engineered full-length molecular clones.,0,Yes,0,No,1,Not reported,1
Human Answer – Yes/No questions,26559830,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,26559830,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No — there were no patient participants or clinical trial subjects in this study.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,26559830,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,27009474,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,27009474,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,27009474,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,27009474,8,Were samples cloned prior to sequencing?,Boolean,Yes,,No,0,No,0,Not reported,0,"Yes, infectious molecular clones and a recombinant infectious molecular clone from the patient's sample were created.",1,Yes,1,Yes,1,Not reported,0
Human Answer – Yes/No questions,27009474,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — the patient whose sample was sequenced was virologically suppressed (plasma HIV-1 RNA <50 copies/ml) on therapy.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,27009474,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No; the report describes a single clinical case and does not indicate participation in a clinical trial.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,27009474,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,The primary sequence in this study was from a treatment-naive individual with transmitted resistance; the paper also references GenBank sequences from raltegravir-experienced individuals.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,27124362,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,27124362,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,27124362,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No sequences or accession numbers are reported in the paper.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,27124362,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — sequencing of patient samples was not reported.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,27124362,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — sequences were not obtained from such individuals in this study.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,27124362,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — the study did not include patients or a clinical trial.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,27124362,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper does not report sequencing of individuals with prior ARV exposure.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,28559249,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,No.,0,No,0,No,0,Yes,1
Human Answer – Yes/No questions,28559249,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,28559249,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report that sequences were made publicly available.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,28559249,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Some viral strains used in the study were derived from full-length molecular clones and site-directed/recombinant clones were constructed.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,28559249,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,Not applicable,1,"The paper used a recombinant clone derived from a patient receiving antiretroviral therapy (AZT, 3TC, ritonavir-boosted lopinavir), but it does not state sequencing was performed on that patient's virus within this report.",0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,28559249,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,No indication that the patients providing isolates for this study were participants in a clinical trial.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,28559249,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Not applicable,0,"Yes — the paper includes a recombinant clone (4.7a) derived from a patient who had received ARV drugs (AZT, lamivudine/3TC, and ritonavir-boosted lopinavir), though sequence data are not presented in this paper.",0,No,0,No,0,Yes,1
Human Answer – Yes/No questions,29373677,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,29373677,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,29373677,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported in the paper,0,Yes,0,No,1,No,1
Human Answer – Yes/No questions,29373677,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No cloning prior to sequencing is described in the paper,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,29373677,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,29373677,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No, the report describes an individual patient case, not a clinical trial",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,29373677,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,30053052,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,30053052,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,30053052,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No GenBank accession numbers provided in the paper.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,30053052,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Yes,0,Yes. Patient-derived fragments were cloned (gag-pol into pNL43; RT subunits into expression vectors).,0,Yes,0,Yes,0,Not reported,1
Human Answer – Yes/No questions,30053052,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes. Sequences (viruses) were obtained from therapy-failure patients (3 viruses), and their drug resistance mutations are reported.",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,30053052,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,"No. Patients were sampled from an observational HIV cohort, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,30053052,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. Sequences from individuals with virological treatment failure (indicating prior ARV exposure) were reported and mutations associated with ARV resistance are listed.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,30803972,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No — the paper does not report sequencing of patient-derived HIV sequences.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,30803972,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,30803972,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report making sequences publicly available.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,30803972,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not Reported,1,"Not applicable — sequencing was not performed; however, the study used molecular clones and constructed site-directed mutants.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,30803972,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — the study did not obtain or report sequences from individuals with virological failure on treatment.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,30803972,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not Reported,1,"No — the paper reports in vitro experiments with virus isolates and clones, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,30803972,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the isolates tested in this study were from ART-naive individuals.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,31988104,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,Yes,0,No,1,Yes.,0,No,1,Yes,0,Yes,0
Human Answer – Yes/No questions,31988104,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,31988104,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No evidence of public deposition is reported.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,31988104,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Yes,0,"Yes, patient-derived fragments were cloned into plasmid backbones to create recombinant viruses.",0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,31988104,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,Not specified.,0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,31988104,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No—patient-derived isolates were used for in vitro experiments; clinical trials mentioned are separate referenced studies.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,31988104,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,32601157,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,32601157,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,32601157,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (no public sequence accession information is provided),1,No,1,No,1,No,1
Human Answer – Yes/No questions,32601157,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Yes (cloned as plasmid constructs prior to sequencing),0,No,1,No,1,No,1
Human Answer – Yes/No questions,32601157,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,32601157,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No (no patients were enrolled; study used in vitro constructs),1,No,1,No,1,No,1
Human Answer – Yes/No questions,32601157,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,33855437,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,33855437,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,33855437,3,Were sequences from the paper made publicly available?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,33855437,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No evidence of cloning prior to sequencing; genotypic analyses were performed on viral RNA and amplified viruses from culture supernatants.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,33855437,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No clear evidence of sequences from individuals with virological failure; most isolates were from drug‑naive individuals, although one isolate (96USSN20) harboured baseline thymidine analogue mutations.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,33855437,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,33855437,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,"Mostly no — isolates were from drug‑naive individuals; however, one isolate (96USSN20) carried baseline thymidine analogue mutations consistent with prior NRTI exposure.",0,No,1,No,1,No,1
Human Answer – Yes/No questions,34516245,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,34516245,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,34516245,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,34516245,8,Were samples cloned prior to sequencing?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Not reported,0
Human Answer – Yes/No questions,34516245,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,34516245,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No (no patients were involved).,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,34516245,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,35730213,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,35730213,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,35730213,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,"NRTI, NNRTI",0,No,1,No (not applicable).,1,No,1,No,1,No,1
Human Answer – Yes/No questions,35730213,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,35730213,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,"No — no sequences were obtained; additionally, virological failure was rare in this cohort.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,35730213,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — they were enrolled in a prospective, registered cohort study (DO-REAL).",1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,35730213,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,35913500,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,No,0,No,0,"No — the paper does not report HIV nucleotide sequences; it reports clinical resistance testing results (eg, an N155H mutation) but does not present sequence data.",0,No,0,No,0,Yes,1
Human Answer – Yes/No questions,35913500,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report any in vitro drug susceptibility assay data.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,35913500,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not indicate that any sequences were deposited or made publicly available.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,35913500,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / not reported — the paper does not describe any cloning or sequencing methods.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,35913500,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,No,0,Not applicable,0,"The paper does not report sequences, but it does report resistance testing and a baseline N155H mutation in a patient with detectable viremia; resistance testing was planned for those with persistent detectable viral load.",0,No,0,No,0,Yes,1
Human Answer – Yes/No questions,35913500,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this was a demonstration project / observational program, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,35913500,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,No,0,Not applicable,0,"Not applicable — no sequences are reported. The study population included individuals with prior ART exposure and reported resistance mutations (eg, N155H) consistent with prior treatment.",0,No,0,No,0,Yes,1
Human Answer – Yes/No questions,35945163,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,No,0,Yes — the paper reports HIV resistance-associated mutations detected in patient samples.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,35945163,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro phenotypic drug susceptibility data.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,35945163,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not indicate that sequences were deposited or made publicly available.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,35945163,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported / No information provided.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,35945163,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,Not applicable,1,Yes — sequences (resistance-associated mutations) were reported from individuals who stopped therapy because of incomplete virological response.,0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,35945163,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — participants were enrolled in a compassionate use programme, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,35945163,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Not applicable,0,"Yes — many participants had prior ART exposure, and resistance mutations reported relate to prior or study treatment.",1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,36415058,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36415058,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36415058,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not applicable),1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,36415058,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / No cloning reported,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,36415058,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,36415058,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,36415058,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36454248,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36454248,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,Yes,0,"No — the paper reports genotype-based predicted susceptibility, not in vitro phenotypic assays.",1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36454248,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36454248,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36454248,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes; sequences were obtained from treated individuals who were in virological failure (VL >50 copies/mL).,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36454248,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No; patients were under clinical follow-up/clinical monitoring, not enrolled in a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,36454248,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36519389,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36519389,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report any in vitro drug susceptibility data.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36519389,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report any HIV sequences or state that sequences were made publicly available.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36519389,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported / Not applicable — cloning prior to sequencing is not described.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36519389,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No sequences were reported. The paper does report virologic elevations in some participants but does not report sequencing from those individuals.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36519389,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — participants were part of the CHARACTERISE study and had previously been part of the randomized ADVANCE trial.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36519389,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the paper does not report HIV sequences. Participants had previously received antiretroviral regimens, but no sequences are presented.",1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,36571282,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36571282,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36571282,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not publicly available).,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36571282,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No indication that samples were cloned prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36571282,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36571282,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36571282,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No.,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,36597160,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. The paper reports patient HIV genotypes (sequence-based resistance testing) obtained from patient samples.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,36597160,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No. The paper does not report in vitro phenotypic drug susceptibility assays; it reports genotypic resistance testing only.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36597160,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No. The paper states that data will not be shared publicly.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36597160,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No. The paper reports Sanger (population) genotyping and does not mention cloning prior to sequencing.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36597160,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes. Genotypic resistance results at the time of virologic failure were obtained for six patients, and five of those had NRTI and INSTI resistance-associated mutations.",1,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,36597160,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No. The study was a retrospective multicenter observational (non-interventional) cohort study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,36597160,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. The cohort comprised ART-experienced patients and many had prior antiretroviral exposure; genotypes reported include pre-switch resistance profiles.,1,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,36645792,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes — the paper reports genotypic sequences from patient plasma (baseline GART performed and numbers of successful baseline GART reported).,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,36645792,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — the paper reports genotypic resistance testing and algorithmic drug susceptibility prediction, not in vitro phenotypic (laboratory) drug susceptibility assays.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,36645792,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported — the paper does not state that sequences were deposited in a public database.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,36645792,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported — the paper does not mention cloning of samples prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36645792,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — participants were enrolled because they had virologic failure on first-line tenofovir–emtricitabine (or lamivudine)–efavirenz, and baseline genotypes were obtained for these individuals.",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36645792,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — this was a randomized, double-blind, placebo-controlled, phase 2 clinical trial (ARTIST), registered as NCT03991013.",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36645792,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — sequences were obtained from individuals who had been on first-line antiretroviral therapy (tenofovir + emtricitabine/lamivudine + efavirenz) and were experiencing virologic failure.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36659824,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,No,0,Yes,1,Yes — the paper reports that HIV resistance genotyping was performed on patient samples.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,36659824,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro susceptibility testing of patient isolates; it only references a literature value for an in vitro protein-adjusted IC95.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36659824,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No — the paper does not state that HIV sequences or sequence accession numbers were deposited in a public database.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36659824,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported / No indication of cloning prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36659824,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,No,0,No,0,Yes — resistance genotyping was performed for individuals with virological non-response and the paper reports that no emergent resistance-associated mutations were detected in those who did not achieve viral suppression.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,36659824,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — this was a registered clinical study (a national, multicentre, prospective, open-label single-arm study) registered on ClinicalTrials.gov (NCT03858478).",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36659824,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,No,0,No,0,No — the study population was ART-naive and pretreated individuals were protocol violations and excluded from the main ITT analysis; the paper does not report sequence data specifically from previously treated individuals.,0,No,0,No,0,No,0
Human Answer – Yes/No questions,36660819,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,** No,0,Yes — the paper reports genotypic (sequence-based) resistance results from participant samples (resistance-associated mutations).,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,36660819,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,** No,1,No — the provided content does not present in vitro drug susceptibility (phenotypic) data or susceptibility assay results.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36660819,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,** No,1,No — the provided paper content does not indicate that sequence data were deposited in a public database; data are available on request to the management group.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36660819,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,** Not applicable,1,Not reported in the provided content.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36660819,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,** Not applicable,0,Yes — sequences (genotypic resistance data) were obtained from individuals with confirmed virologic failure (CVF) and from suspected virologic failure samples.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,36660819,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,** Yes,1,"Yes — patients were participants in the phase 3b randomized, open-label ATLAS-2M clinical trial.",1,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,36660819,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,** Yes,1,"Yes — the study included participants with prior CAB+RPV exposure, and baseline pro-viral RPV resistance-associated mutations were assessed.",1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,36694270,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36694270,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — only genotypic resistance analysis was reported, not in vitro phenotypic susceptibility testing.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,36694270,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No clear public sequence repository accession information is provided.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36694270,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — cloning is not described; PCR products were directly sequenced.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36694270,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,Yes,0,Not explicitly reported / Not stated.,0,No,1,Yes,0,Yes,0
Human Answer – Yes/No questions,36694270,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,No,0,No,0,No,0,No — this was a retrospective observational study of patients admitted to a hospital.,0,No,0,No,0,Not reported,0
Human Answer – Yes/No questions,36694270,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36706364,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,36706364,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36706364,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported).,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36706364,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No (not reported).,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36706364,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,36706364,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36706364,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,36738248,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36738248,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36738248,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,Not reported,1,Not reported as publicly deposited; sequences were stored in internal databases (SwissHIVGenomeDB and SHCS Drug Resistance Database).,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,36738248,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No — cloning prior to sequencing is not described.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,36738248,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not reported,1,Not explicitly reported; virological failure status is not described.,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,36738248,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,"No — patients were enrolled in observational cohort studies (SHCS and ZPHI), not a clinical trial.",1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,36738248,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36751650,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,** Yes.,1,Yes.,1,Yes,1,Yes,1,Yes.,1
Human Answer – Yes/No questions,36751650,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,** No.,1,No.,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,36751650,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,** No.,1,Not reported / No evidence of public deposition in the paper.,0,No,1,No,1,No.,1
Human Answer – Yes/No questions,36751650,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,** No.,1,No (no cloning step described).,1,No,1,No,1,Not reported.,1
Human Answer – Yes/No questions,36751650,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,** No.,1,No.,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,36751650,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,** No.,1,No (they were recruited from voluntary counseling and testing centers; no clinical trial is reported).,1,No,1,No,1,Not reported.,1
Human Answer – Yes/No questions,36751650,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,** No.,1,No.,1,No,1,No,1,Yes.,0
Human Answer – Yes/No questions,36779485,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36779485,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No (the paper reports genotypic predictions rather than in vitro phenotypic susceptibility assays).,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36779485,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / not specified in this paper.,0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36779485,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported / no indication that samples were cloned prior to sequencing.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36779485,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36779485,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No; this was a retrospective analysis of a South African cohort, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36779485,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes; sequences include individuals failing NNRTI-based ART who had prior ARV exposure.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36795586,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36795586,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36795586,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — no sequence data were reported or made available.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36795586,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported / No information provided.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36795586,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,Yes — targeted HIV genotype testing was sporadically available for CALHIV failing second-line ART.,0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36795586,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this was a retrospective cohort (real-world) study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,36795586,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No sequences are reported; however, genotype testing was sporadically performed on ART-experienced (failing second-line) individuals.",1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,36851704,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36851704,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No; the paper reports genotypic resistance predictions from sequences, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,36851704,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report public sequence deposition; data are available on request from the corresponding author.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36851704,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — samples were PCR amplified and Sanger sequenced; cloning is not described.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36851704,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,No,1,No — participants were adults initiating or reinitiating ART (not described as experiencing on-treatment virological failure); all had viral load >1000 copies/mL at enrolment.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36851704,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the study was a nationally representative cross-sectional survey, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36851704,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — 35.6% of participants reported previous exposure to antiretroviral drugs, and sequences include participants with and without prior exposure.",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36851760,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36851760,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — only genotypic (sequence-based) resistance analysis was reported; no phenotypic in vitro susceptibility assays are described.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36851760,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36851760,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No evidence of cloning; samples were amplified by RT-PCR and nested PCR and directly Sanger-sequenced.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,36851760,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — sequences include samples from ART-treated children with virological failure.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36851760,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No indication that patients were enrolled in a clinical trial; samples were collected during a study and routine early diagnosis/follow-up activities.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,36851760,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36920025,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36920025,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36920025,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36920025,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,"Yes; PCR products were either directly sequenced or cloned prior to sequencing, and Primer ID NGS was also used.",0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36920025,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36920025,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36920025,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36931676,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes.,1,Yes.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,36931676,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No.,1,No — the paper reports predicted phenotypic sensitivity but does not report in vitro phenotypic susceptibility assays.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36931676,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No.,1,No — the paper does not state that sequences were made publicly available; data are available only upon reasonable request.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36931676,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable.,1,Not reported.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36931676,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Not reported.,0,"Yes — the cohort includes sequences associated with acquired drug resistance, implying sequences from individuals with treatment failure.",1,No,0,No,0,Not reported,0
Human Answer – Yes/No questions,36931676,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported.,1,"No — this is a registry-based cohort study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,36931676,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes.,1,Yes.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,36961945,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,** Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,36961945,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,** No,1,No — the paper reports genotypic resistance (sequence-based DRMs) but does not report phenotypic/in vitro drug susceptibility assays.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36961945,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,** No,1,Not reported / No accession numbers or public deposition are reported in the paper.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,36961945,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,** No,1,No — cloning is not described; PCR and nested PCR were used to generate amplicons for sequencing.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,36961945,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,** No,1,No — no participants experienced virologic failure during follow-up after ART initiation.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,36961945,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,** Not reported,1,"No — participants were enrolled in the San Diego PIRC cohort (observational study), not described as part of a clinical trial.",1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,36961945,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,** No,1,"No — the study was conducted in antiretroviral (ART)-naïve individuals, so sequences are from ART-naïve persons prior to ART initiation.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,36967989,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No — the paper did not report new HIV sequences from patient samples; it analyzed existing genotype-phenotype data from a public database.,1,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,36967989,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,Yes — the paper used phenotypic (in vitro) drug susceptibility data (fold-change and IC50) from the Stanford PhenoSense assay and external datasets.,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,36967989,3,Were sequences from the paper made publicly available?,Boolean,No,,Yes,0,No,1,No,1,"No novel sequences were reported; however, all data and code used in the study were made publicly available on GitHub and Zenodo.",1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,36967989,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36967989,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,Not specified / not reported.,0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36967989,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,No — the study did not involve patients in a clinical trial; it analyzed retrospective genotype-phenotype data from public databases.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36967989,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,Not specified / not reported.,0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36982978,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,Yes,0,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36982978,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,Yes — the paper summarizes and reports in vitro susceptibility data from published studies.,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,36982978,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not present new sequences and does not provide public sequence accession information.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36982978,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing experiments or cloning are described in this paper.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,36982978,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,Not applicable,1,No — this paper did not obtain or report original sequences from such individuals.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,36982978,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,Not applicable — this is a review article and does not report enrollment of patients in a trial by the authors.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,36982978,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,Yes,0,Not applicable,1,No — the paper does not present original HIV sequences from treated individuals.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37017009,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37017009,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — the paper reports genotypic resistance predictions, not in vitro phenotypic susceptibility testing.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37017009,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No evidence of public deposition is provided in the paper.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37017009,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — samples were PCR-amplified and libraries prepared for direct sequencing; cloning is not mentioned.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37017009,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. All sequenced samples came from children on ART with evidence of virological failure (VL 1000 copies/mL).,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37017009,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No. The study was a cross-sectional, facility-based survey, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37017009,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. All participants were on ART for at least one year and the study collected data on current and previous regimens and PMTCT exposure.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37029656,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — the paper reports genotypic resistance testing (sequencing) performed on patient samples.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37029656,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,"No — the paper reports genotypic interpretation of resistance, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37029656,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported — the paper does not state that sequence data were deposited in public databases.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37029656,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,Not reported; the paper describes direct Sanger sequencing and does not mention cloning.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37029656,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No — sequences were obtained from ART-naive individuals before initiation of therapy, not from people with virological failure on treatment.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37029656,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the study was an observational time-trend, single-centre study of ART-naive people living with HIV.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37029656,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper reports sequences from ART-naive individuals who had not previously received antiretroviral therapy.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37039023,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37039023,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37039023,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes (raw reads deposited to SRA under BioProject PRJNA419915).,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37039023,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37039023,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37039023,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37039023,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. All study participants were on antiretroviral therapy (first- or second-line) and had been receiving ART prior to sampling.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37042390,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37042390,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37042390,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (the paper does not report depositing sequences or providing accession numbers).,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37042390,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,"No, samples were PCR-amplified, gel-purified and directly sequenced; no cloning step is described.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37042390,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes. Genotyping/sequencing was performed for patients who did not attain virological suppression after 12 months; among 13 patients who did not attain suppression, sequencing was done on multiple samples.",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37042390,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this was a single-centre observational study in programmatic conditions, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37042390,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37052343,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37052343,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37052343,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37052343,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not applicable — no sequencing was performed.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37052343,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not reported,1,No — no sequences were obtained or reported.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37052343,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No; they were participants in an observational cohort study (RESPOND).,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37052343,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,"No — participants were treatment-naive, and the paper does not report sequences.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37071019,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37071019,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37071019,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37071019,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not Reported,1,No (no patient samples); plasmids were generated by site-directed mutagenesis and amplified in bacteria prior to Sanger sequencing,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37071019,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37071019,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Yes,0,No — there were no patients in this study,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37071019,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37085698,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37085698,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37085698,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37085698,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37085698,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37085698,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37085698,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37104815,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37104815,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37104815,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported).,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37104815,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No indication of cloning; cloning is not reported.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37104815,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37104815,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — they were participants in the ANRS 170 QUATUOR Phase III randomized clinical trial.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37104815,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37112971,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37112971,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — the paper reports genotypic sequencing and interpretation, not primary in vitro phenotypic susceptibility testing.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37112971,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,"No, the sequence data are not publicly available; they are available on request from the corresponding author.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37112971,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — there is no indication that samples were cloned; sequencing was performed directly from plasma RNA using genotyping kits and Sanger or NGS methods.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37112971,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No — all sequences were from treatment-naïve patients, so not from individuals with virological failure on therapy.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37112971,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the sequences were obtained from routine HIV DR testing, research and clinical projects, and outbreak investigations; there is no indication patients were enrolled in a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37112971,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,"No — the study population consisted of treatment-naïve individuals (i.e., they had not previously received antiretroviral drugs).",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37147875,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37147875,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,No,0,Yes,1,No (the paper does not present new in vitro susceptibility experiments; it cites prior in vitro work).,0,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,37147875,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication that sequences were made publicly available.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37147875,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No indication that samples were cloned prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37147875,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,Yes,0,No,1,Yes,0,"No — the sequences reported were from a newly infected, treatment-naive individual; sequences were not reported from the partner who had adherence difficulties.",1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37147875,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this is a case report/research letter, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37147875,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No — the reported sequences are from an individual who had not yet started antiretroviral therapy prior to sequencing.,1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37272233,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37272233,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37272233,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication of public deposition.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37272233,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported / No indication of cloning prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37272233,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,Not clearly reported; the paper does not state sequences were from individuals identified as having virological failure.,0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37272233,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37272233,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,Yes,0,Yes,0,Yes — some participants had prior ART exposure and some underwent ART before resistance testing.,0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37279764,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37279764,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper reports genotypic resistance inference rather than in vitro phenotypic susceptibility assays.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37279764,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,No,0,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37279764,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No cloning is reported.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37279764,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37279764,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — they were newly diagnosed patients, not participants in a clinical trial as described.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37279764,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37327289,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37327289,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37327289,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37327289,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37327289,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37327289,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37327289,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37340869,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,No,0,No,0,"Yes — the paper reports genotypic (sequence-based) data from participants (e.g., RPV resistance-associated mutations and HIV-1 subtypes).",1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37340869,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not present in vitro drug susceptibility (phenotypic) results in the main text.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37340869,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported — the paper does not state that sequence data were deposited in public databases.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37340869,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported — there is no mention in the paper of cloning prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37340869,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,"Yes — genotypic/subtype data are reported for participants who experienced confirmed virologic failure (CVF); for example, participants with CVF had RPV RAMs and subtype A6/A1 was observed among CVF cases.",0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37340869,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — participants were enrolled in randomized, multicenter, open-label phase 3/3b clinical trials (FLAIR, ATLAS, ATLAS-2M).",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37340869,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,No,0,Not applicable,0,Yes — the study participants were virologically suppressed on antiretroviral therapy prior to randomization and retrospective proviral DNA analyses (identifying RPV RAMs) reflect prior ARV exposure/history.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37358226,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes.,0
Human Answer – Yes/No questions,37358226,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,37358226,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,37358226,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No — not applicable because no sequencing was performed.,1,No,1,No,1,Not reported.,1
Human Answer – Yes/No questions,37358226,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No; no sequences were obtained. The cohort did include individuals with pretransition viremia (>999 copies/mL).,1,No,1,No,1,Yes.,0
Human Answer – Yes/No questions,37358226,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No; they were participants in a prospective open cohort (routine care), not a clinical trial.",1,No,1,No,1,No.,1
Human Answer – Yes/No questions,37358226,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No; the paper does not report HIV sequences, although the cohort consisted of treatment-experienced individuals who had received ARV drugs.",1,Yes,0,No,1,Yes.,0
Human Answer – Yes/No questions,37376649,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37376649,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37376649,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No explicit public sequence deposition is reported.,0,Yes,0,No,1,Not Reported,1
Human Answer – Yes/No questions,37376649,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No indication of cloning; samples were analyzed by NGS without mention of cloning.,0,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,37376649,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No — participants with prior virologic failure were excluded, and the baseline sequencing was performed in participants without previous virologic failure.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37376649,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — they were participants in the randomized TANGO clinical trial (ClinicalTrials.gov, NCT03446573).",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37376649,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Not reported,0,Yes.,1,No,0,No,0,No,0
Human Answer – Yes/No questions,37381002,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37381002,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,Yes,0,No — the paper reports genotypic resistance analysis/predictions rather than in vitro phenotypic susceptibility testing.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37381002,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported in the paper.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37381002,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — cloning is not described; PCR products were directly sequenced (Sanger) or pooled and NGS-sequenced.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37381002,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — sequences were from individuals with antiretroviral therapy (ART) failure (viral load ≥ 1000 copies/ml).,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37381002,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the study is described as a retrospective observational study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37381002,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — individuals had received antiretroviral therapy for more than one year prior to being identified as treatment failures.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37439411,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37439411,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,Yes,0,"No — only genotypic susceptibility interpretations were reported, not in vitro phenotypic assays.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37439411,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / Not specified,0,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,37439411,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported / No indication of cloning prior to sequencing,0,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,37439411,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37439411,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,No,0,No,0,No,0,No — they were part of an observational cohort,0,No,0,No,0,Not Reported,0
Human Answer – Yes/No questions,37439411,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37495103,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37495103,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37495103,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No evidence of public deposition,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37495103,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37495103,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37495103,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37495103,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37498738,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37498738,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37498738,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,Yes,0,Not stated in the main text; data availability is referenced in the Supplementary Appendix 6.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37498738,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No; samples were not cloned—sequencing was performed on near full-length PCR amplicons and single-genome dilutions with whole-genome amplification rather than cloning.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37498738,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No sequences were reported from individuals with virological failure; participants demonstrated sustained virological suppression over 48 weeks.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37498738,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes; participants were enrolled in the Early Simplified Study (ESS), a randomized clinical trial (NCT00537966).",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37498738,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Not reported,0
Human Answer – Yes/No questions,37515095,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37515095,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — only genotypic resistance profiling from sequences was reported, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37515095,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37515095,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No evidence of cloning; samples were processed by RT-PCR and directly sequenced.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37515095,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,Yes,0,Not explicitly reported; virological failure status is not specified in the paper.,0,Yes,0,No,1,Not reported,1
Human Answer – Yes/No questions,37515095,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,968,0,No,1,Not reported,1
Human Answer – Yes/No questions,37515095,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — most sequences were from ART-experienced individuals; only 7 individuals were not undergoing ART.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37515146,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37515146,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37515146,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37515146,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,37515146,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37515146,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,37515146,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37520425,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37520425,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37520425,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37520425,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37520425,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,No,0,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37520425,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37520425,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,No,0,No; the study focused on treatment-naive individuals and excluded treatment-experienced patients.,0,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,37537871,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37537871,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — the paper reports genotypic resistance (sequence-based) interpretation, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37537871,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No public deposition of patient sequences is reported in the paper.,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37537871,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — samples were directly sequenced from viral RNA extracted from plasma (no cloning of patient samples is described).,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37537871,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,No,0,Not reported,0,Not reported / clinical virological failure status was not determined for the sequenced individuals.,0,No,0,No,0,No,0
Human Answer – Yes/No questions,37537871,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — samples were collected from a hospital cohort and no clinical trial is mentioned.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37537871,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,No,0,Not applicable,0,Not specified in the paper.,0,No,0,No,0,No,0
Human Answer – Yes/No questions,37540331,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37540331,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37540331,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37540331,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37540331,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37540331,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37540331,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No sequences reported; participants were treatment-experienced and on ART,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37541705,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,No,0,No,0,No — the paper does not report HIV sequences generated from patient samples.,0,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37541705,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro phenotypic drug susceptibility data.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37541705,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — sequence data were not made publicly available.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37541705,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing or cloning methods are reported.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37541705,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report any sequences from individuals with virologic failure.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37541705,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — participants were enrolled in an international phase I/II clinical trial (IMPAACT 2019, NCT03760458).",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37541705,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,No — the paper does not report any HIV sequences; however most participants (95%) were treatment-experienced prior to study entry.,0,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37546367,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37546367,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,"No — the paper reports genotypic resistance inference, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37546367,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37546367,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No evidence of cloning; PCR products were purified and directly Sanger-sequenced.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37546367,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"No — sequences were obtained from ART-experienced individuals with low-level viremia (200–1000 copies/mL), not specifically described as virological failure.",0,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37546367,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this was a retrospective observational study of routine samples, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37546367,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — all participants had received antiretroviral therapy for at least 6 months.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37554471,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,No,0,No,0,No.,0,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37554471,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,Yes — for non-HIV pathogens (MAI) and HBV drug resistance testing; no HIV phenotypic susceptibility data are reported.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37554471,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report making any sequences publicly available.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37554471,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing or cloning methods are reported.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37554471,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — no sequences were obtained or reported.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37554471,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this report is a single-case clinical report, not a clinical trial participant.",1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37554471,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper does not report any HIV sequences; the described patient had prior ARV exposure.,1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37573167,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37573167,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,"No — the paper reports genotypic resistance and genotypic susceptibility scores, not in vitro (phenotypic) susceptibility assays.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37573167,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication of public sequence deposition.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37573167,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No — the study used standard Sanger sequencing without mention of cloning.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37573167,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — sequences were obtained from virologically suppressed individuals at the time of sampling.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37573167,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the samples and testing were from routine clinical practice, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37573167,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — the cohort consists of drug-experienced individuals, many with prior ARV exposure.",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37574435,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes — the paper reports HIV genotypic resistance data (mutations) from patient samples.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37574435,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro (phenotypic) drug susceptibility assays.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37574435,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report that sequences were deposited or made publicly available.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37574435,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not reported / not specified.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37574435,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes — genotypic resistance data were available for participants who had viral rebound (virologic failure) prior to switching regimens.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37574435,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the study was a single-center, retrospective cohort study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37574435,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes — all participants were antiretroviral-experienced and the paper reports archived resistance mutations from these individuals.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37585352,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37585352,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,No,0,No,0,No,0,No,0,No,0,No,0
Human Answer – Yes/No questions,37585352,3,Were sequences from the paper made publicly available?,Boolean,No,,Yes,0,No,1,No,1,"Yes, available on request through the PANGEA consortium",0,Yes,0,Yes,0,Yes,0
Human Answer – Yes/No questions,37585352,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37585352,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37585352,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes, participants were recruited from a large community HIV incidence trial (the Botswana Combination Prevention Project, registered NCT01965470)",1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37585352,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37593123,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37593123,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,"No — the study reports genotypic resistance inference, not in vitro phenotypic susceptibility testing.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37593123,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Yes — the analysis used sequences obtained from public databases (China CDC records and the Los Alamos HIV sequence database / GenBank annotations).,0,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,37593123,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication of cloning.,0,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,37593123,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No. All sequences were from ART-naïve individuals, so none were from persons failing treatment.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37593123,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No. The study used surveillance/research sequences from databases and describes observational sampling across PLADs, not enrollment in a clinical trial.",1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,37593123,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No. The sequences were from ART-naïve individuals who had not previously received antiretroviral therapy.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37626789,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37626789,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — the paper reports genotypic resistance from sequencing and interpretation via the Stanford HIVDB algorithm, not in vitro phenotypic susceptibility testing.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37626789,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report public deposition of sequences.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37626789,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No cloning prior to sequencing is reported in the paper.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37626789,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37626789,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No; they were part of an observational longitudinal national cohort study.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37626789,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37632026,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37632026,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,Yes,0,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37632026,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37632026,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,37632026,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37632026,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37632026,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37632071,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37632071,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37632071,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — no sequences are reported or deposited.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37632071,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No — cloning and sequencing are not described in the paper.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37632071,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — no sequences were obtained; the study largely included individuals with suppressed or low-level viremia prior to switch.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37632071,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — this was a retrospective cohort study of routine clinical practice.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37632071,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper does not report any HIV sequences; the study population were treatment-experienced individuals on antiretroviral therapy.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37649807,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes.,0
Human Answer – Yes/No questions,37649807,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,37649807,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report any sequences or GenBank deposits.,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,37649807,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed.,1,No,1,No,1,Not reported.,1
Human Answer – Yes/No questions,37649807,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — no sequences were obtained; the paper does report virologic failure based on viral load criteria.,1,Yes,0,No,1,Yes.,0
Human Answer – Yes/No questions,37649807,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not Reported,1,No — patients were part of routine programmatic care and the analysis used retrospective routinely collected data.,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,37649807,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the paper does not report sequences; however, the cohort included many individuals with prior ARV exposure.",1,Yes,0,No,1,Yes.,0
Human Answer – Yes/No questions,37662576,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37662576,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37662576,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper used public PDB structures rather than depositing new sequence data.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37662576,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing or cloning of samples was performed.,1,No,1,No,1,Not applicable,1
Human Answer – Yes/No questions,37662576,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the study did not obtain or report sequences from individuals, including those with virological failure.",1,No,1,No,1,Not applicable,1
Human Answer – Yes/No questions,37662576,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No — there were no patients in this study.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37662576,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — no individual-derived HIV sequences are reported.,1,No,1,No,1,Not applicable,1
Human Answer – Yes/No questions,37674678,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37674678,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,Yes,0,"No — only genotypic (predicted) resistance analyses were reported, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37674678,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,No,0,Yes,1,Not explicitly reported in the manuscript.,0,Yes,1,No,0,No,0
Human Answer – Yes/No questions,37674678,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — samples were amplified by nested PCR and PCR products were directly sequenced; no cloning is described.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37674678,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — all participants were ART-naïve with no history of antiretroviral therapy.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37674678,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — patients were enrolled observationally at voluntary counseling and testing clinics, not as part of a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37674678,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No — the sequences were from ART-naïve individuals with no history of antiretroviral therapy.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37701387,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,No,0,Yes,1,Yes — the paper reports baseline genotype/mutation data from patient samples.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37701387,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro phenotypic drug susceptibility data.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37701387,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report making sequences publicly available.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37701387,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication of cloning prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37701387,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — sequences were from ART‑naïve individuals and the study reported no virological failure-related ART interruptions.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37701387,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — the Rainbow component was a phase IV clinical trial.,1,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,37701387,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,No,0,Not applicable,0,No — the reported sequences/genotype data are from ART‑naïve individuals.,0,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37716367,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,Yes,0,No,1,No,1,No.,1,No,1,No,1,Yes.,0
Human Answer – Yes/No questions,37716367,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,37716367,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not applicable).,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,37716367,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,1,No,1,No,1,Not reported.,1
Human Answer – Yes/No questions,37716367,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,1,No,1,No,1,Not reported.,1
Human Answer – Yes/No questions,37716367,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No (the paper is a guideline; it does not report a clinical trial).,1,No,1,No,1,Not reported.,1
Human Answer – Yes/No questions,37716367,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / not reported.,0,No,1,No,1,Not reported.,1
Human Answer – Yes/No questions,37755428,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes.,1
Human Answer – Yes/No questions,37755428,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — phenotypic in vitro susceptibility testing was not reported; resistance was predicted genotypically.,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,37755428,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No information provided on public sequence deposition.,0,No,1,No,1,No.,1
Human Answer – Yes/No questions,37755428,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No — cloning is not reported; Sanger sequencing was performed on extracted nucleic acids.,1,No,1,No,1,Not reported.,1
Human Answer – Yes/No questions,37755428,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — sequences were from ART-naive infants; no drug resistance testing was done on the mother's virus despite maternal detectable viral load.,1,No,1,No,1,Yes.,0
Human Answer – Yes/No questions,37755428,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,"No — the data derive from a national surveillance survey, not a clinical trial.",1,No,1,No,1,Not reported.,1
Human Answer – Yes/No questions,37755428,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,Yes,0,No,1,"Yes — although infants were ART-naive, the majority had prior exposure to antiretroviral drugs for PMTCT and some infants received postnatal prophylaxis (PNP).",0,Yes,0,No,1,Yes.,0
Human Answer – Yes/No questions,37775947,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37775947,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,"No — the paper reports genotypic predictions (GSS) based on sequence data, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37775947,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication in the paper that sequence data were made publicly available.,0,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,37775947,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — cloning is not reported; samples underwent RNA amplification followed by NGS.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,37775947,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,No,1,No — baseline sequences were obtained from ART‑naïve participants prior to treatment; genotypic tests at time of failure were not conducted.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37775947,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — they were participants in the START randomized clinical trial.,1,Yes,1,Yes,1,Not Reported,0
Human Answer – Yes/No questions,37775947,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No — the participants were ART‑naïve at baseline.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37817087,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37817087,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37817087,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — sequences are not publicly deposited; they are available from the corresponding author upon reasonable request.,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37817087,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37817087,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No — sequences were from newly diagnosed cases (primary resistance); the study did not focus on individuals with virological failure on treatment, although the authors note they cannot fully exclude some treated cases diagnosed abroad.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37817087,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37817087,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,"Generally no — sequences are from newly diagnosed (presumed treatment-naive) individuals, though the authors acknowledge they cannot completely exclude some cases that were previously treated abroad.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37823653,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37823653,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37823653,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No explicit statement of public deposition,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37823653,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37823653,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37823653,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,No,0,No,0,No,0,"Yes — they were enrolled in the Botswana Combination Prevention Project (BCPP), a registered study (ClinicalTrials.gov NCT01965470)",1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37823653,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37872202,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,Yes — the paper uses a transmitted/founder Env derived from a participant (patient-derived sequence) and previously reported patient-derived Env plasmids.,0,No,1,Yes,0,Yes,0
Human Answer – Yes/No questions,37872202,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,No,0,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37872202,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,Yes,0,No — the paper reports deposition of structural data (PDB/EMDB) but does not report deposition of nucleotide sequence data to public sequence databases in the Data availability statement.,1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37872202,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Yes — Env sequences were cloned into expression plasmids and mutations were introduced into Env expressors; the presence of mutations was confirmed by automated DNA sequencing.,0,No,1,No,1,Not reported (as the specific cloning method is not provided in the text),1
Human Answer – Yes/No questions,37872202,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — there is no mention of sequences from individuals with virological failure on treatment.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37872202,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,"No — the paper references a cohort study (RV217 Early Capture HIV Cohort Study), not a clinical trial.",1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37872202,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No — the paper does not report sequences from individuals with prior antiretroviral treatment.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37878637,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes.,1
Human Answer – Yes/No questions,37878637,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,37878637,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not explicitly reported (no public sequence accession numbers provided).,1,Yes,0,Yes,0,Yes.,0
Human Answer – Yes/No questions,37878637,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No evidence of cloning; PCR products were directly sequenced.,1,No,1,No,1,Not reported.,1
Human Answer – Yes/No questions,37878637,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes; sequences were obtained from participants experiencing virological failure (PVL ≥ 1000 copies/mL) who were on ART.,1,Yes,1,Yes,1,Yes.,1
Human Answer – Yes/No questions,37878637,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No; this was a cohort study, not a clinical trial.",1,No,1,No,1,No.,1
Human Answer – Yes/No questions,37878637,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes; participants were receiving antiretroviral therapy (first- or second-line) for at least six months prior to inclusion.,1,Yes,1,Yes,1,Yes.,1
Human Answer – Yes/No questions,37880705,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37880705,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37880705,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,"Yes — sequences were obtained from public repositories (GenBank) when available, and authors were contacted for others.",0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37880705,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported (no mention of cloning prior to sequencing).,0,No,1,No,1,Not applicable,1
Human Answer – Yes/No questions,37880705,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No — sequences were from ART-naïve individuals; studies among ART-experienced individuals were excluded.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37880705,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,Not reported / No indication that patients were in a clinical trial.,0,No,1,No,1,Not applicable,1
Human Answer – Yes/No questions,37880705,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No — the sequences analyzed were from ART-naïve individuals.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37896785,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37896785,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37896785,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37896785,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,37896785,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37896785,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,37896785,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37896860,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37896860,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,Yes,0,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37896860,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37896860,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37896860,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37896860,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes; participants were enrolled in the Opt4Kids randomized controlled trial.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37896860,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37910452,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37910452,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37910452,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37910452,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No / Not applicable,1,No,1,No,1,Not applicable,1
Human Answer – Yes/No questions,37910452,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No / Not applicable,1,No,1,No,1,Not applicable,1
Human Answer – Yes/No questions,37910452,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,Some were — the review included randomized controlled trials among other designs,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37910452,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,Not applicable,1
Human Answer – Yes/No questions,37914679,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37914679,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37914679,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported),1,No,1,No,1,No,1
Human Answer – Yes/No questions,37914679,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No (not reported),1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37914679,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,Yes,0,Yes,0,Yes,0,Yes — baseline sequences were obtained from individuals who subsequently were classified as virological failures,0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,37914679,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — this was a retrospective observational study (not a clinical trial),1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37914679,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,Yes,0,No,1,No — the study enrolled ART-naïve patients,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37920909,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37920909,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37920909,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported),1,No,1,No,1,No,1
Human Answer – Yes/No questions,37920909,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,Not reported (no cloning stated),0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37920909,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37920909,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37920909,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37938856,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37938856,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37938856,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported).,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37938856,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No cloning is reported.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37938856,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37938856,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No; this was a prospective pre/post-intervention cohort study, not a randomized clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37938856,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37941373,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37941373,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,"No — only genotypic (sequence-based) resistance interpretation was reported, not in vitro phenotypic susceptibility assays.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37941373,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — sequences were not publicly deposited; data are available from the first author on request.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37941373,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — no cloning step is described; nested PCR and Sanger sequencing were used.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37941373,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37941373,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37941373,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37946329,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37946329,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37946329,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No explicit public deposition is indicated in the paper.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37946329,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,Not reported / No evidence of cloning prior to sequencing is provided.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37946329,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37946329,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — they were treatment-experienced patients assessed in an observational study, not described as a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37946329,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37957382,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37957382,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper reports genotypic susceptibility scoring and ARV drug level testing but does not report in vitro phenotypic drug susceptibility assays.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37957382,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37957382,8,Were samples cloned prior to sequencing?,Boolean,Yes,,No,0,No,0,No,0,No — sequencing was performed using endpoint dilution single-genome approaches rather than cloning.,0,No,0,No,0,Not reported,0
Human Answer – Yes/No questions,37957382,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Yes,1,Sequences were obtained from individuals on antiretroviral therapy who had persistent low-level (non-suppressible) viremia while on ART; the paper does not characterize these as classic high-level virologic failure but as non-suppressible viremia despite ART.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37957382,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No — the study was observational and used historic comparator cohorts.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37957382,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37966701,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37966701,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37966701,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — no sequences were made publicly available.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37966701,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,No — samples were not cloned prior to sequencing because no sequencing was performed.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37966701,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — no sequences were obtained; the paper does report four confirmed virologic failures but notes resistance data were not available.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37966701,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the patients were part of an observational real-world cohort (OPERA) receiving routine clinical care, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37966701,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the paper does not report HIV sequences from any individuals, though participants had prior antiretroviral exposure (they were initiating CAB + RPV LA, often after stable ART).",1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37973713,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — the paper reports HIV sequences (genotyping) from patient samples.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37973713,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro phenotypic drug susceptibility testing data.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37973713,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Yes — sequences were submitted to the Stanford University HIV Drug Resistance Database.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37973713,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — the paper describes Sanger population sequencing and does not report cloning prior to sequencing.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37973713,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No — sequences were obtained from ART-naïve, newly diagnosed patients, not from individuals with virological failure on treatment.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37973713,13,Were the patients in the study in a clinical trial?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"The study was a registered, multi-center prospective observational cross-sectional study (registered on clinicaltrials.gov, NCT04636736), not an interventional randomized clinical trial.",0,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,37973713,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No — the paper reports sequences from individuals with no history of antiretroviral therapy (ART-naïve).,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37976080,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37976080,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,"No — the paper reports genotypic resistance analysis, not in vitro phenotypic drug susceptibility testing.",1,Yes,0,No,1,No,1
Human Answer – Yes/No questions,37976080,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / Not clearly stated in the paper.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,37976080,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — cloning is not described; PCR amplification followed by Sanger sequencing of the PCR products was used.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37976080,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,Not specifically reported; the study sampled individuals starting or restarting ART and reports prior ARV exposure but does not report sequencing from individuals with documented virological failure.,0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37976080,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this was a multicenter observational cross-sectional study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,37976080,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — some participants (3.2%, n=81) had prior ARV drug exposure, and they were included in the sequencing/PDR analysis.",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37976185,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,37976185,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37976185,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported).,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37976185,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported / No evidence of cloning.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37976185,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"No — sequences were from people with newly diagnosed HIV (baseline genotypes), not described as from individuals with virological failure on ART.",1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,37976185,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37976185,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Not applicable,0,Yes — some individuals had prior antiretroviral exposure via PrEP (TDF/TAF with FTC) before diagnosis and sequencing.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,37993493,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37993493,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,Yes,0,No — the paper reports genotypic predictions and genotypic susceptibility scores rather than in vitro phenotypic susceptibility assays.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37993493,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report public deposition of sequences; data are available upon request from the authors/DUCS platform.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,37993493,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No — samples were not cloned; sequencing was performed by Sanger capillary sequencing of PCR products and sequences were assembled and edited with RECall.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37993493,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,"Yes — sequences were obtained from individuals with unsuppressed viral load (≥ 1000 copies/mL), i.e., virological failure while on ART.",1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,37993493,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — patients were part of a cross-sectional survey of treatment-experienced adults in an urban cohort study, not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,37993493,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes — all participants were treatment-experienced and had been receiving antiretroviral therapy for at least one year prior to inclusion.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38005921,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,Yes,0,Yes,0,Yes,0,Yes. The study used amino acid sequences of HIV proteins derived from clinical samples (Stanford HIV Drug Resistance Database).,0,No,1,Yes,0,Yes,0
Human Answer – Yes/No questions,38005921,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,Yes,0,Yes,0,Yes. The datasets include phenotypic resistance measurements determined by the PhenoSense™ test system.,0,Yes,0,Yes,0,No,1
Human Answer – Yes/No questions,38005921,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes. The datasets used for building the models are provided in the Supplementary Materials and the web service is freely available.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38005921,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported. The paper does not describe any cloning of samples prior to sequencing.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38005921,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not reported,1,Not specified. The paper does not state whether sequences came from individuals with virological failure.,0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38005921,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,"No. The paper used sequences compiled from the Stanford HIV Drug Resistance Database and studies, not from a clinical trial conducted by the authors.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38005921,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,Not specified. The paper does not explicitly state the prior treatment histories of individuals whose sequences were used.,0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38020274,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,38020274,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38020274,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not reported / No evidence of public deposition.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,38020274,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No cloning is reported.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38020274,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38020274,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Yes,0,"No; they were participants in a prospective cohort study, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,38020274,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38022124,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report HIV sequences from patient samples.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38022124,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report in vitro drug susceptibility data.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38022124,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — sequences were not reported or deposited; no public sequence data are provided.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38022124,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not applicable / Not reported — no cloning or sequencing procedures are described.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38022124,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable / Not reported — no sequences were obtained; the study reports virological suppression outcomes but not sequencing from virological failures.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38022124,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — the patients were part of a retrospective, real-life observational study rather than a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,38022124,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Yes,0,"No — the paper does not report HIV sequences from previously treated individuals (sequencing was not performed); however, the cohort did include previously treated patients.",1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38031075,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38031075,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38031075,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38031075,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable (no sequencing performed),1,No,1,No,1,No,1
Human Answer – Yes/No questions,38031075,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No (no sequences were obtained),1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38031075,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38031075,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,38033131,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38033131,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38033131,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38033131,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not applicable — no sequencing or cloning reported,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38033131,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No — no sequences obtained,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38033131,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38033131,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38058846,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,No — the paper reports HIV drug resistance testing results but does not present raw HIV sequences.,0,No,0,No,0,Yes.,1
Human Answer – Yes/No questions,38058846,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No — the paper does not report any in vitro phenotypic drug susceptibility testing.,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,38058846,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No — the paper does not indicate that sequences were deposited in public repositories.,1,No,1,No,1,No.,1
Human Answer – Yes/No questions,38058846,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported.,0,No,1,No,1,Not reported.,1
Human Answer – Yes/No questions,38058846,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes — resistance testing/sequencing was performed in individuals experiencing virological failure while on ART (notably DTG-containing regimens).,1,Yes,1,Yes,1,Yes.,1
Human Answer – Yes/No questions,38058846,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — they were managed in clinical care and included in a case series, not enrolled in a clinical trial.",1,No,1,No,1,No.,1
Human Answer – Yes/No questions,38058846,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes — at least two of the three individuals had prior antiretroviral drug exposure before the resistance testing.,1,Yes,1,Yes,1,Yes.,1
Human Answer – Yes/No questions,38072961,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,38072961,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38072961,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not reported),1,No,1,No,1,No,1
Human Answer – Yes/No questions,38072961,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No (no cloning reported),1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38072961,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,38072961,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38072961,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,No,0,Yes,1
Human Answer – Yes/No questions,38090027,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,No,0,Yes,1,Yes,1,Yes. The paper reports genotypic resistance testing (GRT) results obtained from patient samples (plasma HIV-RNA and PBMC HIV-DNA) in cases of virological failure.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,38090027,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No. The paper reports genotypic resistance testing results but does not present in vitro (phenotypic) drug susceptibility data.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38090027,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No. The paper does not report deposition of sequences or provide public accession numbers.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38090027,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No indication of cloning is reported.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38090027,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,No,0,Yes,1,Not applicable,0,Yes. Genotypic resistance tests were evaluable at virological failure in five patients.,1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,38090027,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No. The study was a retrospective cohort conducted in clinical practice; although a small number later enrolled in clinical trials, the cohort itself was not a clinical trial.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38090027,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,No,0,Yes,1,Yes,1,"Yes. The cohort consisted of treatment-experienced individuals with long prior ART exposure, and GRTs were performed in some of these individuals.",1,No,0,No,0,Yes,1
Human Answer – Yes/No questions,38140553,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38140553,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38140553,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38140553,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No evidence of cloning; samples were amplified by nested PCR and sequenced directly by Sanger methods.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38140553,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,"Not specifically reported; sequences came from patients both receiving ART and not on ART, but virological failure status is not stated.",0,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38140553,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,No.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38140553,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,"Yes; the study included sequences from individuals receiving ART at the time of sampling, though past treatment histories were not fully known for all patients.",0,Yes,0,No,1,Yes,0
Human Answer – Yes/No questions,38140649,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38140649,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,Yes,0,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38140649,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38140649,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,38140649,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38140649,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,38140649,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38140667,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,Yes,0,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38140667,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38140667,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38140667,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported,0,No,1,No,1,No,1
Human Answer – Yes/No questions,38140667,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38140667,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,"No — the paper focuses on real-world observational studies and cohorts (though it references some clinical trials elsewhere), and the review itself did not enroll patients in a trial.",1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38140667,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,Yes,0,Yes,0,Yes,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38142692,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38142692,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38142692,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38142692,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,Not applicable — no sequencing was performed.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38142692,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,"No — no sequences were obtained, although the cohort consisted of individuals with virological failure.",1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38142692,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No — this was a retrospective observational cohort study using routine-care data, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,38142692,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,"No — the paper does not report HIV sequences from any individuals, including those who had previously received ARV drugs.",1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38152686,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38152686,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38152686,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No (not publicly deposited); data are available upon request.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38152686,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,Not reported / not specified.,0,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38152686,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38152686,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,"No; this is a single-patient case report, not a clinical trial.",1,No,1,No,1,No,1
Human Answer – Yes/No questions,38152686,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38314093,1,Does the paper report HIV sequences from patient samples?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes.,1,No,0,Yes,1,Yes,1
Human Answer – Yes/No questions,38314093,2,Does the paper report in vitro drug susceptibility data?,Boolean,No,,Yes,0,No,1,No,1,No.,1,No,1,No,1,No,1
Human Answer – Yes/No questions,38314093,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,Not explicitly reported / not clearly made publicly available.,0,No,1,No,1,No,1
Human Answer – Yes/No questions,38314093,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not reported,1,No — cloning is not reported.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38314093,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Yes,0,No — the sequenced samples were from untreated patients.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38314093,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,No,1,No.,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38314093,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Yes,0,No — the reported sequences were from untreated individuals.,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38427738,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,No,1,"No. The sequences reported were derived from in vitro–propagated laboratory and primary viral isolates in cell culture, not from patient samples.",1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38427738,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,No,0,Yes.,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38427738,3,Were sequences from the paper made publicly available?,Boolean,No,,No,1,No,1,No,1,No public sequence accession is reported; sequences are presented in the paper and/or Supplementary Materials and materials are available upon request.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,38427738,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,Not applicable,1,"Both approaches were used: bulk sequencing of PCR amplicons from genomic DNA was performed, and env amplicons were cloned into plasmids to construct infectious molecular clones which were then Sanger-sequenced/verified.",0,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,38427738,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,Not applicable,1,No. The study did not report sequencing of samples from individuals with virological failure; analyses were performed on viruses passaged in vitro under drug pressure.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,38427738,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not applicable,1,No — there were no patients in this study; experiments used cell lines and laboratory/primary viral clones.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,38427738,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No. The paper does not report sequences from treated individuals; all sequences were obtained from viruses propagated experimentally under antiretroviral pressure in cell culture.,1,No,1,No,1,Not Reported,1
Human Answer – Yes/No questions,38864613,1,Does the paper report HIV sequences from patient samples?,Boolean,No,,No,1,No,1,Yes,0,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38864613,2,Does the paper report in vitro drug susceptibility data?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38864613,3,Were sequences from the paper made publicly available?,Boolean,Yes,,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1,Yes,1
Human Answer – Yes/No questions,38864613,8,Were samples cloned prior to sequencing?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38864613,12,Were any sequences obtained from individuals with virological failure on a treatment regimen?,Boolean,No,,No,1,No,1,No,1,No,1,No,1,No,1,Yes,0
Human Answer – Yes/No questions,38864613,13,Were the patients in the study in a clinical trial?,Boolean,No,,No,1,No,1,Not reported,1,No (no patients were involved),1,No,1,No,1,Not reported,1
Human Answer – Yes/No questions,38864613,14,Does the paper report HIV sequences from individuals who had previously received ARV drugs?,Boolean,No,,No,1,No,1,Not applicable,1,No,1,No,1,No,1,Yes,0
